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Abstract 
 
Transferrin receptor 2 (TFR2) is an important regulator of systemic iron metabolism. Patients with 
TFR2 mutations develop type III hereditary haemochromatosis (HH), which is associated with 
inappropriate mRNA levels of the iron regulatory hormone hepcidin (HAMP). Studies from our 
laboratory using mice with hepatocyte-specific deletion of TfR2 suggested that hepatic TFR2 is 
important in the regulation of body iron homeostasis. How TFR2 regulates Hamp and thus iron 
homeostasis is still unclear, with two main schools of thought. According to one, when body iron 
levels increase, TFR2 interacts with HFE, the haemochromatosis protein, which leads to a 
signalling cascade and increase in HAMP transcription. The second states that HFE and TFR2 can 
act independently of each other to regulate HAMP. 
Although highly expressed in the liver, TfR2 expression has also been reported in erythroid cells, 
macrophages, peripheral blood mononuclear cells, spleen, testes and prostate gland. The role of 
TFR2 in these tissues and cells is not known. Some studies have suggested that TFR2 could have 
roles independent of iron regulation in the spleen and brain. Genome wide association studies have 
shown a strong association between TFR2 and haematological parameters. Recent publications have 
also suggested a role for TfR2 in erythropoiesis. 
The objective of this thesis was to increase our understanding of the biology of TFR2 and its role in 
various tissues. This thesis examines the role that TFR2 plays in iron homeostasis, inflammation-
mediated iron homeostasis and erythropoiesis by investigating various tissue-specific TfR2 
knockout mice. 
In order to examine the putative interaction between HFE and TFR2, a novel stable co-expression 
model system was used. HFE and TFR2 were expressed under the same promoter using a novel 
tricistronic vector. Protein-protein interactions were studied in vivo in the native state of the proteins 
using the proximity ligation assay and by co-immunoprecipitation. Results of these studies indicate 
that HFE and TFR2 do not interact and that they can independently regulate Hamp. 
In order to understand the hepatic function of TfR2, TfR2-/- mice and mice with a hepatocyte-
specific deletion of TfR2 (TfR2f/f/Alb-Cre+/-) were analysed. Results from these studies suggest that 
hepatic TFR2 may be involved in appropriate regulation of bone morphogenetic protein (Bmp) 
signalling in response to increased iron. The loss of TFR2 in hepatocytes leads to reduced BMP 
signalling. The role of TfR2 in cells of the monocyte/macrophage lineage was examined by 
generating mice lacking TfR2 in these cells. TfR2f/f/LysM-Cre+/- mice were generated by crossing 
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TfR2f/f with LysM-Cre+/- mice. In order to examine the role of macrophage TFR2 in iron-regulated 
and inflammation-regulated iron homeostasis the mice were either fed an iron-rich diet or injected 
with lipopolysaccharide (LPS). Analysis of genes involved in the regulation of iron metabolism in 
the liver and spleen of TfR2f/f/LysM-Cre+/- mice indicates that macrophage TfR2 does not play a role 
in regulating systemic iron metabolism in response to increased body iron levels or inflammation. 
The expression level of the iron exporter ferroportin 1 (Fpn1) was lower in the spleen and the livers 
of TfR2f/f/LysM-Cre+/- mice suggesting that macrophage expression of TfR2 may be required for 
transcriptional regulation of Fpn1. Mice treated with LPS had significantly reduced expression of 
all the major genes thought to be involved in the iron regulatory pathway. Previous studies have 
shown a reduction in the levels Fpn1 and hemojuvelin (Hjv) in the liver; the studies in this thesis 
reveal that the impact of inflammatory stimuli on the transcriptional regulation of iron metabolism 
related genes may be broader than previously reported. 
The role of TfR2 in normal and stress erythropoiesis was examined by generating mice with an 
erythroid-specific deletion of TfR2. This was achieved by crossing the TfR2Δ/f mice with Vav-Cre+/-. 
These mice were then fed either an iron-rich or an iron-deficient diet to analyse the effect of stress 
on the erythroid function of TFR2. Mice lacking TfR2 in erythroid cells had significant 
splenomegaly and extramedullary haematopoiesis as compared to control anaemic animals. 
Analysis of the developmental stages of erythropoiesis revealed that the lack of TfR2 in erythroid 
cells leads to a developmental block at the polychromatic erythroblast stage. 
The findings of this thesis have led to a greater understanding of the biology and importance of 
TFR2 in different tissues. The results described in Chapters 3 and 4 contribute to our understanding 
of the role played by TFR2 in the hepatocyte and regulation of iron metabolism in general. The 
results in the fifth chapter reveal an as yet unexplored link between inflammation and BMP-SMAD 
mediated regulation of iron metabolism. The sixth chapter reveals an important role of erythroid 
TFR2 in the differentiation of erythroblasts in stress conditions. It also supports the paradigm that 
proteins expressed at lower levels in some tissues could have tissue-specific functions in addition to 
their predominant role in the main tissue where they are highly expressed. 
iii 
Declaration by the author 
 
This thesis is composed of my original work, and contains no material previously published or 
written by another person except where due reference has been made in the text. I have clearly 
stated the contribution by others to jointly-authored works that I have included in my thesis. 
 
I have clearly stated the contribution of others to my thesis as a whole, including statistical 
assistance, survey design, data analysis, significant technical procedures, professional editorial 
advice, and any other original research work used or reported in my thesis. The content of my thesis 
is the result of work I have carried out since the commencement of my research higher degree 
candidature and does not include a substantial part of work that has been submitted to qualify for 
the award of any other degree or diploma in any university or other tertiary institution. I have 
clearly stated which parts of my thesis, if any, have been submitted to qualify for another award. 
 
I acknowledge that an electronic copy of my thesis must be lodged with the University Library and, 
subject to the General Award Rules of The University of Queensland, immediately made available 
for research and study in accordance with the Copyright Act 1968. 
 
I acknowledge that copyright of all material contained in my thesis resides with the copyright 
holder(s) of that material. Where appropriate I have obtained copyright permission from the 
copyright holder to reproduce material in this thesis. 
 
 
 
Gautam Rishi 
 
iv 
Publications during candidature 
 
Peer-reviewed papers 
• Rishi, G., Crampton, E.M., Wallace, D.F., and Subramaniam, V.N. (2013). In situ proximity 
ligation assays indicate that hemochromatosis proteins HFE and transferrin receptor 2 
(TFR2) do not interact. PLoS One 8, e77267. 
• Wallace, D.F., Secondes, E.S., Rishi, G., Ostini, L., McDonald, C.J., Lane, S.W., Vu, T., 
Hooper, J.D., Velasco, G., Ramsay, A.J., et al. (2014). A critical role for murine transferrin 
receptor 2 in erythropoiesis during iron restriction. Br J Haematol. 168(6):891-901. 
• Rishi, G., Wallace, D. F., Subramaniam, V.N. (2015). Hepcidin: Regulation of the master 
iron regulator. Biosci Rep. 2015 Mar 31: E.pub. 
 
Manuscripts in preparation 
• Macrophage expression of transferrin receptor 2 is not required for iron and inflammation-
mediated hepcidin regulation. Rishi, G., Wallace, D. F., Subramaniam, V.N. 
• Transferrin receptor 2 expression in the haematopoietic cells is essential for stress 
erythropoiesis. Rishi, G., Wallace, D. F., Subramaniam, V.N. 
 
Conference abstracts (* denotes oral presentation) 
• *Gautam Rishi, Daniel Wallace, Eriza Secondes, V. Nathan Surbramaniam. Iron and 
Erythropoiesis: A Novel Role for Transferrin Receptor 2 in Stress Erythropoiesis. (2015). 
Australian Liver Association Research Workshop, Bowral, New South Wales, Australia. 
• *Gautam Rishi, Daniel Wallace, V. Nathan Subramaniam. In-situ proximity ligation assay 
indicates that hemochromatosis proteins HFE and transferrin receptor 2 do not interact. 
(2013). Australian Liver Association Research Workshop, Gold Coast, Queensland, 
Australia. 
• G. Rishi, DF Wallace, VN Subramaniam. Proximity ligation assays indicate that 
haemochromatosis proteins HFE and transferrin receptor 2 (TFR2) do not interact. (2013). 
Australian Society for Medical Research Postgraduate Student Conference, Brisbane, 
Australia. 
• G. Rishi, DF Wallace, VN Subramaniam. Proximity ligation assays indicate that 
haemochromatosis proteins HFE and transferrin receptor 2 (TFR2) do not interact. (2013). 
Fifth Congress of the International BioIron Society, BIOIRON 2013. University College 
London, London, United Kingdom. 
v 
Publications included in the thesis 
 
Rishi, G., Crampton, E.M., Wallace, D.F., and Subramaniam, V.N. (2013). In situ proximity 
ligation assays indicate that hemochromatosis proteins HFE and transferrin receptor 2 (TFR2) do 
not interact. PLoS One 8, e77267– incorporated as Chapter 3. 
Contributor Statement of contribution 
Gautam Rishi Designed experiments (20%) 
 Performed the experiments (90%) 
 Analysed the data (40%) 
 Wrote the first draft of the paper (100%) 
Emily M. Crampton Performed the experiments (5%) 
Daniel F. Wallace Performed the experiments (5%) 
 Designed experiments (10%) 
 Analysed the data (30%) 
 Edited the paper (50%) 
V. Nathan Subramaniam Designed experiments (70%) 
 Analysed the data (30%) 
 Edited the paper (50%) 
 
vi 
Contributions by others to the thesis 
 
• Concept and design of the project 
Prof. V. Nathan Subramaniam and Dr. Daniel F. Wallace contributed to the design and 
analysis of all the experiments. 
• Generation of stable cell lines 
Dr. Daniel F. Wallace and Dr. Emily Crampton generated the stable cell lines used for the 
experiments in Chapter 3. 
• Tissue processing and sectioning 
The staff at QIMR Berghofer Medical Research Institute (QIMRB) Histotechnology Facility 
performed the histology techniques including tissue processing, paraffin-embedding, 
sectioning and H&E staining. 
• Animal breeding and maintenance 
Ms. Eriza Secondes performed the genotyping to identify the correct genotypes for the 
experimental mice and maintained the mice on the special diets. The staff at the QIMRB 
Animal House were involved in maintaining the colonies of the mice. 
• Critical revision of the thesis 
Prof. V. Nathan Subramaniam and Dr. Daniel F. Wallace critically revised the thesis. 
• Statistical analyses 
Dr. Leesa Wockner provided assistance and guidance for performing the statistical analyses. 
  
vii 
Statement of parts of the thesis submitted to qualify for the award of another 
degree 
 
None. 
 
viii 
Acknowledgements 
 
The two most important people who made this thesis and project possible are Prof. V. Nathan 
Subramaniam and Dr. Daniel F. Wallace so I would like to thank them for their support, guidance, 
mentoring, advice and positive criticism. It has been an enlightening experience to work with them 
as they have always provided positive and insightful input at every stage of my project. 
I would also like to thank all the members of my laboratory, past and present who helped me and 
trained me in the techniques that helped me in completing the experiments for this project. I am 
thankful to Eriza Secondes who took care of all the animals and breeding and did the painful task of 
genotyping and maintaining the colonies, if it was not for her help this project would have taken 
much more time. I would like to acknowledge the help, support and training provided by Lesa 
Ostini, who was a great mentor and friend and helped in editing the thesis. I am grateful to Dr. 
Cameron McDonald for his valuable and impartial input in every aspect of the project. I appreciate 
the patience and help of my friend Justin Goh who listened to me patiently and help me cruise 
through the difficult times during my PhD. 
I had to learn a few new techniques including Flow Cytometry during the course of this project and 
it was made possible and easy by the talented staff in the Flow Cytometry and Imaging Department. 
I would like to thank Dr. Grace Chojnowski, Dr. Paula Hall, Dr. Nigel Waterhouse and Dr. Michael 
Rist who trained me in flow cytometry and helped me in the troubleshooting. I would like to thank 
the staff at the Histotechnology Facility at QIMRB for helping me with the tissue sections on short 
notice. Their support helped me to finish the project and the experiments on time. 
I am grateful to the University of Queensland, the Bushell Foundation and the QIMR Berghofer 
Medical Research Institute for the financial support throughout my studies. 
I would also like to thank my family and friends for providing me the much needed emotional and 
mental support not only during the period of my studies but throughout my life. 
The help and support from all of the individuals and organisations mentioned above made it 
possible for me to complete this thesis on time and I will always be grateful to them. 
  
ix 
Keywords 
 
TFR2, transferrin receptor 1, transferrin receptor 2, iron metabolism, hepcidin, erythropoiesis, 
inflammation and iron. 
 
Australian and New Zealand Standard Research Classifications (ANZSRC) 
 
ANZSRC code: 110307, Gastroenterology and Hepatology, 100%. 
 
Fields of Research (FoR) Classification 
 
FoR code: 1103-Clinical Sciences-100%. 
 
x 
Table of Contents 
 
Abstract i 
Declaration by the author iii 
Publications during candidature iv 
Publications included in the thesis v 
Contributions by others to the thesis vi 
Statement of parts of the thesis submitted to qualify for the award of another degree vii 
Acknowledgements viii 
Keywords ix 
Australian and New Zealand Standard Research Classifications (ANZSRC) ix 
Fields of Research (FoR) Classification ix 
Table of Contents x 
List of Figures xv 
List of Tables xviii 
List of Abbreviations xix 
Chapter 1. Introduction 1 
1.1 Iron and its importance 2 
1.1.1 Iron metabolism 2 
1.1.3 Hereditary haemochromatosis 3 
1.2 Proteins involved in iron metabolism 4 
1.2.1 Ferritin 4 
1.2.2 Transferrin 6 
1.2.3 Transferrin receptor 1 (TFR1) 6 
1.2.4 Transferrin receptor 2 (TFR2) 7 
1.2.5 Haemochromatosis protein (HFE) 8 
1.2.6 Ferroportin (FPN) 9 
1.2.7 Hepcidin (HAMP) 9 
1.2.8 Hemojuvelin (HJV) 11 
xi 
1.2.9 Matriptase-2 (TMPRSS6) 12 
1.3 Regulation of hepcidin 13 
1.3.1 The role of HFE-TFR1-TFR2 13 
1.3.2 The signalling pathways involved in hepcidin regulation 14 
1.3.3 The erythroid control of hepcidin 20 
1.3.4 Hypoxia and the hepcidin axis 23 
1.3.5 Hormones and growth factors 26 
1.3.6 Autoregulation by prohecidin 28 
1.3.7 The mTOR pathway and hepcidin 28 
1.4. TFR2 and its role in iron metabolism 29 
1.4.1 Mutations of TFR2 31 
1.4.2 Molecular interactions of TFR2 and their role in iron metabolism 34 
1.4.3 TFR2 in extra-hepatic tissues 37 
1.4.3.1 Macrophages 37 
1.4.4.2 Erythroid cells 39 
1.4.3.3 Brain 40 
1.4.3.4 Heart and Testis 40 
1.5 Brief Outline of the Project 41 
Chapter 2. Materials and Methods 43 
2.1 Tissue culture 44 
2.2 Immunofluorescence (IF) 44 
2.3 Proximity ligation assay (PLA) 45 
2.4 Confocal microscopy 46 
2.5 Animal Breeding 46 
2.5.1 Generation of TfR2f/f/Alb-Cre+/- mice 46 
2.5.2 Generation of TfR2f/f/LysM-Cre+/- 46 
2.5.3 Animal sacrifice and tissue collection 47 
2.5.4 Blood collection 47 
2.6 mRNA quantification 47 
2.6.1 RNA extraction 47 
2.6.2 cDNA preparation 48 
2.6.3 Quantitative real-time polymerase chain reaction (qRT-PCR) 48 
xii 
2.7 Protein expression 51 
2.7.1 Cell lysates 51 
2.7.2 Tissue homogenates 51 
2.7.3 Protein quantitation 51 
2.7.4 Co-immunoprecipitation (Co-IP) 52 
2.7.5 Western blotting 53 
2.8 Histology 56 
2.8.1 Perls’ staining 56 
2.9 Iron Indices 57 
2.9.1 Serum iron concentration 57 
2.9.1.1 Serum iron 57 
2.9.1.2 UIBC 58 
2.9.2 Tissue iron concentration 58 
2.10 Flow cytometric analysis 60 
2.11 Erythropoietin enzyme-linked immunosorbent assay (ELISA) 60 
2.12 Statistical analysis 61 
Chapter 3. Interactions between HFE, TFR1 and TFR2 proteins 62 
3.1 Introduction 63 
3.2 Results 65 
3.2.1 Stable co-expression of HFE and TFR2 in Hepa1-6 cells does not affect their 
         localisation 65 
3.2.2 In situ proximity ligation assay shows that HFE and TFR2 do not interact 69 
3.2.3 Co-Immunoprecipitation experiments confirm the absence of interactions 
         between HFE and TFR2 72 
3.3 Discussion 74 
3.4 Future directions 76 
Chapter 4. Expression of TfR2 in the bone marrow, spleen and liver 77 
4.1 Introduction 78 
4.2 Results 79 
4.2.1 TfR2 is expressed in the bone marrow and spleen 79 
xiii 
4.2.2 TFR2 is required for appropriate BMP-SMAD signalling 83 
4.3 Discussion 88 
4.4 Future directions 92 
Chapter 5. Investigation of the role of TfR2 in macrophages 94 
5.1 Introduction 95 
5.1.1 Inflammation and iron 95 
5.1.2 Macrophages and hepcidin 97 
5.1.3 Iron and the macrophage phenotype 99 
5.1.4 TFR2 and macrophages 100 
5.2 Results 101 
5.2.1 Deletion of macrophage TfR2 does not affect TfR2 expression levels in  
         the liver or systemic iron parameters 101 
5.2.2 Regulation of iron metabolism genes in the spleen of TfR2f/f/LysM-Cre+/- mice 105 
5.2.3 BMP-SMAD-mediated-regulation of Hamp in the liver is not affected in  
         TfR2f/f/LysM-Cre+/- mice 107 
5.2.4 LPS treatment reduces serum iron levels 110 
5.2.5 Effect of LPS treatment on iron metabolism genes in the spleen 113 
5.2.6 LPS treatment reduces TfR2 levels in the liver 114 
5.2.7 LPS treatment leads to a reduction in the expression levels of iron sensing genes 115 
5.3 Discussion 119 
5.4 Future directions 121 
Chapter 6. TfR2 expression in haematopoietic cells is required for stress erythropoiesis 123 
6.1 Introduction 124 
6.1.1 Erythropoeisis and iron metabolism 124 
6.1.2 Erythropoietic regulation of Hamp 126 
6.1.3 Erythropoiesis and TFR2 128 
6.2 Results 132 
6.2.1 TfR2Δ/f/Vav-Cre+/- animals have reduced TfR2 expression in the bone marrow 132 
6.2.2 Reduced TfR2 in the livers of TfR2Δ/f/Vav-Cre+/- mice does not affect  
         iron indices significantly 133 
6.2.3 Effect of reduced TFR2 levels in the liver and bone marrow on iron  
homeostasis in the liver 135 
xiv 
6.2.4 Effect of reduced TFR2 levels in the liver and bone marrow on iron homeostasis in the 
spleen  139 
6.2.5 TfR2Δ/f/Vav-Cre+/- mice fed an iron-deficient diet show splenomegaly and  
         extramedullary haematopoiesis in the spleen and the liver. 140 
6.2.6 Accumulation of immature erythroid cells in the bone marrow and spleen  
         of TfR2Δ/f/Vav-Cre+/- mice fed an iron-deficient diet 149 
6.2.7 Serum erythropoietin levels do not differ in the TfR2Δ/f and TfR2Δ/f/Vav-Cre+/- 
             mice fed an iron-deficient diet 153 
6.3 Discussion 153 
6.4 Future Directions 157 
Chapter 7. Discussion 158 
References 165 
Appendix 185 
  
xv 
List of Figures 
 
Figure 1.1 Systemic regulation of iron metabolism. 3 
Figure 1.2 Hepcidin mediated regulation of iron homeostasis. 10 
Figure 1.3 SMAD family of proteins         16 
Figure 1.4 Molecular regulation of hepcidin. 20 
Figure 3.1 Analysis of expression of HFE, TFR1 and TFR2 in transfected Hepa1-6 cells. 65 
Figure 3.2 Co-localisation of TFR1 with HFE and TFR2. 66 
Figure 3.3 Co-localisation of TFR1 and TFR2 in Hepa1-6 cells. 67 
Figure 3.4 Co-localisation of HFE and TFR1 in Hepa1-6 cells. 68 
Figure 3.5 Co-localisation between HFE and TFR2 in Hepa1-6 cells. 69 
Figure 3.6 Specificity of PLA for transfected Hepa1-6 cells. 70 
Figure 3.7 PLA shows that HFE and TFR2 do not interact. 71 
Figure 3.8 Co-immunoprecipitation experiments reveal that HFE and TFR2 do not form a  
complex. 73 
Figure 4.1 TfR2 is expressed in the bone marrow. 80 
Figure 4.3 Loss of TfR2 does not affect local iron metabolism in the spleen. 82 
Figure 4.4 TfR2f/f/Alb-Cre+/- and TfR2-/- mice have significantly lower splenic iron  
content as compared to WT-Fe mice. 82 
Figure 4.5 TfR2f/f/Alb-Cre+/- and TfR2-/- mice have significantly lower hepatic iron content,  
Hamp and Bmp6 levels compared to WT-Fe mice. 84 
Figure 4.6 TfR2f/f/Alb-Cre+/- and TfR2-/- mice have significantly higher transferrin saturation  
and serum iron levels. 85 
Figure 4.7 TfR2f/f/Alb-Cre+/- and TfR2-/- mice have lower Id1 and Smad7 levels as compared  
to WT-Fe mice and WT mice. 86 
Figure 4.8 TfR2f/f/Alb-Cre+/- and TfR2-/- mice have inappropriate BMP-SMAD signalling 
 as compared to WT-Fe mice and WT mice. 87 
Figure 4.9 Loss of TFR2 results in reduced SMAD1/5 phosphorylation. 88 
Figure 4.10 Schematic representation of the proposed roles of HFE and TFR2 in the regulation 
 of HAMP. 91 
Figure 4.11 TFR2 may play a role in Bmp6 regulation in the non-parenchymal cells of the liver. 93 
Figure 5.1 TfR2f/f/LysM-Cre+/- have reduced expression of TfR2 in the spleen. 101 
Figure 5.2 Mice lacking TfR2 in macrophages have normal systemic iron parameters. 102 
Figure 5.3 TfR2f/f/LysM-Cre+/- mice do not show any morphological differences in the liver. 103 
xvi 
Figure 5.4 TfR2f/f/LysM-Cre+/- mice do not show any morphological differences in the spleen. 103 
Figure 5.5 TfR2f/f and TfR2f/f/LysM-Cre+/- mice fed an iron-rich diet show iron l 
oading in hepatocytes. 104 
Figure 5.6 TfR2f/f and TfR2f/f/LysM-Cre+/- mice fed an iron-rich diet show iron loading  
in the macrophages of the spleen. 104 
Figure 5.7 TfR2f/f/LysM-Cre+/- mice have normal expression of iron metabolism related  
genes in the spleen. 106 
Figure 5.8 TfR2f/f/LysM-Cre+/- mice have normal hepcidin regulation in the liver. 108 
Figure 5.9 An iron-rich diet increases phosphorylation of SMAD1/5 in the livers of  
TfR2f/f and TfR2f/f/LysM-Cre+/- mice. 109 
Figure 5.10 LPS treatment reduces serum transferrin saturation and total serum iron in  
TfR2f/f/LysM-Cre+/-and TfR2f/f. 111 
Figure 5.11 TfR2f/f and TfR2f/f/LysM-Cre+/- mice treated with LPS do not load iron in the liver. 112 
Figure 5.12 TfR2f/f and TfR2f/f/LysM-Cre+/- mice treated with LPS do not load iron in the spleen. 112 
Figure 5.13 LPS treatment results in a reduction in the expression levels of  
Fpn1, Hfe and TfR1 in the spleen. 113 
Figure 5.14 LPS treatment induces Hamp and leads to a reduction in the levels of  
TfR2 in the livers. 115 
Figure 5.15 LPS treatment reduces TFR2 protein levels in the liver. 116 
Figure 5.16 LPS treatment leads to a reduction in the levels of major genes 
 involved in iron mediated regulation of Hamp in the liver. 117 
Figure 5.17 LPS treatment leads to a reduction in the levels of major genes  
involved in iron regulation in the livers of WT male mice. 119 
Figure 6.1 Breeding strategy for generating TfR2Δ/f/Vav-Cre+/- mice. 131 
Figure 6.2 TfR2Δ/f/Vav-Cre+/- mice have reduced expression of TfR2 in the bone marrow  
and liver. 132 
Figure 6.3 TfR2Δ/f/Vav-Cre+/- have reduced expression of TFR2 in the bone marrow. 133 
Figure 6.4 Expression of TFR2 does not change in the spleens of TfR2Δ/f/Vav-Cre+/- mice. 133 
Figure 6.5 Expression of TFR2 in the livers of TfR2Δ/f/Vav-Cre+/- mice. 133 
Figure 6.6 Reduced expression of TFR2 in the livers of TfR2Δ/f/Vav-Cre+/- mice  
does not affect hepatic and splenic iron concentrations. 134 
Figure 6.7 TfR2Δ/f/Vav-Cre+/- mice have similar serum iron levels and transferrin  
saturation as compared to TfR2Δ/f mice on a similar diet. 135 
Figure 6.8 Perls’ staining of the liver sections. 136 
Figure 6.9 Perls’ staining of the spleen sections. 137 
xvii 
Figure 6.10 Gene expression in the livers of the TfR2Δ/f and TfR2Δ/f/Vav-Cre+/- mice 138 
Figure 6.11 Gene expression in the spleens of the TfR2Δ/f and TfR2Δ/f/Vav-Cre+/- mice 140 
Figure 6.12 TfR2Δ/f/Vav-Cre+/- mice fed an iron-deficient diet have enlarged spleens. 140 
Figure 6.13 Haematological parameters and spleen to body weight ratios for TfR2Δ/f  
and TfR2Δ/f/Vav-Cre+/- mice                   142 
Figure 6.14 TfR2Δ/f/Vav-Cre+/- mice fed an iron-deficient diet show signs of  
extramedullary haematopoiesis in the liver. 144 
Figure 6.15 TfR2Δ/f and TfR2Δ/f/Vav-Cre+/- mice fed an iron-deficient diet show  
signs of extramedullary haematopoiesis in the spleen. 145 
Figure 6.16 TfR2Δ/f and TfR2Δ/f/Vav-Cre+/- mice fed an iron-deficient diet have significant  
EMH in the spleen. 146 
Figure 6.17 TfR2Δ/f and TfR2Δ/f/Vav-Cre+/- mice fed an iron-deficient diet have significant  
EMH in the liver. 147 
Figure 6.18 Erythropoietic markers do not differ in the bone marrow of TfR2Δ/f and  
TfR2Δ/f/Vav-Cre+/- mice fed an iron-deficient diet. 148 
Figure 6.19 Accumulation of polychromatic erythroblasts in the bone marrow of  
TfR2Δ/f/Vav-Cre+/- mice fed an iron-deficient diet. 150 
Figure 6.20 Accumulation of polychromatic erythroblasts in the spleen of  
TfR2Δ/f/Vav-Cre+/- mice fed an iron-deficient diet. 151 
Figure 6.21 Increased proportion of polychromatic erythroblasts in the bone marrow  
and spleens of TfR2Δ/f/Vav-Cre+/- mice fed an iron-deficient diet. 152 
Figure 6.22 TfR2Δ/f/Vav-Cre+/- mice fed an iron-deficient diet have a decreased proportion  
of EPOR expressing erythroid cells in the spleen. 152 
Figure 6.23 TfR2Δ/f and TfR2Δ/f/Vav-Cre+/- mice fed an iron-deficient diet have significantly 
 higher serum EPO levels. 153 
Figure 7.1 Schematic representation of the proposed roles of HFE and TFR2 in the r 
egulation of HAMP. 160 
  
xviii 
List of Tables 
 
Table 1.1 TFR2 mutations known to be associated with type III HH in humans 32 
Table 2.1 Primary antibody concentrations used for immunofluorescence studies. 45 
Table 2.2 Thermal cycling conditions for first strand synthesis. 48 
Table 2.3 Composition of a qRT-PCR reaction (per well) using SensiFASTTM SYBR  
No-Rox kit. 49 
Table 2.4 Light Cycler 480 thermal cycling conditions for performing qRT-PCR. 49 
Table 2.5 Sequences of the primers used for qRT-PCR. 49 
Table 2.6 Homogenising conditions for preparing RNA and protein from liver,  
spleen and bone marrow. 51 
Table 2.7 Composition of Solution A for preparing the BCA reagent. 52 
Table 2.8 Composition of 2X Sample buffer for preparing protein samples for loading onto gels. 53 
Table 2.9 Composition of upper buffer for stacking gel. 54 
Table 2.10 Composition of lower buffer for resolving gel. 54 
Table 2.11 Composition of 10X SDS-PAGE running buffer. 54 
Table 2.12 Composition of stacking gel for SDS-PAGE. 54 
Table 2.13 Composition of resolving gel for SDS-PAGE. 54 
Table 2.14 Composition of Tris-buffered saline (TBS). 55 
Table 2.15 Composition of Western transfer buffer 55 
Table 2.16 Details of primary antibodies used for detection of proteins. 55 
Table 2.17 Steps for rehydration/dehydration series for paraffin sections. 56 
Table 2.18 Solution A and B for making Perls’ solution. 56 
Table 2.19 Reaction composition for measuring total serum iron. 57 
Table 2.20 Reaction composition for measuring unsaturated iron binding capacity. 58 
Table 2.21 Acid solution for measuring non-haem iron in tissues. 59 
Table 2.22 Iron standards for assay to measure non-haem iron in tissues. 59 
Table 2.23 Chromagen reagent stock for measuring non-haem iron in tissues. 59 
Table 2.24 Working chromagen reagent for measuring non-haem iron in tissues. 59 
Table 2.25 List of fluorophore-conjugated antibodies used for flow cytometric analyses. 60 
 
  
xix 
List of Abbreviations 
ACD anaemia of chronic disease 
Actb actin 
AD Alzheimer’s disease 
AKT protein kinase B 
Alas2 delta-aminolevulinate synthase 2 
ALK3 bone morphogenetic receptor type IA 
AML12 alpha murine liver 12 cells 
ANOVA analysis of variance 
AP2 adaptor-related protein complex 2 
Apo-TF apo-transferrin 
APS ammonium persulphate 
ARC Australian Research Council 
Arg arginine 
ARNT aryl hydrocarbon receptor nuclear translocator 
Asn Asparagine 
ATOH8 atonal homologue 8 
BCA bicinchoninic acid 
Bcl2l1 B-cell lymphoma 2 like 1 
BFU-E burst forming unit-erythroid 
BM  bone marrow 
BMDM bone marrow-derived macrophages 
BMP bone morphogenetic protein 
BMPR bone morphogenetic protein receptor 
BSA bovine serum albumin 
C/EBPα CCAAT-enhancer binding protein alpha 
cAMP cyclic adenosine monophosphate 
CFU-E colony forming unit-erythroid 
ChIP chromatin immunoprecipitation 
CHO Chinese hamster ovary 
Co-IP co-immunoprecipitation 
CREB cyclic adenosine monophosphate response element binding 
protein 
Co-SMAD Co-sma and mothers against decapentaplegic homologue 
CTRP15 C1q/TNF-related protein family member 15 
xx 
Cys cysteine 
DAPI 4',6-diamidino-2-phenylindole, dihydrochloride 
Del deletion 
DMEM Dulbecco's modified Eagle's medium 
DMT1 divalent metal transporter 1 
Dup duplication 
E2 17β-estradiol 
EDTA ethylenediaminetetraacetic acid 
EGF epidermal growth factor 
EGFR epidermal growth factor receptor 
EKLF erythroid Kruppel-like factor 
ELISA enzyme linked immunosorbent assay 
EMH extramedullary haematopoiesis 
Epas1 endothelial PAS domain protein 1 
EPO erythropoietin 
EPOR erythropoietin receptor 
ER estrogen receptor 
ERE estrogen response element 
ERFE erythroferrone 
ERK1/2 extracellular signal-regulated kinase 1/2 
EtOH ethanol 
FACS fluorescence activated cell sorting 
Fam132b gene encoding erythroferrone 
FCS fetal calf serum 
FDB fluorescence dilution buffer 
Fe-NTA ferric nitrilotriacetate 
FPN ferroportin 
Fpn1 ferroportin 1 
Fs frameshift 
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
GATA1 GATA-binding factor protein 1 
GDF15 growth differentiation factor 15 
Gln glutamine 
Gly glycine 
GPI glycophosphatidylinositol 
xxi 
GWAS genome wide association studies 
Gypa glycophorin A 
H&E haematoxylin & eosin 
HAMP hepcidin 
HEK human embryonic kidney cells 
HEK293T human embryonic kidney 293T cells 
Hep3B human hepatoma 3B cells 
HepG2 human hepatoma G2 cells 
HGF hepatocyte growth factor 
HH hereditary haemochromatosis 
HIF hypoxia-inducible factor 
His histidine 
HJV hemojuvelin 
Hmbs hydroxymethylbilane synthase 
holo-TF holo-transferrin 
Hprt hypoxanthine-guanine phosphoribosyltransferase 
HRE HIF-responsive element 
HRP horse radish peroxidase 
HSC haematopoietic stem cell 
ID1 inhibitor of DNA binding 1 
IF immunofluorescence 
IFNγ interferon γ 
IgG immunoglobulin G 
IL1r interleukin 1 receptor 
IL interleukin  
Ile isoleucine 
Ins insertion 
IRE iron-responsive elements 
IREG1 iron-regulated gene 1 
IRIDA iron-refractory iron-deficiency anaemia 
IRP iron-responsive element-binding protein 
I-SMAD inhibitor-sma and mothers against decapentaplagic 
homologue 
JAK Janus kinase 
K562 erythroleukaemic cell line 
xxii 
KC Kupffer cells 
KO knockout 
LEAP1 liver expressed antimicrobial peptide 1 
Leu leucine 
LPS lipopolysaccharide 
LSEC liver sinusoidal endothelial cells 
Lys lysine 
MAPK mitogen-activated protein kinase 
MDCK Madin-Darby canine kidney cells 
MEL murine erythroleukaemic cells 
Met methionine 
Mg milligram 
MHC major histocompatibility complex 
M-KO TfR2f/f/LysM-Cre+/- 
mTOR mechanistic target of rapamycin 
MTP1 metal transport protein 1 
ND neurodegenerative disorders 
NFκB nuclear factor-κB 
NPC non-parenchymal cells 
NTBI non transferrin-bound iron 
PBS phosphate-buffered saline 
PBSCM phosphate-buffered saline with calcium and magnesium 
PCR polymerase chain reaction 
PD Parkinson’s disease 
PDGF-BB platelet-derived growth factor-BB 
PFA paraformaldehyde 
PHD prolyl-4-hydroxylase domain 
PHZ phenylhydrazine 
PI3K phosphoinositide 3-kinase 
PLA proximity ligation assay 
Polr2a DNA-directed RNA polymerase subunit 2a 
Pro proline 
pSMAD1/5 phosphorylated SMAD 1/5 
pSTAT3 phosphorylated STAT3 
QIMRB QIMR Berghofer Medical Research Institute 
xxiii 
qRT-PCR quantitative real-time PCR 
RAS rat sarcoma homologue 
RBC red blood cell 
rEPO recombinant erythropoietin 
RGM repulsive guidance molecule 
RGMB repulsive guidance molecule B 
rIL22 recombinant interleukin 22 
RNA ribonucleic acid 
R-SMAD receptor-SMAD 
RT room temperature 
SCF stem cell factor 
SDS  sodium dodecyl sulphate 
SDS-PAG sodium dodecyl sulphate-polyacrylamide gel 
Ser serine 
SHC src homology 2 domain containing protein 
SLC11A3 solute carrier family 11 (proton couple divalent metal ion 
transporter) member 3 
SLC40A1 solute carrier family 40 (iron-regulated transporter) 
member 1 
SMAD sma and mothers against decapentaplegic homologue 
SNP single nucleotide polymorphism 
STAT signal transducer and activator of transcription  
STEAP3 six transmembrane epithelial antigen of prostate 3 
TBS tris-buffered saline 
TEMED 1,2-ethanediamine,N,N,N',N'-tetrametyl-1,2-
bis(dimethylamino)ethane 
TF transferrin 
TFR1 transferrin receptor 1 
TFR2 transferrin receptor 2 
TGFB transforming growth factor beta 
Thr threonine 
TIBC total iron binding capacity 
TLR toll-like receptor  
TMPRSS6 transmembrane serine  
TNF tumour necrosis factor 
xxiv 
TNFα tumour necrosis factor alpha 
Trp tryptophan 
TTSP type II transmembrane serine protease 
TWSG1 twisted gastrulation BMP signalling modulator 1 
Tyr tyrosine 
UIBC unsaturated iron binding capacity 
UTR untranslated region 
VHL von Hippel-Lindau protein 
V-KO TfR2Δ/f/Vav-Cre+/- 
WHO World Health Organisation 
WT wildtype 
WT-Fe wildtype mice fed an iron-rich diet 
β2M β2-microglobulin 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1   
Introduction 
Introduction 
 
2 
1.1 Iron and its importance 
Iron is an important element which is required as a cofactor for many enzymes and proteins 
involved in diverse metabolic and physiological functions. These include deoxyribonucleic acid 
(DNA) repair (Fanconi J , mutY homolog), electron transport (cytochrome c, cytochrome c oxidase, 
cytochrome b), oxygen transport (haemoglobin, myoglobin), cell signalling (soluble guanylate 
cyclase), nucleic acid processing (phosphoribosyl-pyrophosphate amidotransferase), DNA 
replication (DNA primase, elongation protein 3), metabolic enzymes (dehydrogense, lipoate 
synthase), and free radical production (catalases, peroxidases) (Pantopoulos et al., 2012). 
The diverse functions of proteins requiring iron as a cofactor indicate that it is essential for a 
number of important cellular and physiological processes. Central to all these functions is the ease 
with which iron undergoes oxidation and reduction reactions. The variety of cellular functions in 
which iron is involved also suggests that the amount of bioavailable iron is important and the body 
needs to regulate its levels appropriately. 
A deficiency of iron leads to anaemia, which is one of the main nutritional deficiencies in the world 
and affects up to two billion people worldwide, according to the World Health Organisation (WHO) 
(http://www.who.int/nutrition/topics/ida/en/). Affected individuals have impaired erythropoiesis and 
develop symptoms such as hair loss (alopecia), fatigue and impaired immune functions. 
An excess of iron is also detrimental to the health of an individual, as it leads to the production of 
free radicals through Fenton chemistry. These free radicals can cause damage to proteins, lipid 
membranes and nucleic acids (Lloyd and Phillips, 1999; McCord, 1998). 
1.1.1 Iron metabolism 
The liver plays a central role in the systemic regulation of iron. In addition, it also acts as a store for 
excess iron which is stored in hepatocytes. In its regulatory role the liver serves as the sensor of 
body iron levels; in response to changes in iron levels it modulates the signal which controls the 
efflux of iron from the sites of absorption (duodenum) or recycling (macrophages). 
Erythroid precursor cells in the bone marrow act as the major site for iron usage. The observation 
that both humans and mice with defects in transferrin develop severe hypochromic and microcytic 
anaemia emphasises the dependency of haemoglobin synthesis on transferrin-mediated iron 
transport (Bartnikas et al., 2011). It has been shown both in vivo and in vitro that transferrin is the 
only known physiologically active chelator that can provide the erythroid precursors with iron 
(Ponka, 1997). It would thus be logical if this site would relay signals to the liver to ensure that 
enough iron was available in the plasma to keep erythropoiesis operational; the molecular details of 
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this signal are still unknown although a number of potential ‘erythroid regulators’ have been 
proposed (Kautz et al., 2014; Tanno et al., 2007; Tanno et al., 2009). 
 
Figure 1.1 Systemic regulation of iron metabolism. A schematic representation of the main 
organs involved in the absorption (duodenum of the small intestine), storage (liver), recycling 
(reticuloendothelial macrophages of spleen), and utilisation (bone marrow) of iron in the body. 
Normal iron content (humans) of different organs and the amount of daily iron usage and flux are 
also indicated. Adapted from (Hentze et al., 2004). 
1.1.3 Hereditary haemochromatosis 
The genetic iron overload disorder hereditary haemochromatosis (HH) is characterised by excess 
iron entry into the blood exceeding normal body iron requirements (Milder et al., 1980). This results 
in a gradual accumulation of iron in tissues and organs leading to their eventual dysfunction. The 
excess iron in subjects with HH deposits mainly in the parenchymal cells of the liver, pancreas, 
heart and pituitary gland (Babitt and Lin, 2011). Generation of reactive oxygen species by excess 
iron damages the tissues, ultimately leading to complications like cirrhosis, diabetes, 
cardiomyopathy, hypogonadism and arthropathy (Babitt and Lin, 2011). The analysis and 
observations made on patients suffering from this disorder have helped us to identify the molecules 
which play an important role in the regulation of iron metabolism. 
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HH is classified into various forms depending on the genes involved. Type I HH is the classical 
form and is caused by mutations in the HFE gene (Feder et al., 1996). The other forms of HH are 
collectively termed non-HFE HH, and they do not involve impairment in HFE function. Type IIA 
and IIB HH are more severe forms of iron overload which present early in life and are caused by 
mutations in the hemojuvelin (HJV) and hepcidin (HAMP) genes respectively (Papanikolaou et al., 
2004; Roetto et al., 2003). Type III HH subjects have mutations in the transferrin receptor 2 (TFR2) 
gene, a paralogue of transferrin receptor 1 (TFR1), the main receptor for transferrin-bound iron 
uptake (Camaschella et al., 2000). Type IV HH or ferroportin disease is characterised by mutations 
in the iron exporter ferroportin (SLC40A1) (Montosi et al., 2001). Although they have a varying 
degree of severity and present clinically at different ages, the first three types of HH have one 
common feature, low levels of the central regulator of iron homeostasis, hepcidin. 
1.2 Proteins involved in iron metabolism 
The absence of a defined mechanism to excrete excess iron from the body and the important 
physiological and cellular roles played by molecules containing iron makes it essential for the body 
to regulate iron levels. This regulation can be at the level of absorption (small intestine), stores 
(liver) or recycling (macrophages). The role of the regulating mechanisms is to maintain the levels 
of bioavailable iron in the body. The proteins that are involved in the uptake, storage, and efflux of 
iron all play an important role in this regulation. The following section is a general introduction to 
the different proteins and their roles in systemic iron metabolism and its regulation. 
1.2.1 Ferritin 
A majority of the iron present in living organisms is in a tight complex with proteins but some of it 
also circulates as a soluble pool in the bodily fluids in the form of low molecular weight molecules 
such as ferric citrate or ferric adenosine triphosphate (Fe-ATP) (Weaver and Pollack, 1989). The 
free iron is harmful, as it gives rise to extremely reactive hydroxyl radicals according to the Harber-
Weiss reaction (equation 3), as shown in equations 1 and 2 (also known as Fenton’s reaction)  
   Fe3+ + O2. -      Fe2+ + O2  (1) 
   Fe2++ H2O2  Fe3+ + OH- + OH. (2) 
   O2- + H2O2 O2+ OH- + OH. (3) 
The free hydroxyl radical is highly reactive and causes lipid peroxidation, DNA strand breaks and 
degradation of other biomolecules (Lloyd and Phillips, 1999; McCord, 1998). In order to protect the 
cells from these toxic effects of iron, vertebrates have two proteins which bind to iron in the ferric 
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(Fe3+) form - extracellular transferrin and intracellular ferritin. The major site of storage for iron is 
intracellular and bound to ferritin; whereas transferrin-bound iron is the usual mode for transport 
around the body. 
Ferritin functions as the main iron storage protein in most mammalian tissues. It is composed of 24 
polypeptide subunits with a collective molecular weight of approximately 500 kDa and can bind up 
to 4,500 iron atoms (Harrison and Arosio, 1996). Ferritin consists of two types of subunits: light 
chain or L-ferritin and heavy chain or H-ferritin (Harrison and Arosio, 1996). L-rich ferritins are 
involved in long term storage of iron and found in organs primarily concerned with this function, 
namely liver and spleen (Harrison and Arosio, 1996). The H-rich ferritins are characteristic of 
organs like the heart and brain and have low iron content (Harrison and Arosio, 1996). 
The different mechanisms and molecules that regulate levels of ferritin include regulation at the 
transcriptional level (tumour necrosis factor (TNF), cyclic adenosine monophosphate (cAMP), 
haematopoietic differentiation, oxidative stress), post-transcriptional regulation by iron regulatory 
proteins (IRPs) and molecules like interleukin 1β (IL1β) (Torti and Torti, 2002). Ferritin levels are 
regulated at a post-transcriptional level in response to the labile iron pool (Torti and Torti, 2002). 
When iron levels are low the synthesis of ferritin drops, whereas an increase in the labile iron pool 
results in increased synthesis (Torti and Torti, 2002). This control is brought about by a well 
conserved mechanism which also regulates other proteins involved in iron metabolism (for example 
TFR1): the iron regulatory element-iron regulatory protein (IRE-IRP) system. 
The IRE-IRP system is mediated by the binding of the RNA binding proteins (IRPs) to a conserved 
sequence in the 5’ or the 3’ untranslated region (UTR) of the mRNA, thus either inhibiting 
translation or stabilising the mRNA (Rouault, 2006). This conserved sequence in the RNA is known 
as the iron responsive element (IRE) and forms a stem loop structure to which the IRPs bind 
(Rouault, 2006). Ferritin has an IRE in the 5’UTR hence in iron deficient conditions the IRP binds 
to the IRE thus inhibiting translation, whereas in iron-replete conditions ferritin and other genes 
which have an IRE in the 5’UTR of their mRNA get freely translated (Rouault, 2006). 
The two IRPs are themselves regulated in different ways. In the presence of abundant iron IRP1 
functions as an aconitase but when iron is scarce it loses the iron-sulphur cluster and binds to IREs. 
IRP2 gets degraded in the presence of high levels of iron but when iron is scarce it is stabilised and 
binds to the IREs (Rouault, 2006). The exact mechanisms governing the iron-mediated regulation of 
IRP2 are not completely understood (Rouault, 2006).  The extra cysteine-rich exon referred to as 
the iron-dependent degradation domain is thought to be responsible for the iron-mediated 
degradation of ferritin as it can facilitate iron-dependent oxidation (Iwai et al., 1998), ubiquitination 
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and proteasomal degradation (Guo et al., 1995; Iwai et al., 1995), whereas other studies have 
questioned the role of this domain (Bourdon et al., 2003; Wang et al., 2004) (reviewed in (Rouault, 
2006)). 
In addition to its role as an iron sequestering protein, a recent study suggested that ferritin plays a 
more direct role in regulating iron metabolism by influencing the expression of the iron regulatory 
hormone hepcidin (Feng et al., 2012). It was shown that ferritin bound to iron can induce bone 
morphogentic protein 6 (BMP6) production in non-parenchymal cells of the liver (stellate cells, 
Kupffer cells and endothelial cells) (Feng et al., 2012). 
1.2.2 Transferrin 
Transferrin (TF) belongs to a family of iron binding glycoproteins that include lactoferrin and 
ovotransferrin (Lambert, 2012). It was discovered in 1946 by Schade and Caroline (Schade and 
Caroline, 1946). Along with ferritin it is one of the major proteins involved in iron sequestration 
and thus protecting the body from the damaging effects of excess free iron. Transferrin can strongly 
and reversibly bind to iron. Each transferrin molecule can bind two ferric (Fe3+) ions. This 
sequestration serves three principle functions (Gkouvatsos et al., 2012). 
i) Maintaining Fe3+ in a soluble form under physiological conditions. 
ii) Helping in transport of iron via bodily fluids and facilitating cellular uptake of iron via 
receptors. 
iii) Preventing the body from the harmful effects of Fe3+ by keeping it in an inert state. 
Patients with a TF deficiency have a rare disorder called congenital 
atransferrinemia/hypotransferrinemia which is characterised by microcytic and hypochromic 
anaemia (Bartnikas, 2012). A mouse model representing the human condition, the 
hypotransferremic (hpx) mouse, is characterised by low levels of TF caused by a splice defect in the 
Tf transcript (Trenor et al., 2000). In addition to its role in the transport and sequestration of iron it 
is also believed that TF regulates hepcidin in an erythropoiesis-dependent and independent manner 
(Bartnikas et al., 2011). 
1.2.3 Transferrin receptor 1 (TFR1) 
The primary receptor for the uptake of TF-bound iron in mammals is the ubiquitously expressed 
TFR1. Similar to many other genes involved in iron metabolism, TFR1 is also regulated by the IRE-
IRP system due to the presence of IREs in its 3’ UTR. In conditions of iron deficiency IRPs bind to 
these IREs thus stabilising the transcript and leading to an increase in protein production (Klausner 
et al., 1993). 
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The uptake of TF by TFR1 has been shown to take place through a high affinity receptor- mediated 
endocytosis pathway which is dependent on the pH and iron status of transferrin. The affinity of 
TFR1 for diferric TF (holo-TF) is greater at the extracellular pH of 7.4, hence it preferentially binds 
to holo-TF (Dautry-Varsat et al., 1983; Morgan, 1983; Young et al., 1984). This complex is then 
internalised via a clathrin-coated vesicle, which is mediated by adaptor protein complex-2 (AP2) 
(Conner and Schmid, 2003). Once internalised the vesicle loses its clathrin coat and gets converted 
into a sorting endosome. An ATP-dependent proton pump then reduces the pH of the endosomes 
(Paterson et al., 1984; van Renswoude et al., 1982); at this acidic pH iron is released from the TF 
complex. TF without iron (apo-TF) and TFR1 are then recycled to the plasma membrane, where TF 
dissociates from TFR1 at the extracellular pH. Within the endosomes of the erythroid precursors 
iron is reduced from Fe3+ to Fe2+ through a ferri-reductase, six transmembrane epithelial antigen of 
the prostrate 3 (STEAP3) (Ohgami et al., 2005) and is transported across the endosomal membrane 
by divalent metal transporter 1 (DMT1). This cytosolic iron is then stored in complex with ferritin 
as explained above, or utilised by the cell for various metabolic processes. 
1.2.4 Transferrin receptor 2 (TFR2) 
TFR2 was cloned independently by two groups. Glockner et al. (Glockner et al., 1998) cloned a 
large portion of human chromosome 7 which contains TFR2 and other important genes such as 
erythropoietin . In a second study Kawabata et al. (Kawabata et al., 1999), in an attempt to identify 
new transcription factor coding genes, cloned TFR2 and found that it coded for two transcripts, the 
α-and the β-form (Kawabata et al., 1999). The α-form has 18 exons and encodes an 801 amino acid 
type II transmembrane protein. The protein has an amino-terminal cytoplasmic domain, a 
transmembrane domain and a carboxy-terminal extracellular domain (Kawabata et al., 1999). The 
β-form lacks exons 1-3 which encode the cytoplasmic, the transmembrane and a part of the 
extracellular domain of the protein, and is thought to be a soluble form of TFR2 protein similar to 
the soluble form of TFR1 (Kawabata et al., 1999). 
The extracellular domain of TFR2 has a high degree of homology with TFR1 (66% similarity and 
45% identity) (Kawabata et al., 1999). Despite the structural similarity between the two transferrin 
receptors, they are different from each other in many ways. Similar to TFR1, TFR2 binds to holo-
TF in a pH-dependent manner but with ~20-fold lower affinity (Kawabata et al., 2000; West et al., 
2000). It was suggested that TFR2 could be involved in the uptake of non-TF bound iron (NTBI), as 
a knockdown of TFR2 in  Chinese hamster ovary (CHO) cells inhibited NTBI uptake (Graham et 
al., 2008) The expression patterns of the two proteins are also significantly different, with TFR1 
being ubiquitously expressed in all tissues, while TFR2 mRNA was found to be highly expressed in 
the liver and to a lesser extent in spleen, lung, muscle, prostate and peripheral blood  mononuclear 
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cells (PBMCs) (Kawabata et al., 2000; Kawabata et al., 2001a; Kawabata et al., 2001b). Although 
both the transferrin receptors bind to holo-TF with different affinities their functions are not 
redundant. TfR1 knockout mice are embryonic lethal, dying of severe anaemia and irregular 
development of the nervous system (Levy et al., 1999), whereas mice with a mutation or knockout 
of TfR2 survive and develop iron overload (Drake et al., 2007; Fleming et al., 2002; Wallace et al., 
2005). 
TFR1 and TFR2 are also regulated differently. Where TFR1 is regulated post-transcriptionally by 
intracellular iron levels through the IRE-IRP system due to the presence of IREs in its 3’ UTR 
(Klausner et al., 1993), TfR2 does not have any IREs  (Kawabata et al., 1999) and mice fed on a 
high iron diet did not show any change in the mRNA levels of hepatic TfR2 (Fleming et al., 2000). 
The detection of TFR2 mutations in patients with non-HFE iron overload (Camaschella et al., 2000) 
indicated that the product of this gene has an important role to play in the regulation of iron 
metabolism rather than the uptake of iron itself. Subsequent studies with mice: TfR2 mutant mice 
(Drake et al., 2007; Fleming et al., 2002), TfR2 knockout mice (Wallace et al., 2005) and mice with 
a hepatocyte-specific knockout of TfR2 (Wallace et al., 2007), confirmed that a disruption of TfR2 
function leads to iron overload. 
1.2.5 Haemochromatosis protein (HFE) 
HFE was first identified in 1996 using linkage disequilibrium and haplotype analysis (Feder et al., 
1996) as the gene responsible for or mutated in HH. HFE is a member of the major 
histocompatibility complex (MHC) class 1 family of proteins, which are involved in the 
presentation of antigens to T-cells. Similar to other members of the family, HFE is composed of 
three extracellular domains (α1, α2 and α3). It is highly expressed in tissues which are involved in 
iron metabolism, namely liver (hepatocytes, Kupffer cells) (Bastin et al., 1998; Zhang et al., 2004), 
in the crypts of Leiberkuhn of duodenum (Parkkila et al., 1997b) and in resident tissue macrophages 
and circulating monocytes (Parkkila et al., 1997a). The development of iron overload in the Hfe 
knockout mouse confirmed that the product of this gene plays an important role in iron metabolism 
(Zhou et al., 1998). 
HFE interacts with β2-microglobulin (β2M) through its α3 domain which is responsible for the 
proper cell surface expression of the protein (Feder et al., 1997). The most common mutation in 
HFE, p.C282Y, disrupts this interaction, consequently leading to iron overload (Feder et al., 1997; 
Waheed et al., 1997). HFE was shown to interact with TFR1 (Feder et al., 1998; Lebron et al., 
1998; Parkkila et al., 1997a). The binding site of HFE with TFR1 overlaps with the site for TF 
binding, suggesting that HFE competes with transferrin for TFR1 binding and that this interaction 
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plays an important role in iron homeostasis. An increase in iron levels increases the TF saturation 
which makes more holo-TF available to bind to TFR1, thus interrupting the HFE-TFR1-β2M 
complex (Feder et al., 1998). In agreement with the proposed importance of this interaction it was 
shown that a constitutive binding of HFE to TFR1 in mice leads to an inability of HFE to regulate 
iron levels and development of iron overload (Schmidt et al., 2008). 
1.2.6 Ferroportin (FPN) 
In 2000, three different groups working independently identified the only known molecule 
responsible for the export of iron from the cell, in mouse and zebrafish (Abboud and Haile, 2000; 
Donovan et al., 2000; McKie et al., 2000). Ferroportin (FPN) is also known as the solute carrier 
family 40 (iron-regulated transporter) member 1(SLC40A1), iron regulated gene 1 (IREG1), solute 
carrier family 11 (proton-coupled divalent metal ion transporter) member 3 (SLC11A3) and metal 
transport protein 1 (MTP1). FPN is found in all cell types that are involved in exporting iron: 
duodenal enetrocytes, hepatocytes, macrophages, and placental syncitiotrophoblasts. 
The mRNA of FPN has a 5’ IRE which indicates that its levels are directly regulated by iron levels 
through the IRE-IRP system. McKie et al (McKie et al., 2000) showed that FPN when expressed in 
Madin-Darby canine kidney (MDCK) cells (a polarised epithelial cell line), was found to localise 
on the basolateral surface of the cells. It was also shown that expression of this molecule regulates 
the efflux of iron in Xenopus oocytes (McKie et al., 2000). An overexpression of FPN in human 
embryonic kidney 293T (HEK293T) cells resulted in the binding of IRP1 to IREs, an indicator of 
iron depletion in the cells (Abboud and Haile, 2000). The effect of iron levels on FPN expression is 
different in enterocytes and Kupffer cells. In enterocytes, the levels of FPN increase with iron 
deprivation, whereas Kupffer cells show a decrease in FPN expression in conditions of iron 
depletion (Abboud and Haile, 2000). Subsequently it was shown that mutations in the FPN gene 
cause a different form of autosomal dominant haemochromatosis (Montosi et al., 2001; Njajou et 
al., 2001). 
1.2.7 Hepcidin (HAMP) 
In 2000, an antimicrobial peptide named liver expressed antimicrobial peptide 1 (LEAP-1) or 
hepcidin anti-microbial peptide (HAMP) was identified by two groups independently and shown to 
play a major role in iron homeostasis (Krause et al., 2000; Park et al., 2001; Pigeon et al., 2001). 
The word hepcidin was derived from two roots- ‘hep’- pertaining to the tissue of origin and ‘cidin’- 
due to its bactericidal properties. 
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HAMP is a 25 amino acid peptide synthesised predominantly in hepatocytes as an 84 amino acid 
pre-pro-peptide which undergoes processing and secretion (Valore and Ganz, 2008). Humans and 
mice with mutations in HAMP develop iron overload (Roetto et al., 2003). It is now known that 
patients with HH type I, IIA and III also have low hepcidin levels relative to body iron stores. These 
observations and many other studies have now confirmed that hepcidin is the master regulator of 
iron metabolism. It is important to note that the mouse genome contains two highly similar 
(paralogous) hepcidin genes, hepcidin 1 and hepcidin 2. The official symbols for these genes are 
Hamp and Hamp2 respectively and are referred to as such throughout the thesis. Unlike the Hamp 
knockout mice the Hamp2 knockout mice did not show any abnormalities in iron metabolism (Lou 
et al., 2004), suggesting that Hamp2 does not act in a similar way to Hamp (Lou et al., 2004). 
Hepcidin is a negative regulator of iron stores; in response to high iron levels in the serum, hepcidin 
synthesis in the liver increases to relay a signal to the sites of absorption (enterocytes), recycling 
(macrophages of the reticuloendothelial system) or storage (hepatocytes) leading to a decrease in 
the release of iron into the blood. 
 
Figure 1.2 Hepcidin mediated regulation of iron homeostasis. Hepcidin-mediated regulation of 
iron homeostasis in disease and normal states. (A) Stimuli like inflammatory cytokines lead to an 
increased production of hepcidin. An increase in production of hepcidin leads to increased 
internalisation and degradation of FPN, decreasing blood iron levels and transferrin saturation. (B) 
In a normal state the levels of iron regulate hepcidin expression and release of iron from the 
enterocytes through FPN. (C) Haemochromatosis, results from insufficient hepcidin levels, causing 
increased iron import into plasma, high transferrin saturation, and excess iron deposition in the 
liver. Adapted from (De Domenico et al., 2007a). 
As shown in Figure 1.2 hepcidin exerts its control over iron homeostasis by regulating the export of 
iron from cells, this is mediated by its action on the iron exporter FPN. It was shown in cell model 
systems that hepcidin binds to FPN and induces its internalisation and degradation (Nemeth et al., 
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2004b). Initially it was thought that this process involved serial phosphorylation of tyrosine residues 
Y302/Y303 by Janus kinase 2 (JAK2) (De Domenico et al., 2007b). More recently it has been 
shown that this process requires ubquitination of lysines 240 and 258, which fall in a lysine-rich 
region, in order for hepcidin to induce internalisation of FPN (Qiao et al., 2012; Ross et al., 2012). 
Treatment of macrophages or macrophage-like cell lines (THP-1) with hepcidin induces a rapid 
degradation of FPN within 1-4 hours post treatment; the same observation was made in the spleens 
of mice (Chaston et al., 2008). On the other hand in a cell line used as a model system for intestinal 
enterocytes (Caco-2) and in mouse duodenum, ferroportin levels were not affected by a similar 
acute hepcidin administration (Chaston et al., 2008). The two possible reasons that were proposed 
were the presence of tissue-specific temporal kinetics of hepcidin action where the ferroportin in the 
enterocytes required more time or a chronic exposure to hepcidin, whereas the response of the 
macrophages was more rapid (Chaston et al., 2008). Secondly this could be attributed to the 
presence of different tissue-specific isoforms or splice variants of FPN which respond differently to 
hepcidin (Chaston et al., 2008). These observations warrant further studies into the mode of action 
of hepcidin on FPN as this is the most important interaction which regulates the release of iron into 
the blood stream. 
1.2.8 Hemojuvelin (HJV) 
The HFE2 gene, which encodes for the protein hemojuvelin (HJV) was identified in 2004 as a 
result of positional cloning in patients with a severe form of iron overload known as juvenile 
haemochromatosis (Papanikolaou et al., 2004). The protein belongs to the family of repulsive 
guidance molecules (RGM) and shares 50-60% amino acid identity and key structural features with 
RGMA and DRAGON (RGMB), hence it is also known as RGMC (Babitt et al., 2006). The protein 
product of this gene can either be cell membrane associated through a 
glycophosphosphatidylinositol (GPI) anchor or a soluble protein. A knockdown of HJV gene 
expression resulted in a corresponding decrease in hepcidin expression in the human hepatoma cell 
line Hep3B (Lin et al., 2005). Subsequent studies identified that HJV regulates hepcidin expression 
by acting as a co-receptor for the bone morphogenetic protein (BMP) receptors in the BMP-sma and 
mothers against decapentaplegic homologue (BMP-SMAD) pathway (Babitt et al., 2006; Kuns-
Hashimoto et al., 2008; Lin et al., 2007; Xia et al., 2008). The soluble and the GPI-anchored forms 
work in a reciprocal fashion. The GPI-anchored form provides a positive signal for the production 
of hepcidin through the BMP-SMAD pathway, whereas the soluble HJV competes with the BMP 
ligands and results in decreased hepcidin signalling (Lin et al., 2005; Lin et al., 2008; Nili et al., 
2010). Initially it was suggested that HJV is required for iron sensing but in a recent study 
(Gkouvatsos et al., 2014) using Hjv-/- mice, which were fed a normal or an iron-rich diet, it was 
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shown that the animals responded to dietary iron by increasing hepcidin irrespective of the presence 
or absence of HJV suggesting that iron-dependent regulation of Hamp could function in the absence 
of HJV (Gkouvatsos et al., 2014). Previous studies (Ramos et al., 2011a) where Hfe-/-, TfR2-/-, and 
Hfe-/-/TfR2-/- mice were fed an iron-rich diet also showed that the animals respond to dietary iron 
changes by increasing Hamp (Ramos et al., 2011a). These results suggest that there appear to be 
more than one pathway involved in the regulation of hepcidin in response to iron levels (Ramos et 
al., 2011a). The response to acute and sudden changes in transferrin saturation (extracellular iron) 
seems to involve HFE and TFR2 which presumably sense the levels of transferrin saturation and 
increase the sensitivity of BMP receptors to iron levels (Ramos et al., 2011a). In response to chronic 
dietary iron overload Hfe-/-, TfR2-/-, Bmp6-/- and Hjv-/- mice all showed an increase in hepcidin 
mRNA levels (Ramos et al., 2011a). This suggests that in addition to BMP signalling there could be 
other pathways involved in regulating hepcidin levels in response to intracellular iron levels (Ramos 
et al., 2011a).  
 
1.2.9 Matriptase-2 (TMPRSS6) 
The gene encoding matriptase-2 was identified first as a result of in silico analysis performed in 
order to identify novel members of the type II transmembrane serine protease (TTSP) family of 
proteases (Velasco et al., 2002). Matriptase-2 also known as trans-membrane serine protease 6 
(Tmprss6) was identified by positional cloning as a molecule affecting iron homeostasis in mask 
mutant mice. The mask phenotype is characterised by alopecia affecting the whole body except the 
face, and results from reduced absorption of dietary iron. It was shown that this phenotype is due to 
a splicing defect in the Tmprss6 gene. It was also shown that mice with a disruption in the Tmprss6 
gene, including the mask mice, develop anaemia (Du et al., 2008; Finberg et al., 2008; Folgueras et 
al., 2008). In adult human and mouse tissues, Tmprss6 is primarily expressed in the liver, kidney 
and to some extent in the uterus as detected by in situ hybridisation (Hooper et al., 2003). 
TMPRSS6 cleaves membrane HJV at an external site (Silvestri et al., 2008b). The cleavage of HJV 
results in a disruption of BMP-SMAD signalling, leading to a decrease in hepcidin transcription. 
Patients with mutations in TMPRSS6 develop a rare form of anaemia known as iron-refractory iron-
deficiency anaemia (IRIDA) which is characterised by high levels of hepcidin due to a constitutive 
activation of the BMP-SMAD pathway, as the TMPRSS6 protein is unable to cleave HJV. 
The roles of the molecules described above in the regulation of iron metabolism, specifically in the 
signalling pathways regulating the levels of hepcidin, will be discussed in detail in the next section. 
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1.3 Regulation of hepcidin 
After it was discovered in 2000, it was soon demonstrated that hepcidin is at the centre of the 
systemic regulation of iron metabolism. Disorders where there is an imbalance or an improper 
hepcidin regulation result in a dysregulation of iron metabolism. Aptly it has been described as the 
‘master regulator’ of iron metabolism or the ‘iron hormone.’ 
Hepcidin acts as a negative regulator of iron stores; in response to increased iron levels, the liver 
increases hepcidin synthesis which then acts on the sites of absorption (enterocytes), storage 
(hepatocytes) or recycling (macrophages of the reticuloendothelial system) leading to a decrease in 
the release of iron from these tissues. 
As shown in Figure 1.2 hepcidin exerts its influence by binding to and inducing the internalisation 
of FPN, the only known iron exporter. Given that iron plays an important role in a variety of 
cellular, metabolic and physiological processes it is not surprising that hepcidin can be regulated in 
response to a wide range of external and internal stimuli. Some of the best studied stimuli include 
iron stores, TF saturation, hypoxia, and inflammation. In addition to this it is also known that 
erythropoiesis also regulates hepcidin levels, but the molecular details of this mechanism are still to 
be deciphered (Evstatiev and Gasche, 2012). 
This section is an attempt to describe the known and potential signalling molecules and pathways 
which are thought to influence hepcidin synthesis and hence iron metabolism. 
1.3.1 The role of HFE-TFR1-TFR2 
The control of hepcidin synthesis involves molecules that can sense either intra- or extra-cellular 
levels of iron and relay these messages through signal transduction to the nucleus for the control of 
hepcidin transcription. Central to this iron sensing mechanism are HFE, TFR1 and TFR2. It has 
been suggested that the interactions between these molecules are important for cells to sense the 
levels of holo-TF. With increasing levels of holo-TF, HFE is displaced from the HFE-TFR1 
complex and this separation is important for signalling that results in the transcription of hepcidin 
(Schmidt et al., 2008).The molecules responsible for the transduction of this signal have been 
proposed to be similar to those of the BMP-SMAD pathway. 
The current model of iron sensing proposes that when levels of holo-TF increase, the displaced HFE 
interacts with TFR2 and this interaction results in signalling to upregulate hepcidin mRNA 
expression. The interaction of HFE with TFR1 has been well characterised and the domains and 
amino acids responsible for this interaction have been mapped (Feder et al., 1998; Lebron et al., 
1998; West et al., 2001). West et al (West et al., 2000), however, failed to detect any interaction 
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between the extracellular domains of human HFE and TFR2 proteins. Subsequent studies (Gao et 
al., 2009; Goswami and Andrews, 2006), involving overexpression of HFE and TFR2 in different 
cell lines, alpha mouse liver 12 (AML12), human embryonic kidney (HEK) and CHO cells, showed 
an interaction between these two proteins. Chen et al (Chen et al., 2007) also demonstrated that the 
interaction with HFE regulates TFR2 levels in Hep3B cells. They also demonstrated that a chimeric 
TFR2 protein made up of amino acids 104-250 (resembling TFR2 Y250X protein, a mutant form of 
TFR2 which lacks most of the extracellular domain of the protein) is localised to the cell surface 
and interacts with HFE. More recently it was suggested that exogenous HFE, TFR2 and HJV all 
form a multi-protein complex on the cell membrane and the formation of this complex is essential 
for the response to holo-TF in HepG2 cells (D'Alessio et al., 2012). 
In contrast to these reports, studies using Hfe-/-/TfR2-/- double knockout mice (Delima et al., 2012; 
Wallace et al., 2009) and others using transgenic Hfe mice (Schmidt and Fleming, 2012) have 
suggested that TFR2 and HFE do not need to interact to regulate hepcidin synthesis. These 
opposing theories suggest that although we know that both HFE and TFR2 are required for the 
proper regulation of hepcidin levels in response to body iron levels as demonstrated by mouse 
models and human patients with mutations in these molecules, the exact molecular mechanism 
underlying this regulation is as yet undefined. 
1.3.2 The signalling pathways involved in hepcidin regulation 
The two most commonly studied pathways that influence hepcidin transcription are the BMP-
SMAD and the JAK-signal transducer and activator of transcription 3 (STAT3) pathways. The 
BMP-SMAD pathway is believed to be predominantly activated in response to changes in iron 
levels in the body whereas the JAK-STAT3 pathway is activated in response to inflammatory 
signals. 
BMPs belong to the transforming growth factor-beta (TGF-β) superfamily of cytokines. They have 
been shown to play crucial roles in development, cell proliferation, cell differentiation and 
apoptosis. Recent studies have established that the BMP-SMAD pathway has a central role in the 
regulation of hepcidin expression in response to body iron levels. Mice with hepatocyte-specific 
knockout of Smad4 develop a severe total body iron overload and have reduced hepatic hepcidin; 
this was the first study that linked the TGF-β superfamily signalling with iron metabolism (Wang et 
al., 2005). 
To date, more than 20 different BMPs have been identified with varying tissue expression profiles 
and functions. The BMPs function by binding to their specific receptors, which are divided into two 
separate groups; BMP receptor (BMPR) type I and type II. The receptors can either form weak 
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homodimers or very strong affinity heterodimers. The type II receptors are constitutively active and 
the coming together of type I and II leads to the activation and phosphorylation of the type I subunit 
of the complex. This phosphorylated type I subunit then activates a signalling cascade through the 
subsequent phosphorylation of the intracellular messengers of BMP signalling. Although the 
intracellular signalling components of this pathway vary according to the cell type and the function 
to be performed by the BMPs, the majority of the signalling is carried out by proteins belonging to 
the SMAD family of proteins, reviewed in (Parrow and Fleming, 2014). 
SMADs are divided into three groups, reviewed in (Massague et al., 2005): 
a. Receptor SMADs (R-SMAD) - These are associated with the receptor complex and are 
phosphorylated upon ligand binding. They include SMAD1, 2, 3, 5 and 8. Typically 
SMAD2/3 are involved in the TGF-β, activin and nodal receptor signalling pathways and 
SMAD1/5/8 are involved in the BMP and anti-Mullerian receptor pathways. Although there 
have been some reports of crosstalk between these two pathways (Figure 1.3). 
b. Common mediator SMAD (co-SMAD) - Once the R-SMADs are phosphorylated they form 
a heterodimeric complex with the co-SMAD, which is common for all the R-SMADs and is 
named SMAD4. Once the R-SMADs and co-SMAD form a complex they are translocated to 
the nucleus where they either bind directly or through other transcriptional protein partners 
to promoter sequences in the DNA to mediate transcription of target genes (Figure 1.3). 
c. Inhibitory SMADs (I-SMADs) – These SMADs interfere with either the R-SMAD-receptor 
or the SMAD-SMAD interactions in order to inhibit the signalling cascade. SMAD6 and 7 
are the I-SMADs in mammals. 
The link between iron metabolism and the BMP-SMAD pathway was discovered in mice with 
hepatocyte-specific deletion of Smad4; these mice developed a severe iron overload which was 
more pronounced in the liver, kidney and pancreas (Wang et al., 2005). The livers of these mice had 
a 100-fold suppression of Hamp expression which suggested that SMAD4 is involved in the 
transcriptional regulation of Hamp. The proposed pathway was the TGF-β pathway, as the 
hepatocytes of the wildtype (WT) mice showed an increase in Hamp levels in response to treatment 
with TGFβ, whereas the response was abrogated in the Smad4-/- hepatocytes (Wang et al., 2005). 
The next breakthrough was made when it was shown that HJV acts as a co-receptor of the BMP 
receptors (Babitt et al., 2006), and that HJV acted through the BMP pathway rather than the TGF-β 
pathway, since the presence or absence of HJV did not affect the luciferase activity of a TGF β-
responsive promoter element (Babitt et al., 2006). Hepatocytes lacking HJV had a blunted response 
to BMP2 treatment, indicating that HJV acts through or plays a role in BMP-SMAD signalling 
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(Babitt et al., 2006). Treatment of primary hepatocytes from mice and a hepatoma cell line with 
BMP2, 4 and 9 could induce hepcidin transcription independently of Hfe, TfR2 or interleukin 6 (Il6) 
(Truksa et al., 2006). It was also suggested that BMP9 is the most potent stimulator of hepcidin 
(Truksa et al., 2006). In addition to this BMP5, 6 and 7 and TGFβ1, 2 and 3 could also induce 
hepcidin transcription to varying degrees (Babitt et al., 2007). Treatment of mice with BMP2 
increased the hepcidin levels in the liver and lowered serum iron levels (Babitt et al., 2007). All 
these results suggested that BMP-SMAD signalling was an important pathway in the regulation of 
iron homeostasis. 
 
 
Figure 1.3 SMAD family of proteins. SMAD1/5/8 act as receptor SMADs for BMP receptors 
whereas SMAD2/3 act as receptor SMADs for TGFβ receptors. Upon ligand binding with the 
receptors (BMPR/TGFβR) the receptor SMADs are phosphorylated, the phosphorylated receptor 
SMADs then form a complex with the co-SMAD (SMAD4). This complex is then translocated to 
the nucleus where it binds to the responsive elements in the genome to result in transcription of the 
target genes. Abbreviations- BMPs-bone morphogenetic proteins, BMPRI and BMPRII- BMP 
receptors I and II, SMAD-sma and mothers against decapentaplegic homologue, TGFβ-
transforming growth factor β, TGFβI and II- TGFβ receptors I and II.  
Bmp6 transcript levels increased concordantly with hepatic Hamp levels in response to dietary iron 
conditions suggesting that increases in iron levels initiate a Bmp6 response in the liver which then 
results in an increase in hepcidin levels (Kautz et al., 2008). Bmp6 null mice develop a rapid and 
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massive accumulation of iron in the liver (Meynard et al., 2009). The nuclei of the hepatocytes of 
Bmp6 null mice showed less phosphorylated SMAD1/5/8 (pSMAD1/5/8) staining as compared to 
WT mice fed a control diet or an iron-enriched diet (Meynard et al., 2009). SMAD1/5/8 are the 
downstream R-Smads for BMP-SMAD signalling and are phosphorylated upon ligand binding 
(BMP6) to the receptors (BMPRs), indicating that it is the defect in this signalling that is 
responsible for the dysregulation of hepcidin transcription. 
Bmp6 null mice had a similar degree of iron overload as the Hjv-/- mice, suggesting that in vivo 
BMP6 is the main ligand important for hepcidin regulation (Babitt et al., 2006; Meynard et al., 
2009). Mice treated with BMP6 exhibited a dose-dependent reduction in serum iron and transferrin 
saturation along with an increase in hepatic Hamp expression, indicating that BMP6 is required for 
proper Hamp transcription (Andriopoulos et al., 2009). 
The suggestion that the serine protease TMPRSS6 acts as an upstream regulator of the BMP-SMAD 
pathway in regulating the transcription of Hamp by cleaving HJV added another layer to this 
complex regulatory pathway (Silvestri et al., 2008b). It had already been shown by this time that 
patients and mice with mutations in the TMPRSS6 gene develop IRIDA and have higher than 
normal levels of hepcidin (Finberg et al., 2008; Folgueras et al., 2008). 
Recent studies have proven that the BMP-SMAD pathway is the predominant pathway responsible 
for regulating the transcription of hepcidin in response to increases in iron levels in the body. 
Although there have been many studies defining the role of this pathway in the regulation of iron 
metabolism, the molecular details of how an increase in hepatic iron concentration (as proposed by 
(Corradini et al., 2011a)) or serum iron levels regulate the production of BMP6 are not known. Hfe 
and TfR2 knockout mice have a dysregulation in the BMP-SMAD signalling pathway (Corradini et 
al., 2011b; McDonald et al., 2014), which suggests that both HFE and TFR2 play a role in this 
pathway, however, the molecular details of the roles of these two proteins are not known. 
The liver is a heterogeneous organ comprised of different cell types, of which hepatocytes form 
approximately 70% of the cells and the rest is comprised of non-parenchymal cells (NPCs) 
including liver sinusoidal epithelial cells (LSECs), hepatic stellate cells and Kupffer cells (KCs) 
(Liu et al., 2011). A growing body of evidence suggests that the regulation of Bmp6 in response to 
increased iron is complicated. It was recently suggested that Bmp6 expression in response to serum 
iron is mediated by the NPCs (Enns et al., 2013) and that this could also be mediated by ferritin 
(Feng et al., 2012). Both studies showed that Bmp6 was predominantly produced in the NPCs, 
especially the LSECs and HSCs, suggesting that BMP6 could be acting in a paracrine fashion to 
regulate hepcidin in hepatocytes. It is known that hepatic cell lines do not respond to holo-TF 
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treatment by increasing expression of hepcidin (Gehrke et al., 2003; Nemeth et al., 2003), and 
results from these studies and a few others (Matak et al., 2009; Sasaki et al., 2014) have pointed to 
an interaction between different cell types in the liver. Sasaki et al. recently showed that when the 
human hepatoma derived cell line HepG2 was co-cultured with the human macrophage cell line 
(THP1) (with or without contact), they could induce expression of hepcidin mRNA and protein in 
response to holo-TF treatment. These studies suggest that the ‘iron sensing’ role could in fact be a 
function of the NPCs, which release a humoral, soluble factor, for example a cytokine like BMP6 in 
response to increased iron levels. This factor then initiates a cascade of events leading to the 
production of hepcidin in hepatocytes. Although this seems to be the likely mechanism the actual 
molecular mechanisms underlying the production of BMP6 in response to either serum iron or liver 
iron stores still remain unidentified. 
The second major signalling pathway known to play a role in the regulation of Hamp is the JAK-
STAT pathway; the stimulus for this regulation comes mainly through inflammatory cytokines. It 
was known that serum iron levels are lower in patients with chronic inflammation such as in the 
anaemia of chronic disease (ACD); the first insight into how this could be mediated was provided 
by the discovery of HAMP itself, where Pigeon et al (Pigeon et al., 2001). showed that treatment of 
hepatocytes with lipopolysaccharide (LPS) led to an increase in HAMP levels. Later, using human 
primary hepatocytes, it was shown that hepcidin is a type II acute phase protein, as it was induced 
by treatment with interleukin 6 (IL6) but not with type I response inducing cytokines like tumour 
necrosis factor α (TNFα) or interleukin 1α (IL1α) (Nemeth et al., 2003; Nemeth et al., 2004a). 
Further studies established that this response to inflammatory signals is not mediated by the KCs of 
the liver, where even after the inactivation of the KCs, the liver was able to induce an increase in 
Hamp in response to IL6 treatment (Lou et al., 2005). The response is mediated through the 
hepatocytes specifically, as mice with hepatocyte-specific deletion of Stat3 did not have an increase 
in Hamp levels after inflammation induced by repeated turpentine injections even though the serum 
IL6 levels increased (Sakamori et al., 2010). Evidence that the Hamp promoter has a STAT3 
binding site provided further molecular details into the mechanism of Hamp regulation in 
inflammation (Verga Falzacappa et al., 2007). 
The JAK-STAT pathway works in a similar way as the BMP-SMAD pathway where the binding of 
a cytokine ligand, e.g. IL6 to its receptor, induces a signalling cascade which results in the 
phosphorylation of STAT3. The phosphorylated STAT3 then translocates to the nucleus where it 
binds to tissue-specific transcription factors and co-factors to mediate the transcriptional activation 
or repression of target genes. In hepatocytes one of these target genes is Hamp. The increase in 
Hamp levels in response to infection seems to be a defence mechanism which has evolved to protect 
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the host from infections. Most micro-organisms require iron for their growth and proliferation, 
hence limiting the release of iron into the blood by increasing the levels of Hamp results in less iron 
availability for infectious agents. Indeed some recent studies have supported this hypothesis. It has 
been shown by our laboratory that increased iron stores result in a worse disease outcome in 
schistosomiasis (McDonald et al., 2010), and by others that iron deficiency leads to better survival 
rates in children with malaria (Gwamaka et al., 2012). Children with iron deficiency had decreased 
prevalence of parasitaemia, and severe malaria. 
There is some evidence suggesting crosstalk between the iron sensing and the inflammatory 
pathways. Initially it was suggested that HFE is required to mediate a hepcidin response, as HFE 
deficient mice were unable to increase hepcidin in response to LPS (Roy et al., 2004). Later studies 
suggested that HFE is not required for LPS and IL6 mediated increases in hepcidin transcription 
(Frazer et al., 2004; Lee et al., 2004). In a recent study published by our laboratory it was shown 
that mice lacking TfR2 alone or both TfR2 and Hfe have a decreased iron withholding response after 
an inflammatory stimulus (Wallace et al., 2011). This was attributed to lower levels of basal 
hepcidin. The low levels of hepcidin also correlated with increased FPN protein expression in the 
spleens of the TfR2 knockout and the double knockout mice (Wallace et al., 2011). Hjv levels 
decrease in response to LPS specifically in the liver (Krijt et al., 2004; Niederkofler et al., 2005; 
Pagani et al., 2011). It was suggested that LPS treatment suppresses the iron sensing machinery of 
the cell temporarily (Niederkofler et al., 2005), but this is contrary to what the body would require 
in cases of infection, where it would be expected to switch on the mechanisms to increase hepcidin 
production. It is also not known whether LPS affects other molecules in the iron sensing pathway as 
well. 
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Figure 1.4 Molecular regulation of hepcidin. A schematic representation of the molecules and 
pathways mediating the transcriptional regulation of hepcidin. This figure shows molecules 
predominantly involved in the iron or inflammation-mediated regulation of iron metabolism. 
BMPs-bone morphogenetic proteins, BMPR-I and -II- BMP receptors I and II, HFE-
haemochromatosis protein, HJV-hemojuvelin, IL-6-interleukin 6, IL-6R-IL6 receptor, JAK-janus 
kinase, SMAD-sma and mothers against decapentaplegic homologue, STAT3-signal transducer and 
activator of transcription 3, TFR1-transferrin receptor 1, and TFR2- transferrin receptor 2. 
1.3.3 The erythroid control of hepcidin 
One of the important functions of iron is as an essential component of the oxygen transporting 
proteins haemoglobin and myoglobin. Iron is crucial for the formation and maturation of red blood 
cells (erythropoiesis), and anaemia caused by dietary iron deficiency is one of the most common 
nutritional disorders in the world. This requirement for iron suggests that erythropoeisis itself is 
involved in regulating the amounts of bioavailable iron in the circulation. In initial studies in mice 
where erythropoiesis was suppressed by irradiation or post-transfusion polycythemia, a dramatic 
increase in Hamp levels was observed, indicating that erythropoiesis can suppress Hamp expression 
(Vokurka et al., 2006). This would be physiologically important for the body in cases of 
haemorrhage or haemolysis, where there is a rapid loss of blood and subsequently a huge increase 
in the demand for iron to increase erythropoiesis to alleviate the condition. In such a situation a 
constant influx and release of iron from the macrophages and the liver would be required to keep up 
with the demand. This can only be maintained if the physiological levels of Hamp are kept low. The 
erythroid regulation of Hamp synthesis is believed to override the regulation by iron stores, as seen 
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in patients with iron loading anaemias like thalassaemia, where a dysregulated erythropoeisis is able 
to suppress Hamp even in the presence of iron overload. 
One of the main signalling molecules that regulate erythropoiesis is erythropoietin (EPO); it is 
produced mainly in the kidney and is required for proper erythropoeisis, as it helps in the 
maturation and development of erythroblasts in later developmental stages (Richmond et al., 2005). 
When human subjects were treated with EPO the levels of circulating hepcidin decreased abruptly 
within 24 hours with the maximal suppression at 72 hours, this suggested that EPO can influence 
HAMP (Ashby et al., 2010). In mice treatment with inhibitors of erythropoiesis or with 
phenylhydrazine (PHZ) did not lead to a suppression of Hamp (Pak et al., 2006). These results 
suggested that although EPO can regulate Hamp, it cannot be the erythroid regulator. 
It was hypothesised that this erythroid factor is a molecule secreted by the erythroblasts, and 
microarray analysis of primary human erythroblasts was performed to identify the molecules that 
responded to this increased demand (Tanno et al., 2007). This study identified two potential 
erythroid regulators, growth differentiation factor 15 (GDF15) and twisted gastrulation BMP 
signalling modulator (TWSG1). GDF15 levels in patients suffering from symptomatic β-
thalassaemia were higher compared to normal controls (Tanno et al., 2007). On treating primary 
hepatocytes or human hepatoma cells (HuH7) with physiological levels of GDF15 the levels of 
HAMP increased to about 1.5-fold whereas at higher concentrations (similar to those found in 
patients with thalassemia) GDF15 was able to inhibit HAMP transcription. Similarly hepcidin was 
repressed in cells cultured in serum from thalassaemic patients (Tanno et al., 2007). 
The second molecule TWSG1 also inhibited HAMP synthesis in HuH7 cells and primary human 
hepatocytes in the presence of BMP2 and 4. In the case of primary murine hepatocytes the 
inhibition did not require BMPs. The TWSG1-mediated inhibition of hepcidin was suggested to be 
mediated by a reduction in the phosphorylation of SMAD1/5/8 (Tanno et al., 2009). Subsequent 
studies have shown that increased GDF15 levels are not correlated to a decrease in HAMP levels. 
Gdf15 knockout mice which were subjected to two consecutive phlebotomies and then sacrificed 
did not exhibit any differences in Hamp levels as compared to WT mice, these results suggested 
that either GDF15 is not the putative erythroid factor or its effects can be overcome by other 
pathways involved in hepcidin regulation (Casanovas et al., 2013). The studies mentioned here 
(Tanno et al., 2007; Tanno et al., 2009) have used HuH7 cells as a model, which were later on 
shown to be a  haemochromatotic cell line (Vecchi et al., 2010). TWSG1 (Tanno et al., 2009) and 
GDF15 (Tanno et al., 2007) were both shown to inhibit HAMP in HuH7 cells and primary 
hepatocytes which suggests that the mechanism of action of GDF15 and TWSG1 does not require a 
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functional HFE protein (absent in HuH7 cells (Vecchi et al., 2010)). This is of particular importance 
as it has been recently shown that Hfe knockout mice have enhanced erythropoeisis (Ramos et al., 
2011b) and that HFE can play an autonomous role in erythropoiesis by limiting iron uptake in 
erythroid cells (Ramos et al., 2011b). 
The most recent addition to the list of erythroid hepcidin regulators is the product of the Fam132b 
gene, named erythroferrone (ERFE), also known as myonectin or C1q/TNF-related protein family 
member 15 (CTRP15) (Kautz et al., 2014) which has been proposed to be the stress erythropoiesis- 
specific erythroid regulator (Kautz et al., 2014). Similar to GDF15 and TWSG1, ERFE is expressed 
in erythroblasts and after EPO treatment the mRNA levels of Fam132b increase only in the 
erythropoietic organs of adult mice (bone marrow and spleen) (Kautz et al., 2014). Mice lacking 
Fam132b have a blunted suppression of Hamp in response to phlebotomy compared to WT mice, 
suggesting that Fam132b is required for hepcidin suppression after blood loss (Kautz et al., 2014). 
The levels of Fam132b were increased in mouse models of β-thalassaemia intermedia, indicating 
that it could be playing a role in the suppression of hepcidin in anaemias with iron overload (Kautz 
et al., 2014). Although these results are promising they need to be verified in human patients. The 
molecular mechanisms of action of ERFE are still not known, although it appears that it is not 
modulated in response to iron and the BMP-SMAD pathway (Kautz et al., 2014). 
In a separate study it was proposed that the repression of HAMP in conditions of hypoxia, anaemia 
and erythropoeisis is through the transcription factor atonal homologue 8 (ATOH8) (Patel et al., 
2014). ATOH8 expression in HEK293T cells increased SMAD1/5/8 phosphorylation and HAMP 
levels (Patel et al., 2014). Mice treated with EPO, PHZ or exposed to hypoxia for 24 or 72 hours 
showed a decrease in Atoh8 mRNA and protein levels (Patel et al., 2014). Using chromatin 
immunoprecipitation (ChIP) it was shown that ATOH8 binds to the E-box elements in the HAMP 
promoter, hence ATOH8 can potentially regulate HAMP both directly (binding to the promoter) and 
indirectly (increasing the phosphorylation of SMAD1/5/8) (Patel et al., 2014). It would be 
interesting to know whether the effects of ERFE are modulated through this transcription factor or 
another pathway. 
In addition to having an effect on Hamp levels, erythropoeisis has also been shown to affect TfR1 
mRNA and IRP1 protein levels. The binding of EPO to EPO receptor (EPOR) results in the 
activation of JAK2 which in turn phosphorylates the cytoplasmic tail of EPOR (Richmond et al., 
2005). The activated phosphorylated tail of EPOR becomes a signal transducer for many other 
pathways such as STAT5 (Richmond et al., 2005). Once activated the phosphorylated STAT5 is 
then translocated to the nucleus where it leads to activation or repression of its target genes such as 
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c-myc. In Stat5 deficient mice the levels of cell surface TFR1 on erythroid cells is reduced (Zhu et 
al., 2008). It was suggested that the TfR1 gene has three STAT5 binding sites or interferon gamma 
binding sites (GAS elements) in the first intron (Zhu et al., 2008). DNA binding of STAT5 to all 
three of the binding sites confirmed that STAT5 is a transcriptional activator of TfR1 in response to 
EPO (Zhu et al., 2008). In addition to this, in erythroid cells lacking STAT5, the RNA binding 
capacity of IRP2 is reduced which is an additional cause for the reduction in TFR1 levels in 
erythroid cells (Kerenyi et al., 2008). 
Although these studies have contributed immensely to our understanding of the molecular 
mechanisms underlying EPO mediated regulation of hepcidin in response to erythroid drive, it is 
worth noting that none of them have been able to completely dissect the pathway. The exact nature 
of the erythroid regulator has yet to be identified, although Fam132b seems to be an interesting 
candidate, it has only been shown to be effective in mouse models and cell lines. It has yet to be 
confirmed that this molecule performs the same function in humans. Another complication is the 
effect that different erythropoietic disorders have on the system. It could be that a specific molecule 
functions in a particular disease setting, whereas it is non-functional in another scenario. In addition 
to this, the regulation switch between erythropoiesis and iron metabolism does not seem to work in 
one direction, very recent data suggests that the molecules involved in the iron-mediated regulation 
of hepcidin (namely Hfe and TfR2) could be involved in regulating erythropoiesis as well (Lee et 
al., 2012; Nai et al., 2014; Ramos et al., 2011b). 
1.3.4 Hypoxia and the hepcidin axis 
The main function of the iron contained in haemoglobin is to bind oxygen; hence the levels of tissue 
oxygen depend on the availability of iron to form haemoglobin. It has long been known that 
hypoxic conditions increase erythropoeisis (Cottrell et al., 1991). Similar to erythropoeisis it was 
shown that Hamp levels decrease in hypoxic conditions (Nicolas et al., 2002a). 
The main mediator of the hypoxic regulation of genes is the transcription factor, hypoxia inducible 
transcription factor (HIF) (Semenza, 2001). There are three known subunits of HIF: HIF1α (Tian et 
al., 1997), HIF2α (Ema et al., 1997; Flamme et al., 1997) and HIF3α (Gu et al., 1998). In the 
presence of oxygen these subunits are modified by the prolyl dehydrogenase (PHD) enzyme and 
subjected to proteasomal degradation by the tumour suppressor von Hippel-Lindau (VHL 
(Semenza, 2001). In oxygen deprived conditions PHD is inactivated leading to a stabilisation of the 
HIF subunits. The subunits then translocate to the nucleus and bind to the aryl hydrocarbon nuclear 
receptor translocator or HIF1β (ARNT/HIF1β) forming a heterodimer (Semenza, 2001). The 
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heterodimers then bind to hypoxia responsive elements (HREs) in the genomic DNA and regulate 
hypoxia specific target genes, one of which is EPO (Semenza, 2001). 
The first direct evidence for involvement of HIFs in the regulation of Hamp was provided in mice 
with a hepatocyte-specific deletion of Hif1α (Peyssonnaux et al., 2007). Unlike the WT mice, the 
knockout mice did not show a decrease in Hamp in response to iron deficiency or hypoxia 
(Peyssonnaux et al., 2007). The levels of HIF1α in WT mice with iron deficiency were also shown 
to be increased, indicating the importance of HIF1α in hypoxia mediated repression of Hamp 
(Peyssonnaux et al., 2007). Using ChIP it was shown that HIF1α binds to three putative HREs in 
the HAMP promoter and reduces HAMP expression in both human cells (HEK293 cells) and mouse 
liver tissues (Peyssonnaux et al., 2007). Hif2α is required for iron absorption, as Hamp KO mice 
lacking Hif2α in the intestinal epithelium developed iron deficiency characterised by low liver and 
serum iron levels (Mastrogiannaki et al., 2009). Contrary to these studies where there was a direct 
effect of HIF2α subunits on iron metabolism related proteins, another study suggested that the 
hepcidin response to hypoxia is not direct (Volke et al., 2009). Although Volke et al (Volke et al., 
2009) did get a reduction in Hamp levels in response to hypoxia, a knockdown of either Hif1α, 
Hif2α or both did not lead to an increase in Hamp levels. Interestingly, induction of hypoxia led to a 
decrease in TFR2 mRNA levels in human hepatoma cells (HepG2) and this correlated with the 
decrease in HAMP (Volke et al., 2009). 
Hypoxia also increases furin mRNA levels through HIF1α in HepG2 and Hepa1-6 (mouse 
hepatoma) cells (McMahon et al., 2005). Furin is a protease that was shown to cleave HJV in the 
endoplasmic reticulum to release soluble HJV (sHJV) (Silvestri et al., 2008a). sHJV is thought to 
act as an antagonist to BMP-SMAD regulation of hepcidin; it binds to BMPs and reduces the 
receptor-ligand interaction both in vivo and in vitro (Babitt et al., 2007). The levels of furin increase 
in hypoxic (McMahon et al., 2005) and iron-deficient conditions (Silvestri et al., 2008a) and it was 
hypothesised that this could be one of the indirect mechanisms of Hamp repression mediated by 
hypoxia (Silvestri et al., 2008a). Hypoxia also regulates the levels of Tmprss6 which as discussed 
above is a negative regulator of BMP-SMAD signalling (Lakhal et al., 2011). In hypoxic or iron-
deficient conditions the levels of TMPRSS6 mRNA increased in Hep3B cells, but this increase was 
not observed in cells where HIF1α was knocked down, suggesting this could be another indirect 
effect of HIF1α (Lakhal et al., 2011). The authors could not find a HRE in the promoter of the 
TMPRSS6 gene, however, one was later shown to be present in the genomic region upstream of the 
promoter at position -472 to -468 (Maurer et al., 2012). 
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Mice with a hepatocyte-specific deletion of Hif2α  were able to regulate hepcidin in response to iron 
deficiency indicating that hepatic Hif2α  is not required, but mice with a constitutively active HIF2α 
(Vhlh/Hif1α KO mice) had lower hepcidin levels in their livers (Mastrogiannaki et al., 2012). 
Contrary to the results by Silvestri et al. (Silvestri et al., 2008a) and Lakhal et al. (Lakhal et al., 
2011), there was no change in the mRNA levels of Tmprss6 and a decrease in the levels of furin in 
these mice (Mastrogiannaki et al., 2012). These results suggest that the reduction in Hamp mRNA is 
not due to a suppression of BMP-SMAD signalling in these mice (Mastrogiannaki et al., 2012). The 
authors also suggested that this repression is mediated through an increase in erythropoietic drive, 
as injection of the mice with EPO over five consecutive days increased Hamp mRNA levels 
(Mastrogiannaki et al., 2012). 
In human volunteers subjected to hypoxic conditions for 6 hours hepcidin levels decreased, the 
levels of other cytokines were also measured, and surprisingly IL6 levels increased in these subjects 
(Sonnweber et al., 2014). In addition to this an increase in platelet-derived growth factor (PDGF)-
BB was also observed (Sonnweber et al., 2014). There was a significant correlation between the 
increase in PDGF-BB and HAMP levels suggesting that PDGF-BB could be the hypoxic mediator 
of HAMP repression (Sonnweber et al., 2014). Treatment with EPO did not affect levels of PDGF-
BB suggesting that the increase in PDGF-BB is EPO independent (Sonnweber et al., 2014). 
Treatment of hypoxic mice with a PDGF receptor kinase inhibitor increased Hamp levels in mice, 
suggesting that hypoxia mediates this effect through the PDGF pathway (Sonnweber et al., 2014). 
PDGF-BB treatment of primary mouse hepatocytes and HepG2 cells transfected with hepcidin 
promoter-luciferase constructs resulted in decreased activity of the promoter (Sonnweber et al., 
2014). The hypoxic mice did not show any changes in the levels of pSMAD1/5/8 or pSTAT3, 
which indicates that the decrease in hepcidin levels in response to hypoxia is not mediated through 
these pathways. The hypoxic mice also had increased levels of CCAAT/enhancer binding protein 
alpha (C/EBPα), cyclic AMP response element binding protein (CREB) and CREB-H. PDGF-BB 
treatment of cells, where CREB-H was knocked down, was unable to repress Hamp, indicating that 
the downregulation of Hamp requires CREB-H (Sonnweber et al., 2014). 
These studies have added to our understanding about the effect of hypoxia on iron metabolism; it is 
now a widely accepted fact that hypoxia increases iron availability by reducing the levels of 
hepcidin. The studies mentioned above suggest that we are still unclear about the exact molecular 
mechanisms underlying this repression, whether it is a direct effect of hypoxia or an indirect 
consequence through the increased erythropoietic drive is still unclear. It is also unclear whether it 
is an effect mediated through HIF1α, HIF2α or both molecules. The observations that hypoxia can 
lead to a change in the transcript and protein levels of iron sensing molecules (TFR2, HJV and 
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TMPRSS6) also points to a deeper link between the hypoxic regulation of hepcidin and systemic 
iron regulation. 
1.3.5 Hormones and growth factors 
Hepatocyte growth factor (HGF) and epidermal growth factor (EGF) can effectively suppress the 
iron or BMP6 mediated induction of hepcidin (Goodnough et al., 2012), these two factors are also 
involved in liver regeneration. The exact mechanism of action was not clear, but the results of the 
experiments suggested that HGF can act in multiple ways (Goodnough et al., 2012). Addition of 
HGF suppressed the BMP-mediated activation of the hepcidin and inhibitor of DNA binding 
protein 1 (ID1) promoters in HepG2 cells, suggesting a direct effect of HGF and EGF on BMP 
pathway dependent transcriptional machinery (Goodnough et al., 2012). Although the levels of 
SMAD1/5/8 phosphorylation did not change, the amount of SMAD1/5/8 translocating to the 
nucleus was less in the cells treated with either HGF or EGF (Goodnough et al., 2012). There was 
also an increase in the amount of a known transcriptional repressor, transcriptional corepressor 
interacting protein (TGIF), which is known to affect the transcriptional effects of SMAD4 
(Goodnough et al., 2012). Only inhibition of the phosphatidylinositol-3-kinase pathway was 
effective in reversing the hepcidin inhibition of HGF, indicating that this pathway was required for 
effective suppression (Goodnough et al., 2012). Increased levels of HGF have been associated with 
a variety of liver diseases including acute and chronic hepatitis (Shiota et al., 1994; Shiota et al., 
1995). In addition, the levels of serum HGF were significantly higher in patients suffering from 
chronic hepatitis, liver cirrhosis or hepatocellular carcinoma (Funakoshi and Nakamura, 2003). It 
would be a clinically relevant question whether this decrease in the active form of HGF in cases of 
chronic liver injury relates to an increase in hepcidin levels and a consequent change in local iron 
levels in the livers of patients. This could lead to better management of patients suffering from these 
disorders. 
The third growth factor that has been added recently is PDGF-BB as discussed above. The molecule 
was shown to repress hepcidin in primary hepatocytes and human cell lines. The serum levels of 
PDGF-BB also increase with hypoxia. Interestingly inhibition of the PDGF pathway has been 
shown to be beneficial in mice with fibrotic livers (Campbell et al., 2005; Hao et al., 2012). It 
would be interesting to measure the levels of PDGF in patients who have other forms of chronic 
liver injury, which can be related to altered hepcidin levels. Both of these molecules seem to be 
good candidates to target elevated hepcidin levels specifically as has been shown in the studies 
mentioned above. It remains to be seen whether the inhibitors are as effective in humans as they 
have been in mice. 
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It has been known that iron levels in postmenopausal women are higher as compared to 
premenopausal women (Jian et al., 2009), until recently, this was attributed to the cessation of blood 
loss associated with the menstrual cycle, when it was shown that 17β-estradiol (E2) can directly 
inhibit hepcidin in hepatocytes and in mice (Yang et al., 2012). The promoter for hepcidin was 
predicted to have at least four half estrogen response elements (EREs) (Yang et al., 2012). 
Bioinformatic analysis of the promoter sequence revealed a ERE half site and an imperfect half site, 
similar to other genes regulated by the estrogen receptor (ER) pathway (Yang et al., 2012). The 
electrophoretic mobility shift assays using the WT and mutated ERE sequence of the hepcidin 
promoter confirmed that the ERα dimers bind to this sequence (Yang et al., 2012). Treatment with 
E2 was shown to decrease luciferase activity of the HAMP promoter in cells (Yang et al., 2012); 
WT and Hfe KO mice treated with E2 also had lower levels of Hamp (Yang et al., 2012). Treatment 
of HuH7 and HepG2 cells with E2 increases HAMP levels, and mice in which the ovary had been 
removed had decreased levels of hepcidin as compared to sham operated mice, suggesting a 
positive regulation of Hamp by estrogen (Ikeda et al., 2012). Although both the studies used E2 at 
similar concentrations they had different results. These results establish a link between iron 
metabolism and the ER receptor pathway but the mechanisms are not yet clear and further studies 
with better controls could help us understand this pathway in detail. 
The relationship between testosterone and iron metabolism is a bit clearer than that between 
estrogen and iron metabolism. Testosterone therapy was correlated with a decrease in hepcidin 
levels in men, establishing the link between the male sex hormone and the iron regulatory hormone 
(Bachman et al., 2010). It is known that testosterone increases erythropoiesis in both sexes (Mirand 
et al., 1965), some studies suggest that this is due to an increase in the levels of EPO itself whereas 
others contradict it (Moriyama and Fisher, 1975). This mechanism was dissected using transgenic 
mice constitutively expressing hepcidin, where treatment with testosterone did not result in a 
decrease in hepcidin or a simultaneous increase in the haematological parameters as was observed 
in the WT mice (Guo et al., 2013). These results indicated that the increase in erythropoiesis in 
response to testosterone treatment may be mediated by a decrease in hepcidin levels (Guo et al., 
2013). This would mean that more iron would be available to the bone marrow, as happens in 
response to an increase in the demand for erythropoiesis (Guo et al., 2013). Even in the presence of 
an EPO neutralising antibody, testosterone was able to suppress hepcidin indicating that its 
mechanism of action does not require EPO as had been suggested earlier (Guo et al., 2013). It was 
hypothesised that the decrease in hepcidin is brought about by interfering with the BMP-SMAD 
pathway (Guo et al., 2013). Treatment with testosterone increased androgen receptor (AR) levels 
and decreased SMAD1 protein levels (Guo et al., 2013), AR formed a complex with SMAD4 and 
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hence affected the association of the SMAD1/5/8 complex with SMAD4 (Guo et al., 2013), an 
essential step for the nuclear translocation of the complex and consequent hepcidin transcription. 
Testosterone also increased epidermal growth factor receptor signalling (EGFR) (Latour et al., 
2013). Inhibition of the EGFR pathway by using selective EGFR inhibitors disrupted testosterone-
mediated downregulation of hepcidin indicating the requirement of the EGFR pathway (Latour et 
al., 2013). 
The regulation of hepcidin by growth factors and hormones indicates the importance of maintaining 
proper iron levels in different physiological and pathological states. Growth factors are involved in 
a variety of processes including cell cycle progression and differentiation; both of these processes 
require iron. This suggests that there could be other growth factors which can regulate hepcidin 
under different sets of conditions. 
1.3.6 Autoregulation by prohecidin 
Hepcidin is synthesised as a prepropeptide, an 84 amino acid precursor (Park et al., 2001) which is 
then processed into the 60 amino acid prohepcidin (Valore and Ganz, 2008). The prohepcidin form 
is converted to a 25 amino acid active hepcidin by proteolytic cleavage mediated by enzymes like 
furin (Valore and Ganz, 2008). Most of the research about hepcidin has focussed on this active 
form, and not much was known about the role of prohecidin, if any, in iron metabolism. A recent 
study examining the role of prohepcidin suggested that it is involved in feedback control of 
hepcidin transcription; using a variety of assays it was shown that prohepcidin binds directly to the 
STAT3 binding site in the HAMP promoter (Pandur et al., 2013). Prohepcidin also localised to the 
nucleus and cytoplasm as well. Transient expression of prohecidin in HepG2 cells increased the 
activity of the HAMP promoter using luciferase reporter assays (Pandur et al., 2013). This is an 
interesting finding which suggests an autoregulatory role of hepcidin and the first mechanism of 
post-transcriptional hepcidin regulation. It remains to be seen whether prohepcidin plays a similar 
role in vivo, as the study was only performed in cell lines. 
1.3.7 The mTOR pathway and hepcidin 
The RAS/ mitogen activated protein kinase (MAPK) and mammalian target of rapamycin (mTOR) 
pathways which are known to be involved in proliferation and growth of the liver were identified as 
novel activators of HAMP regulation in an RNA interference (RNAi) screen. The mTOR pathway is 
also involved in regulating the metabolic state of the cell and plays an important role in the 
maintenance of glucose and lipids in the liver (Mleczko-Sanecka et al., 2014). 
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The identification of these new pathways as contributors/modifiers of HAMP synthesis again 
suggest that regulation of iron is essential and a steady state is maintained by various pathways 
(some of them not known yet) under different stress conditions or disease states. 
1.4. TFR2 and its role in iron metabolism 
Mutations in TFR2 cause type III HH, a form of non-HFE HH (Camaschella et al., 2000). Subjects 
with mutations in the TFR2 gene were found to have very low serum hepcidin levels and high 
transferrin saturation (Nemeth et al., 2005). A deletion (Wallace et al., 2005) or mutation (Drake et 
al., 2007; Fleming et al., 2002) of TfR2 in mice leads to an iron overload phenotype resembling type 
III HH. These observations indicated that TfR2 plays an important role in the regulation of hepcidin 
synthesis. 
The TfR2 gene encodes two transcripts, the α-and β-forms (Kawabata et al., 1999). The α-form has 
18 exons and encodes an 801 amino acid transmembrane protein. The protein has a cytoplasmic, 
transmembrane and extracellular domain. The β-form lacks exons 1-3 and is believed to encode a 
soluble form of TFR2, as it does not have either the cytoplasmic or the transmembrane domain and 
comprises only a part of the extracellular domain. 
The promoter region of TFR2 in both human and mouse has two typical GATA binding protein 1 
(GATA1) (erythroid specific transcription factor) consensus sequences, a putative C/EBP binding 
site, a doublet of CAAT sequences and a CCAAT consensus sequence in the reverse direction 
(Kawabata et al., 1999; Kawabata et al., 2001a). These conserved sequences in the promoter region 
indicate that TfR2 expression is controlled in the same temporal and spatial manner in both humans 
and mice. 
TFR2 was predicted to have four asparagine (Asn/N)-linked glycosylation sites, out of which three 
(Asn 240, 339 and 754) were found to be glycosylated (Zhao and Enns, 2013). N-linked 
glycosylation is known to affect the proper functioning and trafficking of membrane proteins and 
can serve as a signal for cell-cell interactions (Helenius and Aebi, 2001). A mutagenesis analysis of 
these glycosylation sites revealed that glycosylation of TFR2 is not required for its proper 
trafficking to the membrane and does not affect its binding to holo-TF (Zhao and Enns, 2013). The 
non-glycosylated protein was not stabilised in the presence of holo-TF as had been shown earlier 
(Johnson and Enns, 2004; Robb and Wessling-Resnick, 2004; Zhao and Enns, 2013). This suggests 
that mutations affecting these glycosylation sites may affect TFR2 function, although a functional 
analysis of how the decrease in glycosylation affects hepcidin regulation was not performed in this 
study. 
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The mRNA for TFR2 has been found in the spleen, muscle, lung, prostate, immature erythroid cells 
and peripheral blood mononuclear cells (PBMCs), as well as being predominantly expressed in the 
liver (Kawabata et al., 1999; Kawabata et al., 2001b). Apart from the liver it is not known whether 
the mRNA is translated into protein in other tissues. The β-form was suggested to play an important 
role in the spleen where it might help in iron retention (Roetto et al., 2010). 
TFR2 does not have IREs in its mRNA, hence the transcript levels are not regulated by iron levels 
(Kawabata et al., 1999), but iron levels do regulate the stability of the protein (Johnson et al., 2007; 
Robb and Wessling-Resnick, 2004). The addition of holo-TF to culture media of HepG2 cells 
increased the half-life of TFR2 from 4 to 14 hours (Johnson and Enns, 2004; Robb and Wessling-
Resnick, 2004). This effect is specific to hepatocytes, as other cell lines (K562 and CHO-TRVb) did 
not appear to show an increase in the stability of the protein (Johnson and Enns, 2004). This was 
further confirmed in animals where TFR2 protein levels increased or decreased in the livers of rats 
fed a high iron diet or an iron-deficient diet respectively (Robb and Wessling-Resnick, 2004). 
Treatment of cells with other forms of iron (ferric nitrolotriacetic acid (Fe-NTA)) did not increase 
the levels of TFR2 protein; this suggests that there are specific mechanisms in hepatocytes which 
regulate the levels of TFR2 in response to an increase in transferrin saturation. These observations 
further strengthened the hypothesis that TFR2 plays a role in the regulation of iron metabolism 
rather than the uptake of iron. 
TfR2 null mice, in which exons 2-6 were knocked out using homologous recombination (Wallace et 
al., 2004), mice with a mutation in TfR2 (Drake et al., 2007; Fleming et al., 2002), and patients with 
mutations in the TFR2 gene (Type III HH) (Camaschella et al., 2000), all show an iron overload 
phenotype which is more severe than HFE HH. This suggests that the major role of TFR2 in iron 
homeostasis is in the regulation of iron levels rather than direct uptake of iron. Mice and human 
patients lacking a functional TFR2 have low levels of hepatic hepcidin relative to iron stores, 
indicating that TFR2 plays a role in the regulation of hepcidin. In mouse liver and primary 
hepatocytes, extracellular signal-regulated kinases1/2 (ERK1/2) and SMAD1/5/8 phosphorylation 
increased soon after the addition of holo-TF and this was dependent on TFR2 (Ramey et al., 2009; 
Wallace et al., 2009). Mice with a hepatocyte- specific deletion of TfR2 had a similar iron overload 
phenotype as the mice with a total knockout of TfR2, indicating that the hepatocyte-specific 
expression of TFR2 is sufficient to regulate systemic iron levels. (Wallace et al., 2007). 
Introduction 
 
31 
1.4.1 Mutations of TFR2 
The first identification of a mutation in TFR2 which leads to type III HH pointed to a role of this 
gene in the regulation of iron metabolism (Camaschella et al., 2000). Studies in mouse models 
lacking TfR2 (Drake et al., 2007; Fleming et al., 2002; Wallace et al., 2005) showed that the 
deficiency of TFR2 leads to a decrease in Hamp levels which explains the HH phenotype observed 
in mice and humans. Since then approximately thirty deleterious mutations in TFR2 have been 
reported to be associated with type III HH, these are listed in Table 3.1. 
The M167K, Y245X, K685P mutations (mouse homologues of human mutations) result in a protein 
that is not trafficked properly and accumulates in the endoplasmic reticulum (Wallace et al., 2008), 
as shown in studies using mouse hepatoma cell line Hepa1-6, whereas the WT TFR2 is localised in 
endosome-like structures and at the cell surface. In mice with the Y245X mutation, the protein does 
not traffic to the plasma membrane of hepatocytes (Fleming et al., 2002). 
The following table shows the known TFR2 mutations that have been detected in 
haemochromatosis patients in different populations. 
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Table 1.1 TFR2 mutations known to be associated with type III HH in humans 
Chormosome Position Mutation Effect on protein Reference 
chr7:100238797dup c.88dup p.(Arg30Pro fs*31)  Ricerca et al., 2009; Roetto et al., 2001 
chr7:100238590_100238631del c.254_286+9del 
p.(Leu85_Ala96 
delinsPro) (also deletes 
splicing site and part of 
intron) 
 Bardou-Jacquet et al., 2013 
chr7:100238469G>A c.313C>T p.(Arg105*) Le Gac et al., 2004; Ricerca et al., 2009 
chr7:100231138A>T c.515T>A p.(Met172Lys)  Majore et al., 2006; Riva et al., 2004; Roetto et al., 2001 
chr7:100231035T>C c.614+4A>G intronic-splicing (skipping of exon 4)  Pelucchi et al., 2009 
chr7:100230723G>C c.750C>G p.(Tyr250*)  Camaschella et al., 2000; Piperno et al., 2004 
chr7:100229722G>A c.949C>T p.(Gln317*)  Pietrangelo et al., 2005 
chr7:100228596G>A c.1186C>T p.(Arg396*)  Gerolami et al., 2008; Lee and Barton, 2006 
chr7:100228545_100228547del c.1235_1237del p.(Asn412del)  Biasiotto et al., 2008 
chr7:100228547T>A c.1235A>T p.(Asn412Ile)  Bardou-Jacquet et al., 2013 
chr7:100226978C>T c.1288G>A p.(Gly430Arg)  Bardou-Jacquet et al., 2013; Majore et al., 2013 
chr7:100226936C>T c.1330G>A p.(Ala444Thr) 
 Bardou-Jacquet et al., 2013; 
Biasiotto et al., 2008; Le Lan 
et al., 2011 
chr7:100225917C>T c.1403G>A p.(Arg468His)  Hofmann et al., 2002 
chr7:100225851A>C c.1469T>G p.(Leu490Arg)  Koyama et al., 2005 
chr7:100225722T>C c.1511A>G p.(Tyr504Cys)  Majore et al., 2013 
chr7:100225599T>C c.1538-2A>G intronic - splicing   Gerolami et al., 2008; Radio et al., 2014 
chr7:100225540_100225544delinsGTGCTCTTG c.1591_1595delinsCAGGCAAGAG p.(Ser531Glnfs*6)  Radio et al., 2014 
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CCTG CAC 
chr7:100225384del c.1665del p.(Ser556Alafs*6)  Koyama et al., 2005 
chr7:100225041dup c.1841dup p.(Leu615Profs*177)   Radio et al., 2014 
chr7:100225010_100225021del c.1861_1872del p.(Ala621_Gln624del)   Girelli et al., 2002; Hattori et al., 2003; Zamani et al., 2012 
chr7:100224489C>G c.2033G>C p.(Arg678Pro)  Bardou-Jacquet et al., 2013 
chr7:100224453T>G c.2069A>C p.(Gln690Pro)  Mattman et al., 2002 
chr7:100224410dup c.2112dup p.(Met705Hisfs*87)  Bardou-Jacquet et al., 2013 
chr7:100218750C>T c.2137-1G>A intronic - splicing   Biasiotto et al., 2008 
chr7:100218698G>A c.2188C>T p.(Arg730Cys)  Bardou-Jacquet et al., 2013 
chr7:100218683C>T c.2203G>A p.(Gly735Ser)  Bardou-Jacquet et al., 2013 
chr7:100218667G>A c.2219C>T p.(Thr740Met)  Radio et al., 2014 
chr7:100218543C>T c.2343G>A p.(Trp781*)  Bardou-Jacquet et al., 2013 
chr7:100218512C>T c.2374G>A p.(Gly792Arg) 
 Bardou-Jacquet et al., 2013; 
Le Lan et al., 2011; Lee and 
Barton, 2006 
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1.4.2 Molecular interactions of TFR2 and their role in iron metabolism 
In K562 cells (immortalised myelogenous leukaemia cells) and in mouse liver extracts, TFR2 
interacts with TFR1, however the proportion of these interactions was proposed to be less than the 
homotypic interactions seen for TFR1 and TFR2 individually (Vogt et al., 2003). The consequences 
or the importance of this interaction in terms of iron metabolism have not been investigated further. 
In view of the model proposed for holo-TF sensing (Goswami and Andrews, 2006) this interaction 
and the dynamics of HFE-TFR1, TFR1-TFR2 and the proposed HFE-TFR2 interactions become 
even more important. Goswami and Andrews (Goswami and Andrews, 2006) proposed that when 
the TF saturation increases, TFR1 binding to holo-TF increases, displacing HFE from TFR1 and 
thus making it available to interact with TFR2. The interaction of HFE and TFR2 then initiates a 
cascade of signalling events which results in the production of hepcidin. 
Similar to TFR1, TFR2 binds to holo-TF, but the affinity of TFR2 for TF is ~20 times lower 
(Kawabata et al., 2000; West et al., 2000). The interaction of TFR2 with holo-TF stabilises the 
protein; in HepG2 cells the half-life of TFR2 increased from 4 to 14 hours when the cells were 
treated with holo-TF (Johnson and Enns, 2004; Johnson et al., 2007). This effect on protein stability 
is hepatocyte-specific as other cell types failed to replicate the increase in half-life of the protein 
(Johnson and Enns, 2004). 
It was suggested that amino acids 104-205 of TFR2 and the α3 domain of HFE (Chen et al., 2007) 
are involved in the HFE-TFR2 interaction. The Y250X mutation in TFR2 results in a truncated 
mutant protein that lacks most of the extracellular domain, however, it was shown that this 
truncated form of TFR2 could still interact with HFE. In both mice and transfected hepatocyte cell 
lines the truncated protein is not  transported to the cell membrane (Fleming et al., 2002; Wallace et 
al., 2008) which undermines the significance of the interaction shown by Chen et al. Similarly, 
when over-expressed in CHO cells it was suggested that the proteins interact in the Golgi apparatus 
even before being localised to the cell membrane and that this interaction increases the uptake of 
holo-TF (Waheed et al., 2008). The interaction of HFE and TFR2 in WIF-1 cells (a rat/human 
hybridoma cell line which predominantly expresses rat genes) was shown to involve only the α3 
domain of HFE but it also required the backbone of the cytoplasmic domain to interact with TFR2 
(Gao et al., 2009). It was also suggested that the interaction between TFR2 and HFE mediated and 
was required for TF-induced hepcidin production. In HepG2 cells transfected with exogenous HJV, 
HFE and TFR2, all three proteins form a multiprotein complex (D'Alessio et al., 2012). The 
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interaction between TFR2 and HJV was independent of the interaction between TFR2 and HFE and 
the formation of this complex was suggested to be required for the holo-TF induced transcription of 
HAMP (D'Alessio et al., 2012). 
These studies point towards the necessity of an interaction between TFR2 and HFE to mediate TF-
induced hepcidin synthesis, but there have been other studies which contradict this theory. In a 
recent time course study hepcidin levels were measured in subjects with HFE and TFR2 mutations, 
after administration of oral iron (Girelli et al., 2011). The TFR2 patients did not respond at all to 
increases in transferrin saturation whereas there was a minimal response in HFE patients under the 
same conditions, although less than the response in controls (Girelli et al., 2011). The minimal 
response of HFE patients when administered oral iron points to the fact that TFR2 (which is normal 
in those patients) can act independently of HFE in responding to TF saturation. A requirement for 
the interaction would mean a similar response to oral iron in both HFE and TFR2 patients. 
The comparison of Hfe-/-, TfR2-/- and Hfe-/-/TfR2-/- (double knockout) mice (Delima et al., 2012; 
Wallace et al., 2009) reveals that the double knockout mice have higher hepatic iron concentration 
and transferrin saturation as compared to either Hfe-/- or TfR2-/-. Levels of hepatic hepcidin relative 
to body iron stores were also lower in the double knockout mice indicating that both HFE and TFR2 
contribute to the sensing of body iron stores, and that they act in parallel rather than in combination 
(Delima et al., 2012; Wallace et al., 2009). In human subjects it is known that patients with 
mutations in both TFR2 and HFE present with a more severe form of disease (comparable to 
juvenile haemochromatosis) as compared to patients with either the TFR2 or HFE mutations alone 
(Pietrangelo et al., 2005). This indicates that the two molecules (HFE and TFR2) could act in 
parallel with each other; if it was a requirement for them to interact it would result in a comparable 
form of disease in all three types of patients (TFR2, HFE and the patients with compound mutations 
in both). Other evidence suggesting that an interaction between HFE and TFR2 is not required came 
from a study showing that HFE did not co-immunoprecipitate with TFR2 in the hepatocytes of 
transgenic mice expressing myc-tagged HFE. These mice could regulate Hamp in the liver in the 
absence of TfR2, which suggested that HFE and TFR2 can independently regulate Hamp (Schmidt 
and Fleming, 2012). 
These contradictory results lead to different models through which TFR2 and HFE could be 
modulating HAMP levels. In a recent review three alternative models were proposed (Worthen and 
Enns, 2014). 
Introduction 
 
36 
a. HFE and TFR2 do not interact with each other and are able to modulate hepcidin 
independently. 
b. Both HFE and TFR2 independently interact with BMP/HJV complex to independently 
regulate pSMAD levels and hence hepcidin. 
c. HFE/TFR2 complex interacts with BMP/HJV complex upon TF binding and regulates the 
pSMAD which in turn regulates hepcidin transcription. 
A recent study has suggested that HFE interacts with BMP type I receptor (ALK3) and increases the 
stability of the receptor (Wu et al., 2014). The co-expression of HFE and ALK3 increased ALK3 
protein levels in HepG2 and Hep3B cells. These results were also reproducible in liver tissues from 
Hfe knockout mice which had lower levels of ALK3 protein as compared to WT mice (Wu et al., 
2014). It was suggested that HFE inhibits the ubquitination of ALK3 protein in transfected cells and 
hence prevents its degradation through the proteasomal ubiquitin degradation pathway (Wu et al., 
2014). HFE was also suggested to be required for the proper localisation of ALK3 to the cell 
surface (Wu et al., 2014). Although these results are in agreement with the first and the second 
model proposed above, and suggest that HFE and TFR2 can independently regulate hepcidin, we 
are still not clear about the role of TFR2 in this pathway. 
The major drawback in deciphering the actual mechanism of action has been the unavailability of 
specific antibodies that could be used to identify the proteins. Most studies have used cell model 
systems which overexpress the tagged transfected proteins, which could be one of the reasons for 
the contradictory results. On the other hand it could be that any interactions between these proteins 
are weak or transient and can be detected under some conditions but escape detection under other 
conditions. It could also be possible that HFE and TFR2 mediated regulation is a combination of 
more than one of the possibilities mentioned in the models below, that is they can regulate HAMP 
as a complex and independently as well. Irrespective of this it is clear from these results that TFR2 
plays a definitive role in the regulation of hepcidin in response to an increase in iron levels. 
It has been suggested that TFR2 acts as a sensor for iron levels (TF saturation) and initiates a 
signalling cascade to control hepcidin transcription in response to higher iron levels (Chen et al., 
2007; Gao et al., 2009; Gao et al., 2010; Goswami and Andrews, 2006). The molecules acting 
downstream of TFR2 that relay the signal to the hepcidin promoter elements are not known. Some 
evidence (Calzolari et al., 2006; Wallace et al., 2009) from erythroleukemic cell lines and mice 
suggests that this signal is relayed through the MAPK pathway as diferric transferrin and TFR2 
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antibodies were able to increase the phosphorylation of p38MAPK and ERK1/2). Although the 
BMP-SMAD pathway appears to be the major signalling pathway involved in the regulation of 
HAMP in response to iron, there is evidence for the possibility of crosstalk between these two 
pathways in hepatocytes (Ramey et al., 2009), where an increase in the phosphorylation of both 
ERK1/2 and SMAD1/5/8 was observed soon after the addition of holo-TF. It remains to be 
determined how TFR2 relays this signal and at what point, if at all the two pathways cross and 
interlink. 
1.4.3 TFR2 in extra-hepatic tissues 
The dysregulation of iron metabolism in extra-hepatic tissues has been linked to several diseases.  It 
was recently shown that a dysregulation of iron metabolism in the central nervous system 
contributes to the development of disease in amyotropic lateral sclerosis (Jeong et al., 2009). The 
role of iron in neurodegenerative diseases (NDs) like Parkinson’s (PD) and Alzheimer’s (AD) has 
been widely accepted reviewed in (Crichton et al., 2011). The accumulation of iron in the areas 
affected in NDs (hippocampus and cerebral cortex in AD and the substantia niagra in PD), suggests 
that dysregulation of iron is a feature of these diseases (Crichton et al., 2011). 
In patients with iron overload, organs like the heart and pancreas are also affected, with iron 
accumulating in these tissues over time and eventually leading to organ dysfunction and damage. 
Our understanding of the local regulation of iron metabolism in these tissues is very limited. 
TFR2 mRNA is expressed in tissues other than the liver, namely the spleen, smooth muscle, 
PBMCs, immature erythroid cells and prostate gland in humans, but the significance of this is not 
known (Kawabata et al., 1999; Kawabata et al., 2001b). TFR2 is highly expressed in the BM and 
PBMCs of patients suffering from non-malignant haematological disorders (Kawabata et al., 
2001b). It has never been investigated whether these transcripts are translated into functional 
proteins. There have been very few studies examining the role of TFR2 in extra-hepatic tissues, 
which point out that TFR2, could be involved in functions other than hepcidin regulation. 
Alternatively TFR2 could be involved in the regulation of hepcidin expression in extra-hepatic 
tissues and thus play a role in the local regulation of iron metabolism. 
1.4.3.1 Macrophages 
The macrophages play an important role in the regulation of iron homeostasis by recycling the iron 
from erythrocytes. In humans the recycling of iron via macrophages is responsible for providing 
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more iron than iron absorption in the intestine and release of stored iron from the hepatocytes 
combined (Ganz, 2012). It has also been shown using BM transplant experiments that, at least in 
mice, Hfe expression in macrophages is sufficient to increase the basal levels of Hamp in the liver 
and partially rescue the liver iron loading of Hfe-deficient mice (Makui et al., 2005). These 
experiments also suggested that Hfe expression can affect the ability of splenic macrophages to 
store iron, where the spleens of the WT mice injected with Hfe deficient BM had lower iron levels 
as compared to the Hfe deficient mice injected with WT BM (Makui et al., 2005). There have been 
reports suggesting that macrophages can produce hepcidin, in response to inflammatory stimuli (Liu 
et al., 2005). This signalling appears to require toll like receptor 2 (TLR2) and 4 (Layoun and 
Santos, 2012). Peritoneal macrophages from WT mice showed an increase in hepcidin production in 
the presence of TLR2 and TLR4 ligands but this response was absent in the peritoneal macrophages 
derived from TLR2 or TLR4 knockout mice. 
Although HFE and TFR2 have been shown to be expressed in macrophages and the spleen 
(Parkkila et al., 2000; Roetto et al., 2010), their function with respect to iron metabolism is not 
clear, as mice lacking Hfe in macrophages did not develop iron overload (Vujic Spasic et al., 2008). 
Similarly mice with a hepatocyte-specific ablation of TfR2 develop similar iron overload to mice 
which lack TfR2 in all tissues (Wallace et al., 2005; Wallace et al., 2007), suggesting that both HFE 
and TFR2 in macrophages do not play a role in systemic iron regulation. 
In mice where the M167K mutation was introduced to specifically inhibit the β-TfR2 transcript it 
was proposed that this isoform functions as a sensor for recycled iron from erythropoiesis and a 
dysregulation of this sensing leads to spleen iron retention which could be traced back to 
macrophages in the spleen (Roetto et al., 2010). The mice lacking the β-form had a different pattern 
of iron accumulation in the spleen, where it accumulated more in the macrophages in the red pulp as 
compared to the total TfR2 knockout (KO) mice, which were characterised by iron accumulation in 
the white pulp macrophages (Roetto et al., 2010). The reduction in Fpn1 mRNA in the spleen and 
isolated splenic macrophages indicated that the β-isoform positively regulates the transcription of 
Fpn1 (Roetto et al., 2010). The difference in levels of Bmp6 and hepcidin in the mice lacking β-
TfR2 only in the hepatocytes and KO mice (both α-and β-TFR2 absent in all tissues) suggested an 
extra-hepatic role of TFR2 in the signalling pathways for sensing iron levels (Roetto et al., 2010). It 
was further suggested that β-TFR2 plays a role in erythropoiesis in young mice and that in the 
spleen it prevents iron loading of the macrophages and that it needs a normally functioning α-
isoform to perform these functions (Roetto et al., 2010). This was the first study to suggest that 
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TFR2 protein is expressed in macrophages and that it could play a role in the macrophage iron 
metabolism. 
1.4.4.2 Erythroid cells 
The promoter region of TfR2 has two putative GATA1 binding sites and an erythroid Kruppel-like 
factor (EKLF) binding site. Both GATA1 and EKLF are erythroid-specific transcription factors 
indicating that TFR2 could be regulated in response to erythropoiesis. TfR2 mRNA is expressed in 
immature erythroid cells (Kawabata et al., 2001b), suggesting that it could have a functional role in 
these cells. TFR2 also co-immunoprecipitated with EPOR in UT7 (erythroleukemic cells); when 
TFR2 expression was silenced using siRNA, it delayed the differentiation of these cells in vivo 
(Forejtnikova et al., 2010). Patients or mice with TFR2 mutations do not show a defect in 
erythropoiesis which could be due to the high levels of erythropoietin seen in these subjects which 
compensates for the lack of TFR2 (Forejtnikova et al., 2010). It was also reported that silencing of 
TFR2 reduces the expression of GDF15, a candidate erythroid regulator of hepatic hepcidin 
(Forejtnikova et al., 2010); this further supports a role for TFR2 in erythropoeisis. 
Recent genome wide association studies (GWAS) have identified single nucleotide polymorphisms 
(SNPs) in the TFR2 gene region that are associated with haematological parameters like red blood 
cell (RBC) number (Kamatani et al., 2010; Soranzo et al., 2009), haematocrit and mean cell volume 
(Auer et al., 2014; Ganesh et al., 2009), suggesting a link between TFR2 and haematopoiesis. The 
EPO gene is in close proximity to TFR2 on chromosome 7; hence it is not clear whether these 
associations are due to TFR2 or EPO. 
Tmprss6 deficient mice exhibit a severe iron deficiency microcytic anaemia and double mutants for 
Tmprss6 and Hfe or TfR2 have an increased rate of erythropoeisis, although in this study the 
comparison between different mice was not done on the same background (Lee et al., 2012). Mice 
lacking both Tmprss6 and TfR2 had a mild erythrocytosis which was not seen in mice lacking 
Tmprss6 with hepatocyte-specific deletion of TfR2. It was suggested that the increase in red blood 
cells is due to the absence of TfR2 in the erythroid cells (Nai et al., 2014). These results support the 
hypothesis that TfR2 plays an important role in erythroid cells, independent of its role in iron 
metabolism. 
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1.4.3.3 Brain 
In the dopaminergic neurons of rats and monkeys TFR2 is involved in transporting TF bound iron 
to the mitochondria (Mastroberardino et al., 2009). The dopaminergic neurons are the neurons 
affected in PD, and it has long been thought that excess iron deposition causes the degradation of 
these neurons; this was one of the first reports that linked iron metabolism to the development of the 
disease and also the first to predict a mechanism for transport of TF-bound iron to mitochondria. It 
needs to be further determined whether this mitochondrial targeting sequence present at the N-
terminus of the TFR2 protein is involved in the transport of iron to mitochondria in other tissues. 
1.4.3.4 Heart and Testis 
 Apart from the fact that TfR2 mRNA can be detected in these tissues it is not known what role if 
any TFR2 has in these tissues. These organs are of particular interest, as haemochromatosis patients 
can develop cardiac iron loading, cardiomyopathy and hypogonadotropic hypogonadism (attributed 
to the pituitary gland). Hepcidin is produced in the heart (Merle et al., 2007), and it responds to the 
stimuli of hypoxia and inflammation. Immunofluorescence analysis suggests that it localises in the 
intercalating discs (Merle et al., 2007). Whether hepcidin production in the heart is regulated by 
TFR2 is not known and has not been studied. 
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1.5 Brief Outline of the Project 
The aim of this project is to examine the roles of TFR2 in hepatic and extra-hepatic tissues, and 
investigate the molecular mechanisms underlying these roles. The project aims to address the 
following hypotheses:  
a. HFE and TFR2 do not interact in a stable co-expression system. 
b. TFR2 plays an important role in the local regulation of iron metabolism in cells of the 
macrophage/monocyte lineage. 
c. TFR2 is essential for stress erythropoeisis due to iron deficiency. 
As mentioned in the introduction, opinion is divided amongst the scientific community about the 
interaction between HFE and TFR2; one of the primary reasons for this is the overexpression model 
systems used to determine and define this interaction. Overexpression of tagged proteins may lead 
to their aggregation (Hu et al., 2002) or mislocalisation (Lisenbee et al., 2003; Nantel et al., 1999), 
thus affecting their function. 
The first aim of this project will be to study the proposed HFE-TFR2 interaction in an in vitro cell 
model system, where both proteins are stably expressed using a tricistronic vector. The advantage of 
this system is that the expression levels of both proteins are similar, which enables us to circumvent 
the issues related to overexpression of either of the two proteins. The interactions will also be 
localised and quantified using a recently developed technique, the ‘proximity ligation assay’. This 
technique allows the detection, visualisation and quantitation of interactions between two proteins 
at a cellular level in their native state. 
The second and third aims of the project are to determine the role of TFR2 in local iron metabolism 
of extra-hepatic tissues: spleen and bone marrow. These tissues were selected on the basis of either 
their role in iron metabolism (the spleen is enriched for macrophages which are responsible for 
recycling iron from senescent erythrocytes) and the bone marrow is the major site of use of iron for 
erythropoiesis. The expression of genes involved in the regulation of iron metabolism will be 
analysed using real-time PCR, western blotting and immunohistochemical techniques. 
Recent studies have suggested that HFE plays an important role in the function of macrophages; it 
is not known whether TFR2 has a similar tissue-specific role in these cells. In order to examine the 
role of TFR2 in macrophages transgenic mice with a macrophage-specific deletion of TFR2 will be 
generated. These mice will then be characterised for defects in iron metabolism under normal and 
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stress (an iron-rich diet and inflammation) conditions. The mice will be fed an iron-rich diet and 
treated with lipopolysaccharide for 6 hours in order to determine the role of macrophage TFR2 in 
iron and inflammation-mediated regulation of hepcidin. This will form the second aim of the 
project. 
The third aim of the project is to examine the role of TFR2 in erythroid cells. Recent data from our 
laboratory suggests that TFR2 plays an important role in stress-related erythropoiesis. Transgenic 
mice with an erythroid-specific deletion of TFR2 will be generated, these mice will be analysed for 
defects in erythropoiesis and the role of TFR2 in erythroid development. 
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The materials and methods described here were used in experiments for one or more chapters 
described in this thesis. All the chemicals and reagents were of analytical and molecular biology 
grade. The catalogue numbers for the chemicals and reagents have been provided wherever 
possible. 
2.1 Tissue culture 
Hepa1-6 cells (mouse hepatoma cell line) (American Type Culture Collection, Manassas, VA, 
USA, #CRL-1830) were cultured in Dulbecco’s modified Eagle’s media (DMEM) (Life 
Technologies, Mulgrave, Victoria, Australia, #11995-065) supplemented with 10% fetal calf serum 
(FCS) (Hyclone Lab. Inc., Mordialloc, Victoria, Australia) in 25 cm2 culture flasks at 37°C and 5% 
CO2 in a humidified Thermo Forma incubator (ThermoFischer Scientifc, Scoresby, Vic, Australia, # 
model 371 and 381). The stably transfected Hepa1-6 cells (transfected with FLAG-tagged Hfe or 
myc-tagged TfR2, or both) were cultured in DMEM supplemented with 10% FCS and 1μg/ml 
puromycin (Astral Scientific, Gymea, NSW, Australia, #P-1033). 
2.2 Immunofluorescence (IF) 
Cells were seeded on collagen-coated glass coverslips and grown to a confluence of 75-80%. After 
washing with PBSCM (phosphate buffered saline (PBS), 1 mM calcium chloride (Sigma-Aldrich, 
Sydney, NSW, Australia, #C-3881), 1 mM magnesium chloride (Ajax Chemicals, Thermofisher 
Scientific, #296-500G)) three times, the cells were fixed with cold 3% paraformaldehyde (PFA) 
(Sigma-Aldrich, #P-6148) for 15 minutes at room temperature (RT). The fixed cells were then 
washed with 50 mM ammonium chloride (Sigma-Aldrich, #A-4514) to quench the PFA, followed 
by a PBSCM wash, and then permeabilised with 0.1% saponin (Calbiochem, Merck Millipore, 
Kilsyth, Victoria, Australia, # 558255) in PBSCM for 15 minutes at RT and incubated with the 
appropriate primary antibodies (antibody concentrations are shown in Table 2.1) diluted in 
fluorescence dilution buffer (FDB) (5% FCS, 5% normal donkey serum (Merck Millipore, #S30-
100ml), 2% bovine serum albumin (BSA) (Amresco, Solon, Ohio, USA, #0032) in PBSCM, pH 
7.6) for 2 hours at RT. After washing three times in 0.1% saponin/PBSCM the cells were incubated 
with the respective secondary antibodies conjugated to fluorophores (donkey anti-rabbit/anti-mouse 
Alexa 488 or Alexa 594 used at a concentration of 10 µg/ml) for 1 hour at RT. After washing with 
0.1% saponin in PBSCM the cover slips were then mounted using Prolong Gold anti-fade with 4', 
6-diamidino-2-phenylindole dihydrochloride (DAPI) (Molecular Probes, Life Technologies, 
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Mulgrave, Australia #36931). The cells were then visualised and imaged using a Nikon C2 confocal 
microscope (Nikon Corporation, Tokyo, Japan). 
Table 2.1 Primary antibody concentrations used for immunofluorescence studies. 
Antibody Concentration Supplier 
FLAG-M2 1:1,000 Sigma, #F3165 
TFR1 1:500 Zymed, Life Technologies, # 13-6890 
TFR1 1:100 Abcam, Cambridge, UK, #ab84036 
TFR2 1:1,000 (Wallace et al., 2005) 
 
2.3 Proximity ligation assay (PLA) 
The mouse/rabbit red starter DuolinkTM kit (Sigma-Aldrich, # DUO92101) was used for the 
proximity ligation assay (PLA). Hepa1-6 cells stably expressing FLAG-tagged Hfe and myc-tagged 
TfR2 were plated at a cell density of 1.5x104 cells in a 16 well chamber slide (ThermoFisher 
Scientific, #NUN 178599). After 24 hours the cells were incubated with either apo- (Sigma-Aldrich, 
#T1147) or holo-transferrin (Sigma-Aldrich, #T0655) (2 mg/ml) for 24 hours. Following treatments 
the cells were fixed and permeabilised as per the immunofluorescence (IF) protocol (section 2.2). 
The permeabilised cells were blocked overnight with the blocking buffer (provided in the kit) at 
37°C in a humidified chamber. The next day the cells were incubated with the respective primary 
antibodies, diluted in the antibody diluents, for 2 hours at RT. The primary antibodies were used at 
the same concentrations as used in the immunofluorescence protocol (Table 2.1). After incubation 
with the primary antibodies the cells were washed with Buffer A (proprietary, provided in the kit) 
(three times for 15 minutes) and then incubated with the plus and minus PLA probes diluted in the 
antibody diluent for 1 hour at 37°C in a humidified chamber. The cells were then washed with 
Buffer A (three times for 15 minutes) and incubated with the ligation mix (as per instructions) for 1 
hour at 37°C in a humidified chamber. The ligation reaction was followed by two washes with 
Buffer A for 15 minutes and then the cells were incubated with the amplification mix (as per 
instructions) for 2 hours at 37°C in a humidified chamber followed by one wash in Buffer B 
(proprietary, provided in the kit) and one wash in 0.01X Buffer B. The cells were then mounted 
using the mounting media supplied with the kit and visualised and imaged using a Nikon C2 
confocal microscope. 
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2.4 Confocal microscopy 
Cells were visualised and imaged using the Nikon C2 confocal microscope using the 63X oil 
immersion objective. The images were acquired and processed using the NIS elements software 
provided by Nikon. 
2.5 Animal Breeding 
All animal experimentation was approved by the QIMR Berghofer Medical Research Institute 
(QIMRB) Animal Ethics Committee and was performed according to the guidelines of the 
Australian Code of Practice. The animals were housed at the Animal Facility at the QIMRB under a 
12 hour light/dark cycle and were provided with food and water ad libitum. All animals used in this 
project were bred on the C57BL/6J background. 
2.5.1 Generation of TfR2f/f/Alb-Cre+/- mice 
TfR2f/f mice were crossed with Alb-Cre+/- to generate TfR2f/+/Alb-Cre-/- and TfR2f/+/Alb-Cre+/- mice; 
these mice were then interbred to generate the required genotypes for the experiments, which were 
TfR2f/f/Alb-Cre+/- (hepatocyte-specific TfR2 knockout mice) and TfR2f/f/Alb-Cre-/- (littermate control 
mice). The animals were fed a standard rodent chow (Goldmix Stockfeeds, Windera, Queensland, 
Australia). 
2.5.2 Generation of TfR2f/f/LysM-Cre+/- 
TfR2f/f mice were bred with LysM-Cre+/- mice (donated by Prof Christian Engwerda, QIMRB) to 
generate TfR2f/+/LysM-Cre-/- and TfR2f/+/LysM-Cre+/- mice; these mice were then interbred to 
generate the required genotypes for the experiments, which were TfR2f/f/LysM-Cre+/- (macrophage-
specific TfR2 knockout mice (M-KO) and TfR2f/f/LysM-Cre-/- (littermate control mice). The animals 
were fed a standard chow diet for 3 weeks after which the diet was changed to either control diet 
(Specialty Feeds, Glen Forest, Western Australia, #AIN3G) or an iron-rich diet (containing 20 g/kg 
carbonyl iron; Specialty Feeds, # SF07-082). The animals used for the inflammation study were fed 
a standard chow for 5 weeks and then injected intraperitoneally with 1 μg/g body weight of 
lipopolyssacharide (LPS 055:B5 from Escherichia coli 055:B5; Sigma-Aldrich, #L4005) or vehicle 
(saline) control. 
The details of the breeding plan used for generating the TfR2Δ/f/Vav-Cre+/- mice were more 
complicated and have been described separately in Chapter 6. 
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2.5.3 Animal sacrifice and tissue collection 
Mice were anaesthetised by injecting ketamine (Provet Qld Pty Ltd, Northgate, Queensland, 
Australia, #KETA I) and xylazine (Troy Laboratory Ltd, Smithfield, NSW, Australia) 
intraperitoneally. Once the breathing had dropped significantly, the animals were checked for signs 
of pain by a toe pinch. The anaesthetised animals were then dissected by exposing the abdominal 
cavity by a midline incision. Blood was collected from the dorsal aorta using a 26G needle and 1 ml 
syringe. Blood was then divided into three portions for further analysis as explained in section 
2.5.4. Organs were collected in 1.5 ml tubes, snap frozen in dry ice and stored at -80°C until further 
use. The organs to be used for histology were fixed in 10% formalin in PBS (prepared in house by 
the Histotechnology facility at QIMRB) for 24 hours and then transferred to 70% ethanol (EtOH) 
(Chem-Supply, Gilman, SA, Australia) and stored at 4°C until further use. 
2.5.4 Blood collection 
Blood was collected from the dorsal aorta, was divided and used for three different analyses. 
a. Whole blood (100 µl) was added to a tube containing ethylenediaminetetraacetic acid 
(EDTA) powder (Chem-Supply) and was used for analysing haematological parameters. 
The haematological parameters were measured using the Sysmex XE-5000 Haematology 
Analyser (Sysmex Asia Pacific Pte Ltd, Japan) by Pathology Queensland at the Royal 
Brisbane and Women’s Hospital. 
b. Whole blood (10 µl) was used to prepare blood smears on glass microscope slides. 
c. The rest of the blood was allowed to coagulate at RT for at least 1 hour and then centrifuged 
at 10,000 rpm for 5 minutes at 4°C. The serum which separated as a supernatant was then 
aliquoted into 70 µl aliquots and stored at -80°C until further use. 
2.6 mRNA quantification 
2.6.1 RNA extraction 
Total RNA was extracted from tissues using the TRIzol reagent (Life Technologies, #15596026) 
and PrecellysTM 24 tissue homogeniser (Bertin Technologies, Maryland, USA). Liver, spleen (50-
100 mg), or bone marrow (BM) from the left tibia was used for RNA extraction. The homogenising 
conditions for each of the tissues are described in Table 2.6. The tissues were homogenised in 1 ml 
of TRIzol in 2.0 ml tough tubes (Geneworks Pty Ltd, Thebarton, SA, Australia, # MB-13119-500) 
with 500 ng of 1.4 mm zirconium oxide beads (Bertin Technologies). The homogenate was 
incubated at RT for 5 minutes before transferring to a 1.5 ml tube. Chloroform (200 μl) (Asia 
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Pacific Specialty Chemicals, Auburn, Sydney, NSW, Australia) was added to the homogenate, the 
tubes were then shaken vigorously for 20 seconds and incubated at RT for 5 minutes. The samples 
were then centrifuged at 12,000 rpm for 15 minutes at 4°C. The aqueous phase was transferred to 
another 1.5 ml tube and an equal volume of isopropanol (Chem-Supply) was added and mixed by 
inverting the tubes 10 times before incubation for 10 minutes at RT. Samples were then centrifuged 
at 12,000 rpm for 15 minutes at 4°C. The supernatant was discarded and the pellet washed in 1 ml 
of 75% EtOH and centrifuged at 7,500 rpm at 4°C. After removing the supernatant the pellet was 
air dried at RT for 10 minutes and then dissolved in 100 μl of sterile water (Pfizer Australia, 
Sydney, NSW, Australia). The RNA was then quantitated by measuring the absorbance at 260 nm 
using the Nanodrop 2000 (Thermo Fisher Scientific). 
2.6.2 cDNA preparation 
The first strand cDNA synthesis was performed using the SensiFASTTM cDNA synthesis kit 
(Bioline Pty Ltd, Sydney, NSW, Australia, #BIO-65054). RNA (1 ug) was added to 2.5 μl of the 
mastermix (containing 2 μl of the 5X TransAmp buffer and 0.5 μl of Reverse Transcriptase) and the 
volume made up to 10 μl with sterile water. After mixing gently the cDNA synthesis reaction was 
incubated under the conditions listed in Table 2.2. 
Table 2.2 Thermal cycling conditions for first strand synthesis.  
Step Temperature Time 
Primer annealing 25°C 10 minutes 
Reverse Transcription 42°C 15 minutes 
Inactivation 85°C 5 minutes 
Hold 4°C  
 
The resultant cDNA was then diluted 1/20 with sterile water for use in quantitative real-time PCR 
(qRT-PCR). Two negative controls were used for each set of samples, an RNA negative (all 
components of the reaction except RNA) and a reverse transcriptase negative (all components of the 
reaction except the reverse transcriptase). 
2.6.3 Quantitative real-time polymerase chain reaction (qRT-PCR) 
Quantitative real-time PCR (qRT-PCR) was performed using the SensiFASTTM SYBR No-Rox kit 
(Bioline, Australia Pty Ltd, #BIO-98020). The primer sequences used for analysis of the genes 
studied in this thesis are given in Table 2.5. All the primers were obtained from Integrated DNA 
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Technologies (Chatswood, NSW, Australia) or Sigma-Aldrich. In order to maintain consistency 
between the samples, a master mix for each gene was prepared as explained in Table 2.3. 
Table 2.3 Composition of a qRT-PCR reaction (per well) using SensiFASTTM SYBR No-Rox 
kit. 
Component Volume 
5X SYBR mix 5 μl 
5’ Primer (2 μM) 1 μl 
3’ Primer (2 μM) 1 μl 
 
Mastermix (7 μl) was then dispensed into each well of 384 well plates (Roche Diagnostics, 
Australia) and then 3 μl of the diluted cDNA was added to it. The master mix and the sample were 
dispensed using a CAS 1201 Robot (Corbett Research, Mortlake, NSW, Australia). In addition to 
the two cDNA controls another negative control (sterile water) was added to each set of samples. 
Thermal cycling of this reaction mix was performed on the Light Cycler 480 (Roche Diagnostics) 
using the cycling conditions shown in Table 2.4. 
Table 2.4 Light Cycler 480 thermal cycling conditions for performing qRT-PCR. 
Step Temperature Time 
Preincubation 95°C 5 minutes 
Amplification (45 cycles) 95°C 10 seconds 
 60°C 15 seconds 
 72°C (Data acquisition) 10 seconds 
Melting Curve 95°C 5 seconds 
 65°C 1 minute 
 65 to 97°C (Continuous acquisition) Ramp rate 2.5°C per second 
Cooling 40°C  
 
The analysis of the relative expression of genes (relative to the geometric mean of three reference 
genes) was done using the ΔCt method. 
Table 2.5 Sequences of the primers used for qRT-PCR. 
Primer Sequence (5’→3’) 
Actb-F GACGGCCAAGTCATCACTATTG 
Actb-R CCACAGGATTCCATACCCAAGA 
Hprt-F GGACTGATTATGGACAGGA 
Hprt-R GAGGGCCACAATGTGATG 
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Polr2a-F AGCTGGTCCTTCGAATCCGC 
Polr2a-R CTGATCTGCTCGATACCCTGC 
Hamp-F AGAGCTGCAGCCTTTGCAC 
Hamp-R ACACTGGGAATTGTTACAGCATTTA 
Bmp6-F ATGGCAGGACTGGATCATTG 
Bmp6-R CCATCACAGTAGTTGGCAGCG 
TfR1-F CATGAGGGAAATCAATGATCGTA 
TfR1-R GCCCCAGAAGATATGTCGGAA 
TfR2-F CTATCTGGTCCTGATCACCCT 
TfR2-R TCAGGGTTGACATCTTCATCGA 
Hfe-F CTGAAAGGGTGGGACTACATGTTC 
Hfe-R GGACACCACTCCCAACTTCGT 
Gypa-F GCATGGGTGAAAGCGTTAGT 
Gypa-R GCCACAAAGCCTCTGAGTTC 
Hmbs-F CATACTACCTCCTGGCTTTACTATTGG 
Hmbs-R TTTGGGTGAAAGACAACAGCAT 
Alas2-F CAGGGGCTTTCCTGTTATCC 
Alas-2R TGCTGTTGAGTGCTGCATTA 
Epor-F CCGGACCCCAAGTTTGAGAG 
Epor-R CTGGTGCAGGCTACATGACT 
Bcl2l1-F TTGGACAATGGACTGGTTGA 
Bcl2l1-R GGGCCTCAGTCCTGTTCTCT 
Epo-F GAGGCAGAAAATGTCACGATG 
Epo-R CTTCCACCTCCATTCTTTTCC 
Fam132b-F CAGCGAGCTCTTCACCATCT 
Fam132b-R AGTGAGAGCCACTGCGTACC 
Hjv-F TTCGGGGCAATCATGGAGAAAG 
Hjv-R TCCCAGATGATGAGCCTCCTACC 
Tmprss6-F CATCAACTTCACCTCCCAGA 
Tmprss6-R CAGTCCATTCACAGAGCAGAG 
Fpn1-F TTGCAGGAGTCATTGCTGCTA 
Fpn1-R TGGAGTTCTGCACACCATTGAT 
Smad7-F ACGGGAAGATCAACCCCGAG 
Smad7-R TTCCGCGGAGGAAGGTACAG 
Id1-F ACCCTGAACGGCGAGATCA 
Id1-R TCGTCGGTGGAACACATG 
Gdf15-F AGCTGTCCGGATACTCAGTCC 
Gdf15-R CTTCAGGGGCCTAGTGATGTCC 
Abbreviations- Actb- actin, Hprt- Hypoxanthine-guanine phosphoribosyltransferase, Polr2a- gene 
encoding for DNA-directed RNA polymerase II subunit RPB, Hamp- Hepcidin, Bmp6- Bone 
morphogenetic protein6, TfR1- Transferrin receptor 1, TfR2- Transferrin receptor 2, Gypa- 
Glycophorin A, Hmbs- hydroxymethlybilane synthase, Alas2- Delta aminolevulinate synthase 2, 
Epor-Erythropoietin receptor, Epo- Erythropoietin, Fam132b- gene encoding erythroferrone, Hjv- 
Hemojuvelin, Tmprss6- Transmembrane serine protease 6 (matriptase-2), Fpn1- Ferroportin 1 , 
Smad7- sma and mothers against decapentaplegic homologue 7, Id1- Inhibitor of differentiation 1, 
Gdf15- Growth differentiation factor 15. 
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2.7 Protein expression 
2.7.1 Cell lysates 
Cells were cultured to confluence in 25 cm2 flasks and then lysed in an extraction buffer (200 mM 
Tris (Sigma, #T1378) pH 8.0, 100 mM sodium chloride (Ajax Fine Chemicals, #465), 1 mM EDTA 
(Chem-Supply), 10% glycerol (APS Chemicals, #242), 1 mM sodium orthovanadate (Calbiochem, 
Merck, #567540), 1 mM sodium fluoride (Sigma, #201154), 1 mM sodium pyrophosphate (Sigma, 
#221368), 2 mM phenylmethylsuphonylfluoride (Sigma, #P7626), DNAase (1:1000), Protease 
Inhibitor Cocktail (1:100) (Sigma, #P8340) and 20% Igepal (NP-40) (Sigma, #I3021) using a 21G 
needle and syringe. The lysate was then  spun on an orbital shaker for 1 hour to further facilitate the 
lysing of the cells. After 1 hour the lysate was spun at 12,000g for 5 minutes at 4°C and stored at -
20°C until further use. 
2.7.2 Tissue homogenates 
Liver, or spleen tissue (50-100 mg) or BM cells from the femur were used for extracting proteins 
using the buffer defined in 2.7.1. The tissues were homogenised using the PrecellysTM 24 tissue 
homogeniser. The homogenising conditions used are specified in Table 2.6. 
Table 2.6 Homogenising conditions for preparing RNA and protein from liver, spleen and 
bone marrow. 
Tissue RNA conditions Protein conditions 
Liver 6,500 rpm /1 cycle/ 30 seconds 6,500 rpm/2 cycles/ 30 seconds 
Spleen 6,000 rpm/ 1 cycle/ 30 seconds 6,000 rpm/2 cycles/30 seconds 
BM 5,500 rpm/1 cycle/ 20 seconds 5,500 rpm/1 cycle/30 seconds 
 
The samples were homogenised without any detergent. After homogenisation the samples were 
incubated with an equal amount of buffer containing 2X the detergent (NP40) on an orbital shaker 
for 2 hours. 
2.7.3 Protein quantitation 
Protein quantitation was performed using the bicinchoninic acid (BCA) assay (Thermofisher 
Scientific, #23230).The reagents were prepared in the laboratory as two solutions, A and B. 
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Solution A 
Table 2.7 Composition of Solution A for preparing the BCA reagent. 
Reagent Concentration (w/v) 
BCA 1% 
Sodium carbonate (Ajax Chem., #A475) 2% 
Sodium bicarbonate (Merck) 0.16% 
Sodium tartrate (Sigma, #S-8640) 0.4% 
Sodium hydroxide (Ajax Chem.) 0.95% 
Hydrochloric acid (Chem-Supply) To adjust pH to 11.25 
MilliQ water To adjust to a final volume of 200 ml 
 
Solution B was 4% w/v cupric sulphate pentahydrate (Sigma, # C7631) dissolved in MilliQ water. 
The two solutions were stored at RT until further use. The BCA reagent was made by mixing 200 μl 
of solution B with 10 ml of solution A. 
A standard curve was generated using 10 serial concentrations of BSA ranging from 0.1 to 1 mg/ml. 
In order to make sure that the unknown protein concentration (the sample) was within the range of 
the standard curve, a 1 in 50 dilution (in MilliQ water) of the samples was used for the assay. The 
assay was run on a 96 well plate format, 10 μl of the standard or diluted sample was added to each 
well along with 200 μl of BCA reagent. The mixture was then incubated in the dark at 37° for 1 
hour before measuring the absorbance at 560 nm using a spectrophotometer. 
2.7.4 Co-immunoprecipitation (Co-IP) 
To perform co-immunoprecipitation with HFE, anti-DYKDDDDK beads were used (Clontech 
Laboratories Inc. CA, USA). All the other antibodies used for immunoprecipitation were 
crosslinked with protein A/G beads (Roche, Dee Why, NSW, Australia) using dimethyl 
pimelimidate (Sigma, #80490). After pre-clearing with a mixture of anti-rabbit and anti-mouse IgG 
agarose (Sigma), 1 mg of protein lysate was incubated with anti-DYKDDDDK, anti-TFR2, anti-
rabbit IgG or anti-mouse IgG beads overnight at 4°C. The beads were then washed with 0.5% NP-
40, 150 mM sodium chloride, 50 mM Tris pH 8.0, 5 mM EDTA (NET buffer) and resuspended in 
1X sample buffer (Table 2.8) containing 5% β-mercaptoethanol (Sigma, #M6250) and stored at -
20°C until further use. 
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2.7.5 Western blotting 
Tissue homogenates (liver homogenates- 25 µg, BM or spleen homogenates- 40 μg) or cell lysates 
(25 µg) were electrophoresed on 10 or 12 % sodium dodecyl sulphate polyacrylamide gels (SDS-
PAG) (Table 2.12 and Table 2.13) at 200 V for 1 hour 15 minutes. The proteins were then 
transferred onto nitrocellulose membranes (0.2 μm pore size) (Bio Rad Laboratories P/L, 
Gladesville, NSW, Australia, #1620112) using the Trans-blot Turbo blotting apparatus (Bio Rad) at 
25 V, 2.5 A for 30 minutes in the transfer buffer (Table 2.15). The membrane was then blocked in 
10% skim milk powder in TBST (Tris-buffered saline with 0.1% Tween 20 (Sigma-Aldrich, 
#P2287); blocking buffer) at RT for 2 hours. After blocking the membrane was incubated with the 
primary antibody (concentrations of the primary antibodies given in Table 2.16) overnight at 4°C. 
The next day the membranes were washed three times for 15 minutes with TBST and incubated 
with the respective goat anti-mouse/rabbit heavy and light chain IgG conjugated to horseradish 
peroxidase (HRP) (Invitrogen) (used at 1:10,000 in blocking buffer) or goat anti-mouse/rabbit light 
chain (for Co-IP westerns) IgG conjugated to HRP (Jackson Immunoresearch, West Grove, PA, 
USA) (used at 1:5000 in blocking buffer) for one hour at RT. The membrane was then washed three 
times for 15 minutes with TBST, followed by two 5 minute washes in TBS before incubating with 
the chemiluminescent substrate Lumina Forte (Merck Millipore, #WBLUF0500) for 5 minutes. 
Blots were then exposed to X-ray film (Fujifilm, Brookvale, NSW, Australia) for various times and 
films developed using a Minolta film processor (Konica Minolta Medical and Graphic Ltd, Tokyo 
Japan, #SRX101A). 
The processed films were then scanned using Scanmaker 9800 XL plus (Microtek International Inc. 
Hsinchu, Taiwan). The densitometric analysis for quantitation of the proteins was performed using 
the Genetools software (version 4.0) (Syngene, Cambridge, UK). 
Table 2.8 Composition of 2X Sample buffer for preparing protein samples for loading onto 
gels. 
Component  Final concentration 
Tris pH 6.8 100 mM 
SDS (Bio Rad, #161-0302) 20% 
Glycerol 20% 
Bromophenol blue (Sigma, #B8026) 0.2% 
β-mercaptoethanol (added fresh) 10% 
MilliQ water To adjust to a final volume of 50 ml 
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Table 2.9 Composition of upper buffer for stacking gel. 
Component  g/litre 
Tris base 60.5 g 
SDS 4.0 g 
Hydrochloric acid (Chem-Supply) To adjust pH to 6.8 
MilliQ water To adjust to a final volume of 1 litre 
 
Table 2.10 Composition of lower buffer for resolving gel. 
Component g/litre 
Tris base 181.5 g 
SDS 4.0 g 
Hydrochloric acid To adjust pH to 8.8 
MilliQ water To adjust to a final volume of 1 litre 
 
Table 2.11 Composition of 10X SDS-PAGE running buffer. 
Component  g/litre 
Tris base 30.25 g 
Glycine (Chem-Supply) 144.0 g 
SDS 10.0 g 
MilliQ water To adjust to a final volume of 1 litre 
 
Table 2.12 Composition of stacking gel for SDS-PAGE. 
Component  Volume (for 5 ml) 
Upper buffer (Table 2.9) 1.25 ml 
30% Acrylamide (BioRad, #161-0156) 0.75 ml 
10% Ammonium persulphate (APS)  
(Sigma, #9164) 50 µl 
N,N,N’,N’-Tetramethyl-ethylenediamine 
(TEMED) (Sigma, #T9281) 15 µl 
MilliQ water 3 ml 
 
Table 2.13 Composition of resolving gel for SDS-PAGE. 
Component  Volume for 5 ml Volume for 5 ml 
 10% 12% 
Lower buffer (Table 2.10) 1.25 ml 1.25 ml 
30% Acrylamide 1.7 ml 2 ml 
10% APS 25 µl 25 µl 
TEMED 12.5 µl 12.5 µl 
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MilliQ water 2.05 ml 1.75 ml 
 
Table 2.14 Composition of Tris-buffered saline (TBS). 
Component  g/litre 
Tris base 2.42 g 
Sodium chloride 8 g 
Hydrochloric acid To adjust pH to 7.6 
MilliQ water To adjust to a final volume of 1 litre 
 
Table 2.15 Composition of Western transfer buffer  
Component  g/litre 
Tris base 3.05 g 
Glycine 14.4 g 
Methanol (Chem-Supply) 100 ml 
MilliQ water To adjust to final volume of 1 litre 
 
Table 2.16 Details of primary antibodies used for detection of proteins.  
Antibody Size Dilution Diluent Supplier 
Actin 42kDa 1:40,000 Blocking buffer Sigma, # A0266 
BMP6 
58kDa 
and 
28kDa 
1:3,000 Blocking buffer Merck, # MAB1048 
FLAG-M2 (HFE-Flag) 50kDa 1:1,000 Blocking buffer Sigma, #F3165 
GAPDH 37kDa 1:100,000 Blocking buffer Merck, MAB374 
SMAD1 (total) 55kDa 1:500 Blocking Buffer Invitrogen, Life Technologies, #38-5400 
SMAD1/5 (phospho) 
(Clone DB510) 55kDa 1:2,000 
5% BSA in  
TBST 
Cell Signalling 
Technology (CST), 
Danvers, MA, USA, 
#13280 
STAT3 (total) 80kDa 1:3,000 Blocking buffer CST, #9139 
STAT3 (phospho) 80kDa 1:4,000 5% BSA in TBST CST, #9131 
TFR1 100kDa 1:1,500 Blocking buffer 
Zymed, Life 
Technologies, # 13-
6890 
TFR2 105kDa 1:20,000 Blocking buffer (Wallace et al., 2005) 
Abbreviations: BMP6- Bone morphogenetic protein 6, GAPDH- Glyceraldehyde-3-phosphate 
dehydrogenase, SMAD- Sma and mothers against decapentaplegic homologue, STAT- Signal 
transducer and activator of transcription, TFR1- Transferrin receptor 1, TFR2- Transferrin receptor 
2. 
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2.8 Histology 
Tissues stored in 70% ethanol were processed by the Histotechnology Facility at QIMRB. After 
processing the tissues were embedded in paraffin and sectioned. Sections were then either stained 
for Haematoxylin and Eosin (H&E) by the Histotechnology Facility or used in the laboratory for 
Perls’ staining as described in Section 2.8.1. The images of the H&E sections were captured using 
the Aperio AT-Turbo slide scanner (Aperio, Vista, CA, USA) and analysed using the ScanScope 
Software (Aperio). 
2.8.1 Perls’ staining 
Sections obtained from the Histotechnology Facility (QIMRB) were de-paraffinised and rehydrated 
in distilled water (Table 2.17). The rehydrated sections were then incubated with freshly made 
Perls’ solution (made by mixing Solution A and Solution B (Table 2.18) 1:1) for 20 minutes.  
Table 2.17 Steps for rehydration/dehydration series for paraffin sections. 
Wash Time 
Xylene (Chem-Supply) 4 minutes 
Xylene 1 minute 
100% EtOH 1 minute 
100% EtOH 1 minute 
100% EtOH 1 minute 
90% EtOH 1 minute 
70% EtOH 1 minute 
 
Table 2.18 Solution A and B for making Perls’ solution. 
Component Amount 
Solution A 
Potassium ferrocyanide (Sigma, # P-9387) 2 g 
MilliQ water 100 ml 
Solution B 
Hydrochloric acid 2 ml 
MilliQ water 98 ml 
 
After washing in gently running distilled water for 5 minutes the sections were then counterstained 
with Nuclear Fast Red (100 mg of Nuclear Fast Red dissolved in 5% aqueous aluminium sulphate 
and filtered before use, this solution was prepared by the QIMR Berghofer Histotechnology 
Facility) for 5 minutes and washed in gently running distilled water to remove the excess stain. The 
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sections were dehydrated through the alcohol series as in Table 2.17 and then mounted in Depex 
using the Leica CV5030 machine in the Histotechnology Facility at QIMRB. The images were 
captured using the Aperio AT-Turbo slide scanner and analysed using the ScanScope software. 
2.9 Iron Indices 
2.9.1 Serum iron concentration 
The serum obtained from mice as explained in section 2.5.4 was used to measure total serum iron, 
unsaturated iron binding capacity (UIBC), total iron binding capacity (TIBC) and transferrin 
saturation using the Iron/TIBC reagent set (Pointe Scientific, Canton, MI, USA). This method of 
detection is based on the chromagen ferrozine which has been previously described (Stookey, 
1970). The manufacturer’s protocol has been modified and adapted to use a minimal amount of 
serum in a 96 well format, in duplicates. The reaction volume used for experiments in this thesis 
was 40 times less than the manufacturer’s recommended volumes. The measurements were made in 
two sets as shown in section 2.9.1.1 and 2.9.1.2. 
2.9.1.1 Serum iron 
The following components were added to each well 
Table 2.19 Reaction composition for measuring total serum iron. 
Component Volume 
Iron buffer reagent 62.5 µl 
MilliQ water (for blank) or iron standard or 
serum sample 12.5 µl 
 
The components were mixed for 10 seconds on a plate shaker and then the absorbance was 
measured at 560 nm and recorded as A1 (Sample or Standard). Then 1.25 µl of the iron colour 
reagent was added to each well and mixed. The plate was then incubated at 37°C for 10 minutes and 
the absorbance measured at 560 nm. The second reading was recorded as A2 (Sample or Standard). 
The total serum iron was then calculated using the following formula 
  Total Serum iron (µg/dl)= (A2Sample−A1Sample)(A2 Standard−A1Standard) × Conc. of the std. 
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2.9.1.2 UIBC 
UIBC buffer reagent (55 µl) was added to each well before adding the components shown in Table 
2.20. 
Table 2.20 Reaction composition for measuring unsaturated iron binding capacity. 
Well Blank Standard Sample 
Component    
MilliQ water 25 µl 12.5 µl 0 
Iron standard 0 12.5 µl 12.5 µl 
Serum sample 0 0 12.5 µl 
 
After adding the components the plate was shaken on a plate mixer for 10 seconds and the 
absorbance at 560 nm was recorded as A1 (Sample or Standard). Then 1.25 µl of the iron colour 
reagent was added to each well and mixed. The plate was then incubated at 37°C for 10 minutes and 
the absorbance measured at 560 nm. The second reading was recorded as A2 (Sample or Standard). 
The UIBC was then calculated using the following formula 
  UIBC (µg/dl) =Conc. of the std.−( (A2Sample−A1Sample)(A2 Standard−A1Standard) × Conc. of the std. ) 
The total serum iron and UIBC values were then used to determine the TIBC and transferrin 
saturation as follows 
    TIBC =Total serum iron + UIBC 
    Transferrin Saturation =Total serum iron
TIBC
× 100 
2.9.2 Tissue iron concentration 
The method used here is a modification of the method described by Torrance and Bothwell 
(Torrance and Bothwell, 1968). Tissue (liver or spleen, 50-100 mg) was wrapped in aluminum foil 
and dried in an oven at 110°C for 24 hours. Dried tissue (15-20 mg) was weighed out in 1.5 ml 
screw cap tubes and acid solution (1 ml) (Table 2.21) was added to each tube. The standards were 
prepared as shown in Table 2.22. The standards and samples were then incubated at 65°C for 20 
hours. The next day the samples were mixed and then centrifuged before allowing them to cool 
down to RT. Sample or standards (5 µl) were added to each well (in duplicates) followed by 200 µl 
of the working chromagen reagent (Table 2.24). The components of the wells were mixed and 
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incubated at 37°C for 30 minutes before measuring the absorbance at 535 nm. The amount of iron 
in the sample (Fe µg/ml) was calculated by generating a standard curve for each plate, this value 
was then used to calculate the tissue iron concentration using the formula below 
Tissue iron concentration (µg/g dry wt. of the tissue) = Fe
dry wt of the sample  X vol of acid added 
 
Table 2.21 Acid solution for measuring non-haem iron in tissues. 
Component (acid solution) Final concentration 
Hydrochloric acid 3 M 
Trichloroacetic acid (Sigma, #T-0699) 0.6 M 
 
Table 2.22 Iron standards for assay to measure non-haem iron in tissues. 
µg Fe/ml Stock (1mg/ml) µl Acid (µl) 
0 0 200 
2 4 196 
5 10 190 
10 20 180 
20 40 160 
50 100 100 
75 150 50 
 
Table 2.23 Chromagen reagent stock for measuring non-haem iron in tissues. 
Component Concentration (wt/vol) 
Bathophenanthroline disulphonic acid 
 (Sigma, #B1375) 0.1% 
Thioglycollic acid (Sigma, #T-6750) 1% 
 
Table 2.24 Working chromagen reagent for measuring non-haem iron in tissues. 
Component Ratio 
Chromagen reagent stock (Table 2.23) 1 
Saturated sodium acetate solution 5 
MilliQ water 5 
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2.10 Flow cytometric analysis 
BM cells and splenocytes were isolated by passing through a 40 µm cell strainer into 10 ml PBS 
with 2% FCS (staining buffer). The cells were then centrifuged at 2,000 rpm at 4°C for 5 minutes 
and the pellets were resuspended in 5 ml of staining buffer. BM cells and splenocytes (1 million 
each from BM and spleen) were then transferred to 1.5 ml tubes and centrifuged at 3,000 rpm for 3 
minutes at RT. After discarding supernatants pellets were resuspended in 100 µl of the staining mix 
containing fluorophore-conjugated antibodies (Table 2.25) and incubated at 4°C for 1 hour. Excess 
unbound antibodies were removed by centrifuging the cells at 3,000 rpm for 3 minutes at RT. The 
pellets were then resuspended in 500 µl of FACS staining buffer and passed through a 40 µm cell 
strainer to remove clumped cells. The stained single cell suspensions were then analysed using the 
LSRFortessa 4 cytometer (BD Biosciences, Franklin Lakes, NJ, USA). The data plots were 
generated and analysed using the FlowJo software package (Tree Star Inc., Ashland, OR, USA). 
Table 2.25 List of fluorophore-conjugated antibodies used for flow cytometric analyses. 
Antibody (clone) Conjugate Concentration Supplier 
CD44 (IM7) Allophycocyanin 1:100 
Biolegend, San 
Diego, CA, USA 
#103012 
CD71 (R17217) BV421 1:200 Biolegend, 113813 
EPOR Phycoerytherin 1:100 Sino Biological Inc, Beijing, China 
TER119 Fluoroscein-isothiocyanate 1:100 
Milteyni Biotec, 
Bergisch Gladbach, 
Germany, # 130-091-
786 
2.11 Erythropoietin enzyme-linked immunosorbent assay (ELISA) 
Serum erythropoietin (EPO) levels were measured using the mouse EPO ELISA kit from R&D 
Systems (Minneapolis, MN, USA) according to the manufacturer’s instructions. Prior to using the 
kit, all the components of the kit were brought to RT. The serum was thawed and a 2-fold dilution 
was made using the Calibrator Diluent RD6Z provided in the kit. Assay diluent (50 µl) was added 
to 50 µl of sample, standard or controls (the standards and controls were provided with the kit) and 
the plate was incubated at RT for 2 hours on a horizontal shaker set at 500 rpm. After 2 hours, the 
wells were washed four times in the wash buffer and the liquid was removed completely after each 
wash. Mouse EPO conjugate (100 µl) was added to each well and incubated at RT for 2 hours on a 
shaker. After four washes, 100 µl of substrate solution was added to each well and incubated in the 
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dark for 30 minutes at RT. Stop solution (100 µl) was added to stop the reaction and absorbance 
was measured at 450 nm and 540 nm, the readings at 540 nm were subtracted from the readings at 
450 nm to correct for the optical imperfections in the plate. The concentration of EPO in the serum 
samples was calculated by using the standard curve plotted using the readings from the standards.  
2.12 Statistical analysis 
Statistical analysis on the variables between different groups of mice was performed by using 
Student’s t-test, one-way analysis of variance (ANOVA) and two-way ANOVA. Post-hoc analysis 
was performed to compare the differences between individual groups using Tukey’s. P-values 
<0.05 were considered to be statistically significant. The P-values of statistically significant 
comparisons have been stated in the text. Statistical analysis was performed using the GRAPHPAD 
PRISM 6 software (GraphPad Software, San Diego, USA). 
 
  
 
 
 
 
 
 
 
 
 
Chapter 3   
Interactions between HFE, TFR1 and TFR2 
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3.1 Introduction 
HFE and TFR2 have been shown to be involved in the regulation of iron metabolism. Patients with 
mutations in HFE and TFR2 have hereditary haemochromatosis (HH) (Camaschella et al., 2000; 
Feder et al., 1996). Mice with mutations or deletions in these genes develop iron overload (Fleming 
et al., 2002; Wallace et al., 2005; Zhou et al., 1998). It was also shown that the primary cause of 
iron overload in these mice is related to inappropriate levels of the iron hormone hepcidin (Ahmad 
et al., 2002; Wallace et al., 2005). Although HFE and TFR2 are known to be expressed in a range of 
tissues, hepatocyte-specific knockout models of Hfe and TfR2 demonstrated that the hepatic 
expression of HFE and TFR2 was enough to regulate systemic iron metabolism. These mice 
developed similar levels of iron overload as the total knockout models (Vujic Spasic et al., 2008; 
Wallace et al., 2007). These studies have increased our knowledge about the contribution of HFE 
and TFR2 to the regulation of iron metabolism, but have not explained the roles they play in the 
signalling pathways regulating hepcidin expression. Subsequent studies concentrated on how these 
two proteins interact with each other and TFR1 (the ubiquitously expressed receptor responsible for 
uptake of TF bound iron), leading to the iron sensing hypothesis. 
The current hypothesis which explains how HFE and TFR2 function in sensing iron levels in the 
body involves an interaction between the two molecules. HFE has been shown to interact with 
TFR1 (Feder et al., 1998; Lebron et al., 1998; Parkkila et al., 1997a). The site of interaction 
overlaps with the site where TFR1 binds to transferrin (West et al., 2001). In the current model, 
when TFR1 binds to iron-saturated transferrin (holo-TF), HFE is released and made available for 
binding to TFR2. The interaction of HFE and TFR2 is then thought to initiate a signalling cascade 
to regulate hepcidin. Initial studies using extracellular domains of HFE and TFR2 failed to detect an 
interaction between the two molecules (West et al., 2000). Subsequent studies using transient 
overexpression systems, however, identified an interaction between HFE and TFR2 (Chen et al., 
2007; Gao et al., 2009; Goswami and Andrews, 2006) and suggested that this interaction is required 
for the regulation of hepcidin (Gao et al., 2009). Studies using adeno-associated virus expression 
systems (Gao et al., 2010) have also suggested a requirement of both Hfe and TfR2 for regulating 
liver and serum iron levels. It was shown that expression of Hfe in Hfe KO mice and TfR2 in TfR2-
deficient mice was able to increase Hamp mRNA levels whereas expression of Hfe in TfR2-
deficient mice and vice versa did not have the same effect (Gao et al., 2010). In a recent study using 
the human hepatoma cell line (HuH7) and transient expression systems it was shown that HFE, 
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TFR2 and HJV form a complex on the membrane, and the formation of this complex is required for 
the regulation of hepcidin (D'Alessio et al., 2012). 
Using transgenic mice expressing myc-tagged HFE, no interaction was detected between the myc-
tagged HFE and TFR2 (Schmidt and Fleming, 2012). In addition, hepatocyte-specific expression of 
myc-tagged HFE reduced iron stores and induced hepcidin synthesis in TfR2 mutant mice (Schmidt 
and Fleming, 2012). These results suggest that TFR2 is not required for HFE-mediated hepcidin 
synthesis (Schmidt and Fleming, 2012). In a time-course study in subjects with HFE and TFR2 
mutations, hepcidin levels were measured after administration of oral iron (Girelli et al., 2011). It 
was shown that the patients with mutations in TFR2 did not respond to increases in transferrin 
saturation whereas there was a minimal hepcidin response in patients with HFE mutations under the 
same conditions (Girelli et al., 2011). The hepcidin response in patients with HFE mutations 
suggests that TFR2 can regulate hepcidin independently of HFE. 
The comparison of Hfe-/-, TfR2-/- and double knockout mice (Hfe-/-/TfR2-/-) (Delima et al., 2012; 
Wallace et al., 2009) shows that there is a gradation in hepatic iron overload, with the hepatic iron 
concentration and serum transferrin saturation increasing from WT<Hfe-/-<TfR2-/-< Hfe-/-/TfR2-/-. 
The levels of hepatic hepcidin relative to body iron stores also follow a gradient in the following 
order WT>Hfe-/->TfR2-/->Hfe-/-/TfR2-/-, indicating that both HFE and TFR2 contribute to the sensing 
of body iron stores (Delima et al., 2012; Wallace et al., 2009). In agreement with this, patients with 
mutations in both TFR2 and HFE present with a more severe form of disease compared to patients 
with either TFR2 or HFE mutations alone, with a phenotype similar to juvenile haemochromatosis 
(Pietrangelo et al., 2005). These observations suggest that HFE and TFR2 do not need to interact 
with each other to mediate a hepcidin response. 
The studies that have been able to detect an interaction between HFE and TFR2 were transient 
overexpression studies in cell models (Chen et al., 2007; Gao et al., 2009; Goswami and Andrews, 
2006), whereas in animal models and patients the results are indicative of an independent regulation 
of Hamp by HFE and TFR2 as shown by our laboratory and others (Pietrangelo et al., 2005; 
Schmidt and Fleming, 2012; Wallace et al., 2009). One of the reasons for these varying results 
could be the overexpression of the proteins in cells. In order to circumvent potential artefact issues 
associated with transient overexpression, a novel co-expression system, in which FLAG-tagged 
HFE and myc-tagged TFR2 are stably expressed under the same promoter was generated and used 
in this study. Importantly, the relative levels of HFE and TFR2 were similar, unlike the previous 
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studies where either of the two proteins was transiently overexpressed. The expression and cellular 
localisation of HFE, TFR1 and TFR2 were determined by immunoblotting and 
immunofluorescence. The interactions between HFE, TFR1 and TFR2 were examined at a cellular 
level by the use of a recently developed commercial assay (DuolinkTM) based on the principle of 
proximity ligation assay. 
3.2 Results 
3.2.1 Stable co-expression of HFE and TFR2 in Hepa1-6 cells does not affect 
their localisation 
In order to determine the interactions between HFE, TFR1 and TFR2, Hepa1-6 cells stably 
expressing N-terminal myc-tagged wildtype (WT) TFR2 or Y245X (YX) mutant TFR2 alone or in 
combination with FLAG-tagged WT HFE were utilised. The Y245X TFR2 mutant used here has 
been characterised previously (Fleming et al., 2002; Wallace et al., 2008) and in humans the 
corresponding truncation mutation, Y250X, is associated with HH type III (Camaschella et al., 
2000). Figure 3.1 shows the relative expression of HFE, TFR1 and TFR2 in untransfected and 
transfected cells which were detected using anti-FLAG, anti-TFR1, anti-TFR2 antibodies 
respectively. There are two bands for TFR2 which could be due to a glycosylated form of the 
protein (Kawabata et al., 2000). Figure 1B shows the truncated TFR2Y245X protein at approximately 
45 kDa. TFR1 is endogenously expressed in Hepa1-6 cells. 
 Figure 3.1 Analysis of expression of HFE, TFR1 and TFR2 in transfected Hepa1-6 cells. 
Hepa1-6 cells stably co-expressing FLAG-tagged HFE and myc-tagged TFR2 (WT), or truncated 
TFR2 (YX) were analysed by Western blotting using anti-FLAG, anti-TFR2, anti-TFR1 and anti-
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actin antibodies. (A) Immunoblot showing the relative expression levels of TFR1, TFR2 and HFE 
in untransfected Hepa1-6 cells (UT) and Hepa1-6 cells transfected with a vector to co-express HFE 
and WT TFR2 (WT). (B) Immunoblot showing the expression of FLAG-tagged HFE, TFR1 and 
truncated YX TFR2 (~45kD) in Hepa1-6 cells transfected with a vector to co-express HFE and YX 
TFR2. Actin was used as a loading control in all the immunoblots. 
Overexpression of tagged proteins may lead to their aggregation (Hu et al., 2002) or mislocalisation 
(Lisenbee et al., 2003; Nantel et al., 1999), thus affecting their function. In order to determine 
whether stable co-expression of HFE and TFR2 in Hepa1-6 cells affects their localisation, the 
localisation patterns of these proteins in cells expressing either myc-tagged WT TFR2 or FLAG-
tagged WT HFE singly or in cells co-expressing both HFE and TFR2 was examined. The confocal 
images in Figures 3.2, 3.3, 3.4 and 3.5 show that both HFE and TFR2 have a similar localisation, 
whether expressed singly or together. This indicates that the co-expression of HFE and TFR2 does 
not affect their localisation and function. FLAG-tagged HFE, endogenous TFR1 and myc-tagged 
TFR2 localised mostly intracellularly but expression of all three proteins on the plasma membrane 
was also detected as shown in Figures 3.2, 3.3, 3.4, and 3.5. 
 
Figure 3.2 Co-localisation of TFR1 with HFE and TFR2. Confocal microscopy analysis of TFR1 
(green in A and red in E), TFR2 (red) and HFE (green) in Hepa1-6 cells expressing either myc-
tagged TFR2 alone (A, B and C) or FLAG-tagged HFE alone (E, F and G). The transfected proteins 
were co-localised with endogenous TFR1. Images were obtained using a Nikon C2 confocal 
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microscope. The enlargements D and H show the co-localisation represented by arrows. Scale bar = 
20 µm. 
Co-localisation of two proteins suggests that they are present in the same subcellular compartment. 
In order to examine the co-localisation between HFE, TFR1 and TFR2 a double 
immunofluorescence experiment was performed. Figures 3.3C and 3.3D show that TFR1 partially 
co-localises with WT TFR2. Previous work from the laboratory had shown that TFR2Y245X has a 
defect in trafficking and is retained in the endoplasmic reticulum (Wallace et al., 2008); Figure 3.3B 
and Figure 3.3F shows that the truncated and WT TFR2 protein localise differently. The different 
localisation of TFR2Y245X leads to a decrease in co-localisation of TFR1 and TFR2 as seen in Figure 
3.3H. The co-localisation signal could be observed intracellularly, as well as on the surface of the 
cells. In the cells expressing HFE and WT TFR2 or TFR2Y245X, there was significant co-localisation 
between HFE and TFR1 (Figure 3.4C and D). 
Figure 3.3 Co-localisation of TFR1 and TFR2 in Hepa1-6 cells. Confocal microscopy analysis of 
Hepa1-6 cells stably co-expressing FLAG-tagged HFE and either myc-tagged TFR2 (WT) or 
truncated myc-tagged TFR2YX (YX). The localisation of TFR1 (in green) (A, E) appears to be 
endosomal as previously shown, the WT TFR2 (in red) (B, C and D) also localises to an endosomal 
compartment and to the plasma membrane, represented by white arrows, whereas the TFR2YX (in 
red) (F, G and H) appears to accumulate in the endoplasmic reticulum. TFR2YX does not co-localise 
with TFR1 (H). Images were obtained using a Nikon C2 confocal microscope. Scale bar = 20 µm. 
It was reported previously that HFE and TFR2 co-localise intracellularly in the crypt cells of the 
duodenum (Griffiths and Cox, 2003). In our hepatoma cell co-expression system there was a 
nominal co-localisation between HFE and WT TFR2 in punctuate intracellular vesicles (Figure 
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3.5C and D). The minimal co-localisation of the two proteins suggests that they could transiently 
co-exist in the same subcellular compartment and hence could be involved in an interaction. 
Figure 3.4 Co-localisation of HFE and TFR1 in Hepa1-6 cells. Confocal analysis was performed 
to determine the co-localisation of HFE and TFR1 in Hepa1-6 cells stably co-expressing FLAG-
tagged HFE and either myc-tagged TFR2 (WT) or truncated myc-tagged TFR2YX (YX). HFE (in 
green) (A and E) and TFR1 (in red) (B and F) co-localise in endosomal compartments and on the 
membrane (represented by white arrows) in the cells stably co-expressing HFE and WT TFR2 (C 
and D) or YX TFR2 (G and H). The images were obtained using a Nikon C2 confocal microscope. 
Scale bar = 20 µm. 
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Figure 3.5 Co-localisation between HFE and TFR2 in Hepa1-6 cells. Confocal microscopy 
analysis of Hepa1-6 cells stably co-expressing FLAG-tagged HFE and either myc-tagged TFR2 
(WT) or truncated myc-tagged TFR2YX (YX) reveals that HFE and TFR2 show minimal co-
localisation in cells stably co-expressing HFE (in green) and WT TFR2 (in red) (C and D) or 
truncated YX TFR2 (in red) (G and H). There is a small degree of overlap (white arrows) seen in 
some structures in WT (D) suggesting that HFE and TFR2 could be transiently present in the same 
subcellular structures. Images were acquired using Nikon C2 confocal microscope. Scale 
bar=20µm. 
3.2.2 In situ proximity ligation assay shows that HFE and TFR2 do not interact 
Co-immunoprecipitation (co-IP) is a standard method to determine whether two proteins of interest 
form a complex; however sometimes this technique fails to detect weak or transient interactions 
(Berggard et al., 2007). Co-IP involves lysis of the cells, this could bring proteins which are usually 
in different subcellular compartments together and result in false positive detection of an interaction 
(Berggard et al., 2007). The nominal co-localisation observed between HFE and TFR2 in Figure 3.5 
suggests that a small proportion of molecules may be involved in an interaction. A recently 
developed commercial assay (Duolink) based on the proximity ligation assay (PLA) overcomes 
these limitations (Soderberg et al., 2006). 
PLA uses oligonucleotides attached to the secondary antibodies as a surrogate marker for the 
detection of the protein of interest. Based on the proximity between the two proteins of interest the 
oligonucleotides serve as templates for the circularisation of the connector oligonucleotides. This 
circularised DNA is then amplified by a DNA polymerase, using one of the oligonucleotides as a 
primer. This amplified DNA is then hybridised with fluorescently labelled probes to identify the 
interactions between the proteins of interest (Soderberg et al., 2006). The advantage of PLA over 
conventional co-IP is that it identifies individual interactions between two proteins in their native 
form that may be weak or transient in nature. The assay results in a fluorescent signal in the form of 
a spot when the two proteins of interest are closer than 40 nm. To determine the interactions 
between HFE, TFR1 and TFR2 using PLA, Hepa1-6 cells stably expressing HFE and TFR2 were 
used. 
The specificity of the assay was tested using single antibodies directed against FLAG, TFR1 and 
TFR2; these also served as negative controls (Figures 3.6A, B, C and D). The absence of any spots 
indicates that the assay is specific with minimal non-specific proximity signals. 
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Figure 3.6 Specificity of PLA for transfected Hepa1-6 cells. PLA was performed on Hepa1-6 
cells stably co-expressing FLAG-tagged HFE and myc-tagged TFR2 (WT). The non-specific signal 
was examined by incubating Hepa1-6 cells with single antibodies directed against FLAG (A), TFR1 
(mouse) (B), TFR1 (rabbit) (C), or TFR2 (D). The absence of any proximity signal indicates that 
the assay is specific. TFR1 (mouse) – anti- TFR1 antibody raised in mouse, TFR1 (rabbit) – anti- 
TFR1 antibody raised in rabbit. 
The PLA was able to identify TFR1 and TFR2 as partners in Hepa1-6 cells, as indicated by the red 
dots in the confocal images (Figure 3.7A); each red dot represents a molecular interaction between 
the two proteins of interest. This is in agreement with previously published data (Vogt et al., 2003) 
where it was shown that TFR1 and TFR2 can form heterodimers. Similarly, HFE and TFR1 were 
also identified as proximity partners (Figure 3.7B). The absence of any PLA signal in Figure 3.7C 
indicates that HFE and TFR2 do not interact in the Hepa1-6 cells co-expressing HFE and TFR2. 
The proposed iron sensing model suggests that in the presence of holo-TF, HFE is released from 
TFR1 and is available to interact with TFR2. No interaction was observed between HFE and TFR2, 
suggesting that under normal conditions there is little or no interaction between HFE and TFR2. In 
order to determine the dynamics of HFE and TFR2 interaction in the presence of holo-TF, the cells 
expressing WT HFE and TFR2 were treated with 2 mg/ml of holo-TF or apo-TF (as previously 
described (Chen et al., 2007)) for 24 hours; PLA was performed on these treated cells. Figures 
3.7D-F represent the cells treated with apo-TF and Figures 3.7G-I represent the cells treated with 
holo-TF. The results show that in the presence of apo- or holo-TF, TFR1 and TFR2 form 
heterodimers (3.7D and G, respectively), and HFE and TFR1 interact (3.7E and H, respectively). 
The holo-TF treatment resulted in a decrease in the number of red spots per nucleus (Figure 3.7G 
and H). It has been shown that in the presence of holo-TF, TFR1 is internalised and the interaction 
between HFE and TFR1 decreases (Gao et al., 2009). The absence of any proximity signals in 
Figures 3.7F and I indicates that HFE and TFR2 do not interact in the presence of either apo- or 
holo-TF in Hepa1-6 cells. These results are contrary to the previously published data which 
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suggests that in the presence of holo-TF, the interaction between HFE and TFR2 increases (Chen et 
al., 2007; Gao et al., 2009). 
Figure 3.7 PLA shows that HFE and TFR2 do not interact. PLA was performed on Hepa1-6 
cells stably co-expressing FLAG-tagged HFE and myc-tagged TFR2 (WT). Previously 
characterised interactions between TFR1 and TFR2 (A, D and G) and HFE and TFR1 (B, E and H) 
were detected. HFE and TFR2 do not interact in untreated WT cells (C) or cells treated with apo-TF 
(F) or holo-TF (I). The arrows indicate the red spots representative of the interactions between the 
proteins of interest, each red spot is equivalent to one molecular interaction. Images were acquired 
using a Nikon C2 confocal microscope. Scale bar = 20 µm. Apo-TF cells were cultured in 2 mg/ml 
of apo-TF for 24 hours and Holo-TF cells were cultured in 2mg/ml of holo-TF for 24 hours. FLAG 
(HFE)+TFR1 represents the experiment where antibodies against FLAG-tagged HFE and TFR1 
(raised in rabbit) were used, Similarly TFR1+TFR2 represents the experiment where TFR1 (raised 
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in mouse) and TFR2 were used, and FLAG (HFE)+TFR2 represents the experiment where 
antibodies against FLAG-tagged HFE and TFR2 were used. 
3.2.3 Co-Immunoprecipitation experiments confirm the absence of interactions 
between HFE and TFR2 
Since no interaction could be detected between HFE and TFR2 using the highly sensitive PLA, it 
was hypothesised that the interaction could be transient. To ensure that the weak and transient 
interactions were stabilised, cells were treated with bissulphosuccinimidyl suberate (BS3), a surface 
crosslinker, for 30 minutes at 4 °C before harvesting the cells for protein extraction. The lysates 
from Hepa1-6 cells stably expressing HFE and TFR2 were used to precipitate proteins which form 
complexes with either HFE (FLAG) or TFR2. Rabbit immunoglobulin G (IgG) and mouse IgG 
were used as controls to detect any non-specific binding. Figure 3.8A shows that TFR1 can form 
complexes with HFE and TFR2 as previously shown.. A small amount of non-specific binding of 
TFR1 can be detected in the lanes representing rabbit IgG and mouse IgG IPs. Figure 3.8B indicates 
that neither HFE nor TFR2 are present in a protein complex with each other in the Hepa1-6 cells. 
The absence of any bands in the IgG lanes indicates that the assay is specific. In a previous study 
involving a domain swap of TFR1 and TFR2 (Chen et al., 2007) it was shown that amino acid 
residues 104-249 of TFR2 are sufficient for it to interact with HFE. A co-IP experiment with anti-
Flag and anti-TFR2 antibodies using lysates from cells expressing HFE and TFR2Y245X  was 
performed; Figure 3.8C shows that the truncated form of TFR2 which contains only the first 244 
amino acids of TFR2 does not exist in a complex with FLAG-tagged HFE. 
According to the current hypothesis, TFR2 interacts with HFE in the presence of holo-TF. The 
immunofluorescence results suggested that HFE and TFR2 could be present in the same subcellular 
compartment. PLA could not detect any interaction between the two molecules under any treatment 
conditions. In order to rule out the possibility of the PLA being a false negative test, a co-IP was 
performed on cells treated with holo and apo-TF. A Co-IP performed on the lysates of cells treated 
with apo- and holo-TF shows that HFE and TFR2 do not interact with each other in either of the 
conditions (Figure 3.8D). These results are contrary to the previously published data which 
suggested that in the presence of holo-TF, HFE and TFR2 form a complex (Chen et al., 2007; Gao 
et al., 2009; Goswami and Andrews, 2006). 
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Figure 3.8 Co-immunoprecipitation experiments reveal that HFE and TFR2 do not form a 
complex. Hepa1-6 cells stably co-expressing FLAG-tagged HFE and myc-tagged TFR2 (WT) were 
used to determine interactions between HFE, TFR1 and TFR2. (A) TFR1 interacts with HFE and 
TFR2. A co-IP with IgG rabbit and mouse antibodies shows some non-specific binding with TFR1. 
(B) Co-immunoprecipitation with anti-DYKDDDDK (Flag) beads and anti-TFR2 antibody reveals 
that HFE and TFR2 do not form a complex with each other. (C) HFE and TFR2 do not interact with 
each other in Hepa1-6 cells co-expressing FLAG-tagged HFE and myc-tagged TFR2YX. (D) WT 
cells were cultured in 2 mg/ml apo- or holo-TF for 24 hours and a Co-IP was performed with anti 
DYKDDDDK (Flag) beads and anti TFR2 antibody. HFE and TFR2 do not interact with each other 
in the presence of either apo- or holo-TF. SM - starting material or input, IgG M - IgG mouse, IgG 
Rb - IgG Rabbit, Apo-TF- apotransferrin and Holo-TF- holo-transferrin. 
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3.3 Discussion 
Previous studies using transient overexpression systems showed that HFE and TFR2 interact (Chen 
et al., 2007; Gao et al., 2009; Goswami and Andrews, 2006) and that this interaction is important 
for HFE and TFR2 mediated regulation of hepcidin (D'Alessio et al., 2012; Gao et al., 2009). Some 
recent studies have suggested that HFE and TFR2 can independently regulate hepcidin and could be 
acting in parallel to each other rather than synergistically (Girelli et al., 2011; Schmidt and Fleming, 
2012; Wallace et al., 2009). There is growing evidence about the hypothesis that TFR2 and HFE 
can independently regulate hepcidin in response to iron. The emerging hypothesis is that TFR2 acts 
upstream of BMP6, being involved in its regulation in response to iron, with HFE acting 
downstream (McDonald et al., 2014). The position of HFE in the hepcidin-regulatory pathway is 
supported by a recent study where it was shown that HFE specifically interacts with the BMP type I 
receptor ALK3 (Wu et al., 2014). 
To examine putative interactions between these proteins a novel expression system was developed 
where both HFE and TFR2 are stably co-expressed using a tricistronic vector. Using 
immunofluorescence and co-IP it was shown that a stable co-expression of HFE and TFR2 does not 
affect their localisation or function. There is partial co-localisation between TFR1 and HFE, and 
TFR1 and TFR2 suggesting that these proteins could be present in the same subcellular 
compartments and hence could interact or form a complex. As previously described, it was shown 
that the Y245X mutant of TFR2 (which contains only the first 244 amino acids of the protein) is 
retained in the endoplasmic reticulum (Wallace et al., 2008). 
The co-localisation studies indicated some overlap between HFE and TFR2 localisation in the cells 
expressing HFE and WT TFR2, hence it was hypothesised that they could be involved in a transient 
or weak interaction which sometimes cannot be detected using co-IP. The PLA is a sensitive 
technique which can be used to visualise weak and transient interactions at a cellular and molecular 
level. A signal is observed only if the two proteins of interest are in close proximity with each other 
(40 nm or less). This is the first report describing the interactions between HFE-TFR1 and TFR1-
TFR2 at a cellular level. The confocal images in Figure 3.7 suggest that there are more TFR1-TFR2 
dimerisation events as compared to interactions between HFE and TFR1. Although previous studies 
have suggested that HFE and TFR2 interact, no interactions between HFE and TFR2 could be 
detected using the stable co-expression expression system and either the highly sensitive PLA or 
Co-IP. It was shown earlier that a chimera of TFR1 and TFR2 consisting of TFR2104-250 is able to 
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interact with HFE (Chen et al., 2007). A co-IP experiment performed using cell lysates from the co-
expression system shows that TFR2Y245X and HFE do not form a complex with each other. 
The iron sensing model suggests that in the presence of holo-TF the interaction between HFE and 
TFR2 increases and this interaction signals a cascade of events which leads to HFE and TFR2 
mediated regulation of hepcidin. Hepa1-6 cells stably co-expressing HFE and WT TFR2 were 
treated with apo- or holo-TF in order to determine whether HFE and TFR2 interact in the co-
expression system under different iron conditions. The results suggest that HFE and TFR2 do not 
form a complex with each other when they are stably co-expressed. The results from these 
experiments and recent studies (Schmidt and Fleming, 2012; Wallace et al., 2009) indicate that HFE 
and TFR2 can act independently and do not need to interact, as earlier studies had suggested. 
Although previous in vitro studies using transient expression systems have been able to detect 
interactions (Chen et al., 2007; Gao et al., 2009; Goswami and Andrews, 2006), the results in these 
experiments probably differ because of a stable co-expression of the two proteins. This is supported 
by a recent in vivo study showing that mice expressing transgenic HFE could regulate hepcidin 
independently of TFR2 (Schmidt and Fleming, 2012). The authors did not observe any interaction 
between HFE and TFR2 and had suggested that some inhibitor in the tissue lysate could be 
responsible for degrading or inhibiting the complex (Schmidt and Fleming, 2012). However, the 
results shown here indicate that even in pure cell populations expressing the two proteins, HFE and 
TFR2 do not form a complex. One of the drawbacks of this system is that unlike some previously 
published studies (D'Alessio et al., 2012; Gao et al., 2009) it was not possible to measure the 
regulation of hepcidin in the presence of holo-TF as the cell lines used for these experiments do not 
respond to holo-TF treatment by upregulating hepcidin. 
In addition to the experiments described in this chapter, a large scale immunoprecipitation was 
performed in our laboratory using a previously characterised, highly specific TFR2 antibody 
generated in the lab (Wallace et al., 2005) and total liver homogenates, to identify the protein 
partners that could interact with TFR2. A mass spectrometric analysis of the immunoprecipitated 
complexes did not reveal HFE as a binding partner of TFR2. In the same experiment TFR1 was 
identified as a binding partner for TFR2. 
The results from these studies combined with that of previous studies suggest independent roles for 
HFE and TFR2 in regulating hepcidin. 
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3.4 Future directions 
Future studies will be aimed at dissecting the roles of HFE and TFR2 in the regulation of iron 
metabolism. The exact molecular roles of these two molecules still remain unidentified. The animal 
models available in the laboratory will be utilised to identify the interacting partners of HFE and 
TFR2. Using tissue homogenates from liver, co-immunoprecipitation experiments will be 
performed with HFE and TFR2 antibodies and the precipitated complexes will be used for mass 
spectrophotometric analysis. A part of this study has already been done once with the TfR2 KO 
mice and WT mice.  
In recent years protein microarray technology has made many advances, and these days protein 
microarrays can be reliably used to predict the signalling molecules associated with a particular 
protein or physiological condition (Pelech et al., 2008; Skalnikova et al., 2008; Zhang and Pelech, 
2012). Using total liver homogenates from knockout mice available in the laboratory (TfR2 and 
Hfe), the signalling pathways that require these two molecules will be identified using specific 
protein microarrays. The results of these studies will enable us to identify and understand the 
signalling mechanisms mediated by HFE and TFR2 to regulate hepcidin and iron homeostasis. 
 
  
 
 
 
 
 
Chapter 4  
Expression of TfR2 in the bone marrow, 
spleen and liver 
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4.1 Introduction  
While TfR2 is predominantly expressed in the liver, reverse transcriptase PCR analysis has also 
shown it to be expressed in the spleen, lung, muscle, prostate gland and PBMCs (Kawabata et al., 
1999). TFR2 mRNA was also detected in erythroid cell lines, whereas it was either undetectable or 
was present at very low levels in myeloid cell lines (Kawabata et al., 2001b). The mRNA levels of 
TfR2 decrease with the maturation of erythroid cells (Kawabata et al., 2001b). TFR2 was also 
detected in the BM and PBMCs of patients with different leukaemic conditions (Kawabata et al., 
2001b). In another study it was suggested that normal erythroid cells from humans do not express 
TFR2 protein although they do have a very low expression level of TFR2-α mRNA (Calzolari et al., 
2004). 
The BM is the predominant site where iron is utilised to maintain a steady synthesis of red blood 
cells. In order to ensure a steady supply of iron to the erythroid compartment, the BM regulates iron 
metabolism by influencing Hamp transcription in the liver. Hepcidin is regulated by an, as yet 
unknown, ‘erythroid regulator’, although a number of likely candidates e.g GDF15 (Tanno et al., 
2007), TWSG1 (Tanno et al., 2009) and more recently ERFE (Kautz et al., 2014), have been 
proposed, suggesting a humoral factor which is secreted by maturing erythroblasts. It has not been 
established whether the BM has its own local regulation of hepcidin in addition to its influence on 
the systemic regulation by the liver. The role of TfR2 in the BM is also unknown. 
The spleen is another organ which is involved in the regulation of iron metabolism and where TfR2 
mRNA and protein have been shown to be expressed (Roetto et al., 2010). The macrophages of the 
reticuloendothelial system are involved in recycling iron from senescent red blood cells. Recycling 
of iron by macrophages, by itself, provides more iron than intestinal absorption and release of iron 
from hepatocytes combined (Ganz, 2012). This makes the spleen the second most important organ 
for maintaining iron homeostasis. The majority of studies in this field have focused on 
understanding the molecular mechanisms underlying iron homeostasis in the liver, with very few 
studies analysing the role of the spleen. A comparison of TfR2-α and TfR2-β lacking mice suggested 
that TfR2-β could have a role in the regulation of macrophage Fpn1 mRNA regulation (Roetto et al., 
2010). 
In terms of importance, the BM and spleen are the two major organs, after the liver, which are 
involved in the systemic regulation of iron metabolism as they form the predominant sites of iron 
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usage and recycling respectively. The presence of TfR2 in these organs suggests that there could be 
some local regulation of iron metabolism in these tissues. 
Based on the available information it was hypothesised that TfR2 plays a role in the regulation of 
local iron metabolism in the spleen and BM. In addition, the pattern of expression observed for 
TfR2 (Kawabata et al., 2001b) in erythroid cells suggests that it could play a role in regulating the 
uptake of iron in developing erythroid cells or even contribute to local hepcidin regulation in the 
BM. In order to test this hypothesis mouse models available in the laboratory were utilised. 
The following groups of mice were used for the experiments described in this chapter. 
1. Wildtype C57BL/6 mice (WT). 
2. WT mice fed an iron-rich (2% carbonyl iron) diet for 2 weeks (WT-Fe). 
3. TfR2 knockout mice (TfR2-/-). 
4. Mice with hepatocyte-specific deletion of TfR2 (TfR2f/f/Alb-Cre+/-). 
4.2 Results 
4.2.1 TfR2 is expressed in the bone marrow and spleen 
Previous studies have suggested that TfR2 is expressed in the BM and spleen of mice (Kawabata et 
al., 1999; Kawabata et al., 2001b; Roetto et al., 2010). Although Kawabata et al. suggested the 
presence of TfR2 in the BM on the basis of semi-quantitative PCR, an appropriate negative control 
was not used (Kawabata et al., 2001a; Kawabata et al., 2001b). As shown in Figure 4.1 TfR2 mRNA 
can be detected in the BM of the WT and TfR2f/f/Alb-Cre+/- mice and is absent in TfR2-/- mice. WT 
mice fed an iron-rich diet were used as controls for the high iron levels found in the TfR2-/- and 
TfR2f/f/Alb-Cre+/- mice, in order to differentiate between the differences caused by either increased 
iron levels or the absence of TFR2. 
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Figure 4.1 TfR2 is expressed in the bone marrow. mRNA expression levels of TfR2 and Hamp 
(relative to the geometric mean of three reference genes: β-actin, Hprt and Polr2a) were measured 
in the BM of 5-week-old male WT (WT) mice, WT mice fed an iron-rich diet (WT-Fe), mice with a 
hepatocyte-specific deletion of TfR2 (TfR2f/f/Alb-Cre+/-) and TfR2 knockout mice (TfR2-/-) (n = 5 per 
group). Data are shown as dot plots, showing the mean and the standard error of the mean (SEM). 
Statistically significant differences (one way ANOVA with Tukey’s multiple comparison test; 
p<0.05) are denoted as (a) compared to WT, (b) compared to WT-Fe and (c) compared to 
TfR2f/f/Alb-Cre+/-. 
qRT-PCR analysis showed that the levels of TfR2 in the BM of WT-Fe (P=0.0425) and TfR2f/f/Alb-
Cre+/- (P=0.016) mice were significantly higher than WT mice, indicating that high levels of iron 
could be playing a role in regulating TfR2 transcription in the BM. This contradicts the present 
knowledge of TfR2 regulation in the liver where it has been shown that TfR2 does not have any 
IREs and hence is not regulated by iron at the transcriptional level (Kawabata et al., 1999). 
Although levels of Hamp exhibited an upward trend in animals with higher iron levels in the BM 
(WT-Fe and TfR2f/f/Alb-Cre+/-), the increases were not significant, suggesting that TfR2 may not be 
involved in the local regulation of Hamp in the BM. Additionally, to the best of my knowledge, this 
is the first time it has been shown that Hamp mRNA is expressed in the BM. 
Figure 4.2 TfR2 is expressed in the spleen. mRNA expression levels of TfR2 and Hamp (relative 
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to the geometric mean of three reference genes: β-actin, Hprt and Polr2a) were measured in the 
spleens of 5-week-old male WT (WT) mice, WT mice fed an iron-rich diet (WT-Fe), mice with a 
hepatocyte-specific deletion of TfR2 (TfR2f/f/Alb-Cre+/-) and TfR2 knockout mice (TfR2-/-) (n = 5 per 
group). Data are shown as dot plots, showing the mean and SEM. Statistically significant 
differences (one-way ANOVA with Tukey’s multiple comparison test; p<0.05) are denoted as (a) 
compared to WT, (b) compared to WT-Fe and (c) compared to TfR2f/f/Alb-Cre+/-. 
qRT-PCR analysis showed that TfR2 is expressed in the spleen of WT, WT-Fe and TfR2f/f/Alb-
Cre+/- mice (Figure 4.2); the absence of any TfR2 mRNA in the TfR2-/- mice indicates that the TfR2 
primers used in the qRT-PCR amplify a specific product. This is in agreement with previous studies 
where it was suggested that TfR2 is expressed in PBMCs (Kawabata et al., 1999; Kawabata et al., 
2001b) and macrophages (Roetto et al., 2010). The levels of TfR2 appear to be increased in the mice 
with higher iron levels, as seen in the BM (Figure 4.1) but the differences in the spleen were not 
significant. Hamp levels in the spleens of the iron-loaded mice also showed an increasing trend as 
seen in the BM (Figure 4.1) but the differences were not significant. 
These results suggest that although TfR2 is expressed in the BM and spleen of mice it does not 
appear to play a significant role in the local regulation of Hamp in these organs. In addition to 
determining relative levels of Hamp and TfR2 in the spleen, mRNA expression of other genes 
involved in the regulation of iron metabolism were also measured (Figure 4.3). 
There were no significant differences in the levels of Bmp6, Fpn1, Hfe and TfR1 in the spleens of 
any of the groups (Figure 4.3). The levels of TfR1 were lower in the spleens of WT-Fe, TfR2f/f/Alb-
Cre+/- and TfR2-/- mice but these differences were not significant. 
The SIC of the TfR2f/f/Alb-Cre+/- (P <0.0001) and TfR2-/- (P<0.0001) mice was lower than the WT-
Fe mice (Figure 4.4). This is expected, as unlike the WT mice which have a normal liver Hamp 
response to increased body iron stores, TfR2f/f/Alb-Cre+/- and TfR2-/- mice do not have an appropriate 
liver Hamp response (Wallace et al., 2007). As a result of reduced circulating hepcidin there is less 
degradation of the FPN protein on the surface of reticuloendothelial macrophages in the spleen. 
This results in the release of more iron from the reticuloendotheial cells of the TfR2f/f/Alb-Cre+/- and 
TfR2-/- mice and hence lower SIC than WT mice. 
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Figure 4.3 Loss of TfR2 does not affect local iron metabolism in the spleen. mRNA expression 
levels of Bmp6, Fpn1, Hfe and TfR1 (relative to the geometric mean of three reference genes: β-
actin, Hprt and Polr2a) were measured in the spleens of 5-week-old male WT (WT), WT mice fed 
an iron-rich diet (WT-Fe), mice with a hepatocyte-specific deletion of TfR2 (TfR2f/f/Alb-Cre+/-) and 
TfR2 knockout mice (TfR2-/-) (n = 5 per group). Data are shown as dot plots, showing the mean and 
SEM. Statistical analyses were analyses performed using one-way ANOVA and the multiple 
comparisons were made using Tukey’s multiple comparison test. 
    
Figure 4.4 TfR2f/f/Alb-Cre+/- and TfR2-/- mice have significantly lower splenic iron content as 
compared to WT-Fe mice. Splenic iron concentration(SIC) was measured in 5-week-old male WT 
(WT), WT mice fed an iron-rich diet (WT-Fe), mice with a hepatocyte-specific deletion of TfR2 
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(TfR2f/f/Alb-Cre+/-) and TfR2 knockout mice (TfR2-/-) (n = 5 per group). Data are shown as dot plots, 
showing the mean and SEM. Statistically significant differences (one-way ANOVA with Tukey’s 
multiple comparison test; p<0.05) are denoted as (a) compared to WT and (b) compared to WT-Fe. 
These results suggest that although TfR2 is expressed in the BM and spleen it may not necessarily 
be involved in the regulation of Hamp in these organs. To my knowledge, this is the first time it has 
been shown that Hamp is expressed in the BM, suggesting that there is some degree of local 
regulation of iron metabolism, although compared to the liver, the expression levels are very low 
(167-fold lower in the BM and 9400-fold lower in the spleen of WT mice as compared to the liver, 
the fold change was calculated by comparing the mean Hamp values for the three tissues). Another 
significant result is that Hamp does not seem to be affected by serum iron levels in the BM, as the 
mRNA levels were not significantly different between the WT-Fe and WT mice. Although the 
possibility that Hamp is regulated by iron in the BM cannot be completely ruled out, as the iron 
levels in the BM were not measured in this study. 
4.2.2 TFR2 is required for appropriate BMP-SMAD signalling 
As the liver is the major site involved in the systemic regulation of iron metabolism, mRNA levels 
of major genes involved in the BMP-SMAD signalling pathway were also measured using qRT-
PCR. In addition, hepatic iron concentrations, serum iron levels and transferrin saturation were 
measured as previously described. 
TfR2f/f/Alb-Cre+/- (P<0.0001) and TfR2-/- (P<0.0001) mice had significantly lower Hamp and Bmp6 
mRNA expression levels (Figure 4.5) as compared to WT-Fe mice. TfR2f/f/Alb-Cre+/- (P= 
.00325)and TfR2-/- (P=0.005)mice had significantly higher hepatic iron levels as compared to the 
WT animals and lower hepatic iron levels in comparison to WT-Fe mice (Figure 4.5). The 
transferrin saturation of the TfR2f/f/Alb-Cre+/- mice was significantly higher than any other group 
(Figure 4.6). Although the non-transferrin-bound iron (NTBI) was not measured in the samples,  the 
concentrations of total serum iron and transferrin saturation (Figure 4.6) suggest an increase in the 
amount of NTBI in the WT-Fe, TfR2f/f/Alb-Cre+/- and TfR2-/-. It has been shown that NTBI uptake is 
increased in the hepatocytes of Hfe knockout mice (Chua et al., 2004). The increase in NTBI may 
increase cellular cytotoxicity by increasing the amount of iron in the cells, although not much is 
known about the pathophysiology associated with this increased NTBI. 
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Figure 4.5 TfR2f/f/Alb-Cre+/- and TfR2-/- mice have significantly lower hepatic iron content, 
Hamp and Bmp6 levels compared to WT-Fe mice. mRNA expression levels of Bmp6, Hamp and 
TfR2 (relative to the geometric mean of three reference genes: β-actin, Hprt and Polr2a) and hepatic 
iron concentration (HIC) were measured in the livers of 5-week-old male wild type (WT), WT mice 
fed an iron-rich diet (WT-Fe), mice with a hepatocyte-specific deletion of TfR2 (TfR2f/f/Alb-Cre+/-) 
and TfR2 knockout mice (TfR2-/-) (n = 5 per group). Data are shown as dot plots, showing the mean 
and SEM. Statistically significant differences (one-way ANOVA with Tukey’s multiple comparison 
test; p<0.05) are denoted as (a) compared to WT and (b) compared to WT-Fe. 
The relative expression levels of other genes involved in the regulation of iron metabolism were 
also measured in the livers (Figure 4.7). There were no significant differences between the levels of 
Fpn1, Hjv and Hfe in any of the groups. The levels of TfR1 were significantly lower in the 
TfR2f/f/Alb-Cre+/- (P=0.001), TfR2-/- (P<0.001) and WT-Fe mice (P=0.0045). This is to be expected, 
as the HIC for these groups is higher than for the WT mice. 
Surprisingly the relative expression levels of two other downstream molecules in the BMP-SMAD 
signalling pathway; Id1 and Smad7 were significantly lower (P<0.001 for both genes and both 
genotypes) in the mice lacking TfR2 (Figure 4.7) as compared to WT-Fe mice. 
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Figure 4.6 TfR2f/f/Alb-Cre+/- and TfR2-/- mice have significantly higher transferrin saturation 
and serum iron levels. Serum iron indices were measured in 5-week-old male wild type (WT), WT 
mice fed an iron-rich diet (WT-Fe), mice with a hepatocyte-specific deletion of TfR2 (TfR2f/f/Alb-
Cre+/-) and TfR2 knockout mice (TfR2-/-) (n = 5 per group). Data are shown as dot plots, showing 
the mean and SEM. Statistically significant differences (one-way ANOVA with Tukey’s multiple 
comparison test; p<0.05) are denoted as (a) compared to WT, (b) compared to WT-Fe and (c) 
compared to TfR2f/f/Alb-Cre+/-. 
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Figure 4.7 TfR2f/f/Alb-Cre+/- and TfR2-/- mice have lower Id1 and Smad7 levels as compared to 
WT-Fe mice and WT mice. mRNA expression levels of Fpn1, Hfe, Hjv, Id1, Smad7 and TfR1 
(relative to the geometric mean of three reference genes: β-actin, Hprt and Polr2a) were measured 
in the livers of 5-week-old male WT (WT), WT mice fed an iron-rich diet (WT-Fe), mice with a 
hepatocyte-specific deletion of TfR2 (TfR2f/f/Alb-Cre+/-) and TfR2 knockout mice (TfR2-/-) (n = 5 per 
group). Data are shown as dot plots, showing the mean and SEM. Statistically significant 
differences (one-way ANOVA with Tukey’s multiple comparison test; p<0.05) are denoted as (a) 
compared to WT and (b) compared to WT-Fe. 
Figures 4.5 and 4.7 show that mice lacking TfR2 have lower Bmp6, Hamp, Id1 and Smad7 
expression in the livers as compared to livers of WT-Fe mice. These results suggest that TFR2 
expression in the liver is required for downstream signalling in the BMP-SMAD pathway. In order 
to test this hypothesis the ratios between HIC and Bmp6 and its downstream molecules (Hamp, Id1 
and Smad7) were calculated. These ratios indicate whether the signalling pathway is responding 
appropriately to increased iron levels. Figure 4.8 shows that although there were no significant 
differences between the Bmp6/HIC ratios of the TfR2f/f/Alb-Cre+/-, TfR2-/-and WT-Fe mice, the 
ratios for all three downstream molecules of Bmp6 (Hamp, Id1 and Smad7) are significantly lower 
in the mice lacking TfR2 as compared to WT and WT-Fe mice. These results suggest that loss of 
TfR2 results in a reduction in BMP-SMAD signalling which itself may be due to the lower Bmp6 
levels in the TfR2f/f/Alb-Cre+/- and TfR2-/- mice (Figure 4.5).  The lower Bmp6 mRNA levels in the 
liver may also be due to the lower HIC levels in TfR2f/f/Alb-Cre+/- and TfR2-/- mice as compared to 
the WT-Fe mice. Further studies comparing WT-Fe, TfR2f/f/Alb-Cre+/- and TfR2-/- mice with similar 
iron levels may be informative in delineating the role of iron and TFR2 in the regulation of liver 
Bmp6 mRNA levels. 
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Figure 4.8 TfR2f/f/Alb-Cre+/- and TfR2-/- mice have inappropriate BMP-SMAD signalling as 
compared to WT-Fe mice and WT mice. The ratios Bmp6/HIC, Hamp/HIC, Id1/HIC and 
Smad7/HIC were calculated in 5-week-old male WT (WT), WT mice fed an iron-rich diet (WT-Fe), 
mice with a hepatocyte-specific deletion of TfR2 (TfR2f/f/Alb-Cre+/-) and TfR2 knockout mice (TfR2-
/-) (n = 5 per group). Data are shown as dot plots, showing the mean and SEM. Statistically 
significant differences (one-way ANOVA with Tukey’s multiple comparison test; p<0.05) are 
denoted as (a) compared to WT and (b) compared to WT-Fe. 
In order to determine the levels of the proteins involved in BMP-SMAD signalling, western blotting 
was performed with total liver homogenates. Figure 4.9 shows a representative image of a blot 
performed at least three times and on all five mice from each group. The densitometric analysis of 
the blot shows significantly reduced levels of the immature non-processed form of BMP6 (pre-
BMP6) ( P= 0.0024 for TfR2f/f/Alb-Cre+/- and P=0.035 for TfR2-/-) as compared to WT-Fe mice and 
reduced phosphorylation of SMAD1/5 (P= 0.0035 for TfR2f/f/Alb-Cre+/- and P=0.0089 for TfR2-/-) as 
compared to WT-Fe mice (Figure 4.9 B) indicating reduced BMP-SMAD signalling as suggested in 
Figure 4.8. The levels of mature BMP6 protein were slightly lower in the mice lacking TfR2, 
although the differences were not significant between the groups. 
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Figure 4.9 Loss of TFR2 results in reduced SMAD1/5 phosphorylation. (A) Immunoblotting 
was performed using 25µg of total liver homogenate from 5-week-old male WT (WT), WT mice 
fed an iron-rich diet (WT-Fe), mice with a hepatocyte-specific deletion of TfR2 (TfR2f/f/Alb-Cre+/-) 
and TfR2 knockout mice (TfR2f/f) (n = 5 per group) and probed with antibodies against TFR2, 
phosphorylated SMAD1/5 (pSMAD1/5), Actin, pre-BMP6 (Pre) and mature BMP6 (mature). (B) 
Densitometric analyses of the protein bands were carried out for BMP6 (mature and pre) and 
pSMAD 1/5 and measured relative to actin. The blots were quantitated using Genetools software 
version 4. The graphs show the levels of BMP6 (mature), BMP6 (Pre) or pSMAD1/5 relative to 
Actin. Data are shown as dot plots, showing the mean and SEM (n = 5 per group). Statistically 
significant differences (one-way ANOVA with Tukey’s multiple comparison test; p<0.05) are 
denoted as (a) compared to WT and (b) compared to WT-Fe. 
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4.3 Discussion 
Previous studies have shown that TfR2 is expressed in the BM, PBMCs and macrophages of the 
spleen (Kawabata et al., 2001b; Roetto et al., 2010); the function of TfR2 in the BM and spleen is 
unclear. In one study, using a complex genetic strategy and breeding program, it was suggested that 
the β-transcript of TfR2 is somehow related to the regulation of Fpn1 in macrophages (Roetto et al., 
2010). This study also suggested that mice with a genotype similar to Type III HH, having the 
M167K (equivalent to the M172K in humans) mutation in the TfR2 gene do not develop iron 
overload. Contrary to this, studies from our laboratory using transfected cell model systems have 
shown that the mouse TFR2 protein harbouring this mutation does not reach the cell surface and 
accumulates in the endoplasmic reticulum. This mislocalisation of the mutant protein was suggested 
to impair its function, hence leading to inappropriate Hamp regulation (Wallace et al., 2008). 
It has been reported that splenic macrophages can produce Hamp in response to various infectious 
stimuli that act in an autocrine manner (Nguyen et al., 2006; Sow et al., 2007; Sow et al., 2009; Wu 
et al., 2012). In order to examine the role of TfR2 in regulating Hamp in macrophages, mRNA 
levels of Hamp were measured in different groups of animals; no significant differences were 
observed in any of the groups, including the TfR2 knockout mice, suggesting that TfR2 does not 
play a role in the regulation of Hamp in the spleen. Unlike a previous report, there were no 
significant differences in the levels of Fpn1 in the spleens of the mice lacking TfR2 (Roetto et al., 
2010) (Figure 4.3). This difference could be because the TfR2f/f/Alb-Cre+/- and TfR2-/- mice lack 
both α-and β-forms of TFR2 in the liver, as the knockout deletes exons 2-6 of TfR2 (Wallace et al., 
2004). 
BM and PBMCs express TfR2 (Kawabata et al., 1999; Kawabata et al., 2001b), but whether these 
proteins have a functional role in these tissues has not been investigated, i.e. whether TFR2 plays a 
role in regulating local iron metabolism within these tissues In order to examine the role of TFR2 in 
the local iron metabolism of the BM, Hamp levels were measured using qRT-PCR. There were no 
significant changes in Hamp mRNA levels in the mice with a deletion of TfR2. This suggested that, 
similar to the spleen, the TFR2 in the BM does not play a role in the regulation of Hamp. Although 
the possibility that TFR2 is required for iron uptake in the BM could not be ruled out as the iron 
content of the BM was not measured. The results shown here suggest that Hamp is produced in the 
BM; this has not previously been reported in the literature. An appropriate qRT-PCR control in 
order to rule out false positive results and to confirm the expression of Hamp in the BM would have 
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been the BM of Hamp KO mice. The results shown here suggest that Hamp in the BM is not 
regulated by systemic iron levels as it is in the liver (Figures 4.1 and 4.5). The factors regulating 
Hamp could be one of the erythroid regulators, ERFE, GDF15 or TWSG1 (Kautz et al., 2014; 
Tanno et al., 2007; Tanno et al., 2009) that have been proposed to regulate Hamp in response to 
erythropoeisis in the liver and the BM. 
Earlier studies have suggested that both Hfe and TfR2 knockout mice can regulate Bmp6 in response 
to increased iron levels, implying that both these proteins work downstream of Bmp6 (Corradini et 
al., 2011b). These results were in accordance with the current iron sensing model where HFE and 
TFR2 have been proposed to interact with each other (Goswami and Andrews, 2006). The 
Bmp6/HIC ratios in the mice lacking TFR2 were lower than in the WT mice (Figure 4.8), 
suggesting that in the absence of TFR2 there is an improper regulation of Bmp6 in response to 
hepatic iron stores. Recent studies, including the analysis of potential HFE and TFR2 interactions, 
as described in Chapter 3, have challenged this model and suggest that both HFE and TFR2 can act 
independently of each other in the regulation of Hamp (Rishi et al., 2013; Schmidt and Fleming, 
2012). It was recently shown in both mice and hepatic cell lines (Hep3B) that HFE is required for 
the cell surface expression and stabilisation the type I BMP receptor ALK3 (Wu et al., 2014). 
Studies published by our laboratory have recently shown that TFR2 is required for appropriate 
Bmp6 regulation in parenchymal cells. (McDonald et al., 2014). TfR2-/- and Hfe-/-/ TfR2-/- mice had 
lower Bmp6/HIC and Hamp/HIC ratios as compared to WT and Hfe-/- mice  (McDonald et al., 
2014). This difference was not observed in animals injected with iron-dextran supporting the 
hypothesis that TFR2 is required for an appropriate Bmp6 regulation and BMP-SMAD signalling in 
response to increased parenchymal iron  (McDonald et al., 2014).   These recent developments have 
shed new light on our understanding of how HFE and TFR2 act in the iron signalling pathway. 
Combined with the results shown here and recent studies from our laboratory (McDonald et al., 
2014) and others (Wu et al., 2014) , a new model for HFE- and TFR2-mediated regulation can be 
proposed (Figure 4.10). These results suggest that TFR2 may be involved in the appropriate 
regulation of Bmp6 signalling in response to iron and HFE is required to transport the type I BMP 
receptor to the surface of the hepatocyte (Wu et al., 2014), where it can bind to BMP6, initiating a 
signalling cascade resulting in the expression of Hamp. It has been shown that BMP6 treatment 
ameliorates iron overload in Hfe knockout mice (Corradini et al., 2010), although it is worth 
mentioning that the doses of BMP6 used were supraphysiologic. The fact that Hfe-/-, TfR2-/- and Hfe-
Chapter 4 
 
91 
 
/-/TfR2-/- mice fed an iron-rich diet were all able to upregulate Bmp6 suggests that there are other 
mechanisms that can influence the iron-mediated regulation of Bmp6 in addition to TFR2 
(Corradini et al., 2011b). 
 
  
Figure 4.10 Schematic representation of the proposed roles of HFE and TFR2 in the 
regulation of HAMP. Based on recently published studies from our laboratory (McDonald et al., 
2014) and others (Wu et al., 2014) it can be hypothesised that in response to increased iron levels 
TFR2 may be involved in a signalling pathway (denoted by the broken line and a question mark) 
which could result in the increased expression of BMP6 (McDonald et al., 2014) . BMP6 protein is 
then secreted, and interacts with the BMP receptors (BMPR). HFE is required to transport BMPR 
type I to the surface and hence is required for the proper interaction between BMPs and their 
receptors (Wu et al., 2014). In this model, the absence of a functional TFR2 may lead to reduced 
BMP signalling in response to increased iron levels resulting in an inappropriate HAMP response. 
In the absence of a functional HFE the type I BMPR is not properly localised to the surface of 
hepatocytes resulting in impaired pSMAD signalling and hence inappropriately low HAMP levels. 
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4.4 Future directions 
One of the most interesting findings shown here is the observation that TFR2 may be required in for 
increasing Bmp6 levels in response to iron. Future work will be directed towards deciphering the 
molecular mechanisms underlying this response. Co-immunoprecipitation (co-IP) experiments will 
be performed on lysates of livers from WT, WT-Fe, TfR2f/f/Alb-Cre+/-and TfR2-/- mice using the 
TFR2 antibody generated in our laboratory. This will help us identify binding partners of TFR2. 
Bioinformatic analyses of these binding partners will indicate the potential molecules involved in 
this pathway. In addition, primary hepatocyte cultures from the livers of the above groups of mice 
will be treated with apo-TF and holo-TF in the presence or absence of inhibitors of the signalling 
pathways identified from the co-IP experiments and bioinformatic analyses. The results of these 
experiments will enable us to better understand how iron metabolism and Hamp are regulated in 
response to increases in body iron levels and the role of TFR2 in the regulatory pathway. 
Recent studies have suggested a role for non-parenchymal cells of the liver (stellate cells, sinusoidal 
cells and Kupffer cells) in the production of Bmp6 in response to increased iron levels (Enns et al., 
2013; Feng et al., 2012). It was also shown that incubation with holo-TF increases Bmp6 levels in 
stellate cells but not in hepatocytes. 
In the results shown in this chapter the relative levels of Bmp6 in the liver of TfR2-/- mice are 
slightly lower than TfR2f/f/Alb-Cre+/- (Figure 4.5). On removing the WT-Fe group from the analysis, 
allowing a comparison between the changes only due to the loss of TfR2 and not diet, the 
differences between the two groups (TfR2f/f/Alb-Cre+/- and TfR2-/-) are statistically significant 
(Figure 4.11). This suggests that TfR2 expression in non-parenchymal cells could be contributing to 
the regulation of Bmp6 expression in the liver. 
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Figure 4.11 TFR2 may play a role in Bmp6 regulation in the non-parenchymal cells of the 
liver. mRNA expression levels of Bmp6 (relative to the geometric mean of three reference genes: β-
actin, Hprt and Polr2a) were measured in the livers of 5-week-old male wild type (WT), mice with 
a hepatocyte-specific deletion of TfR2 (TfR2f/f/Alb-Cre+/-) and TfR2 knockout mice (TfR2-/-) (n = 5 
per group). Data are shown as dot plots, showing the mean and SEM. Statistically significant 
differences (one-way ANOVA with Tukey’s multiple comparison test; p<0.05) are denoted as (a) 
compared to WT and (b) compared to TfR2f/f/Alb-Cre+/-. 
Previously it was suggested that co-culture of the activated macrophage cell line THP1 and the 
human hepatoma cell line HuH7 resulted in increased activity of the HAMP promoter (Matak et al., 
2009). These results indicate that regulation of Hamp in response to increased iron levels could 
involve intercellular crosstalk in addition to intracellular signalling. The results shown in Figures 
4.5 and 4.11 suggest that TfR2 could be involved in this intercellular crosstalk. In order to examine 
the role of TfR2 in the non-parenchymal cells of the liver, co-cultures of different cell types from 
the liver could be performed using cells isolated from WT and TfR2-/- mice. The non-parenchymal 
cells isolated from WT and TfR2-/- mice could be treated with holo- or apo-TF prior to incubation 
with hepatocytes from WT or TfR2-/- mice in order to determine the cell types involved in the 
crosstalk. Additionally the hepatocytes could be incubated with culture media from the treated non-
parenchymal cells; this could help in determining whether the crosstalk involves a secreted signal. 
These experiments would further enhance our understanding of the molecular and signalling 
pathways involving TFR2 and its role in regulating iron homeostasis.  
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5.1 Introduction 
5.1.1 Inflammation and iron 
It has long been known that inflammation and iron metabolism are linked; an early study in dogs 
showed that a subcutaneous injection of turpentine (an inflammatory agent) results in reduced 
uptake of a radioactive isotope of iron (Hahn et al., 1946). Similar observations were later made in 
mice where a subcutaneous injection of inflammatory agents reduced serum iron significantly 
(Nemeth et al., 2004a; Nicolas et al., 2002a). Patients suffering from the ACD were shown to have 
reduced serum iron levels and transferrin saturation (Douglas and Adamson, 1975), these early 
studies laid the groundwork for later research which clearly established an important link between 
inflammation, infections and iron metabolism. The decrease in serum iron and transferrin saturation 
appears to be one of the defense mechanisms used to limit the growth of pathogens in the host. 
Most infectious pathogens require a steady supply of iron to carry out their functions, and in 
response to an infection the host tries to limit the access of micro-organisms to the iron pool, thus 
linking infection and iron homeostasis. 
Recent studies have supported this hypothesis. It has been shown by our laboratory that increased 
iron stores result in a worse disease outcome in a mouse model of schistosomiasis (McDonald et al., 
2010). Another study showed that iron deficiency leads to a better survival rate in children with 
malaria (Gwamaka et al., 2012). Children with iron deficiency had decreased prevalence of 
parasitaemia and severe malaria. These results have initiated further discussion about the treatment 
of patients suffering from the ACD. Although the negative consequences of anaemia can be 
detrimental to the health of the patient, an increase in iron levels by iron therapy may support the 
pathogen and lead to a worse prognosis, hence warranting closer and more careful monitoring of 
such patients. 
After the discovery that hepcidin is involved in the regulation of iron homeostasis in response to 
body iron levels (Nicolas et al., 2001; Pigeon et al., 2001) it was also shown that a single injection 
of turpentine could cause up to a 6-fold reduction in liver Hamp mRNA levels and a 2-fold decrease 
in serum iron levels (Nicolas et al., 2002a). This was a significant step towards understanding the 
interplay between inflammation and iron metabolism, as it was soon shown that hepcidin binds to 
the iron exporter FPN and induces its internalisation and degradation, hence limiting the release of 
iron from the sites of absorption (enterocytes), storage (hepatocytes) or recycling (macrophages) 
(Nemeth et al., 2004b). 
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The next breakthrough in understanding the mechanistic details of inflammation-mediated Hamp 
regulation was made when it was shown that treating primary hepatocytes with either IL6 or LPS 
increases Hamp levels by up to 25-fold (Nemeth et al., 2003). In the case of IL6 this change could 
be observed within 8 hours of treatment, indicating that this was an acute response to limit the 
amount of serum iron (Nemeth et al., 2003). It was suggested that Hamp is a type II acute phase 
protein as it was produced in response to treatments with IL6 and LPS and not tumour necrosis 
factor-α (TNFα) or interleukin 1α (IL1α) (Nemeth et al., 2003). Il6 knockout (KO) mice with 
subcutaneous turpentine abscesses did not show an increase in Hamp levels as compared to 
wildtype (WT) mice, confirming the requirement for IL6 in the inflammation-iron axis (Nemeth et 
al., 2004a). In other studies it was shown that in addition to IL6, both IL1α and IL1β could induce 
Hamp in primary hepatocytes from WT, Il6-/-, and TfR2-/-, mice suggesting that other inflammatory 
molecules could be involved in the regulation of Hamp (Lee et al., 2005). Absence of HFE, TFR2 
or β2-microglobulin does not interfere with the LPS-mediated induction of Hamp in mice 
suggesting that these molecules are not required (Frazer et al., 2004; Lee et al., 2004). 
Further mechanistic details were uncovered with studies in the hepatoma cell line HepG2/2.1 
showing that the IL6-mediated transcriptional regulation of HAMP (IL6 could increase HAMP 
levels after cycloheximide treatment, thus ruling out an indirect translational effect) required 
STAT3 (Wrighting and Andrews, 2006). Chromatin immunoprecipitation studies (ChIP) proved 
that STAT3 directly binds to the HAMP promoter (Wrighting and Andrews, 2006). These 
discoveries uncovered a signalling pathway which was capable of regulating HAMP transcription in 
response to inflammation. 
IL6 signalling mechanisms had already been elucidated before this discovery and it was known that 
one of the ways this cytokine mediated its effect was by binding to the complex of IL6 receptor and 
GP130 (Heinrich et al., 2003). This binding induces the activation of JAK resulting in the 
phosphorylation of STAT3 which translocates to the nucleus to bind to STAT regulatory elements 
(Carbia-Nagashima and Arzt, 2004) and controls transcription of target genes (Levy and Lee, 2002). 
When infected with either bacteria (Streptococcus pneumoniae) or a virus (influenza A (PR8) the 
Il6 KO mice failed to produce an appropriate Hamp response, indicating the requirement of IL6 for 
the inflammatory regulation of Hamp (Rodriguez et al., 2014). On treating WT mice with a panel of 
pathogen derived molecules (PAMPs) stimulating different toll like receptors (TLRs) (which are 
involved in mediating inflammatory responses to various infectious stimuli) including TLR1/2, 
TLR2/6, TLR4, TLR5, TLR3, TLR7 and TLR9, an increase was observed in the case of treatments 
with ligands for TLR1, 2, 3, 4, 5 and 6 but not TLR7 (Rodriguez et al., 2014). In the case of the Il6 
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KO mice PAMPs failed to induce Hamp indicating that IL6 is required for a variety of 
inflammatory signals in order to elicit a Hamp response (Rodriguez et al., 2014). Treatment of 
primary human hepatocytes with the same PAMPs induced an increase in HAMP which was 
reduced in the presence of IL6 or IL6 receptor neutralising antibodies, again emphasising the 
requirement of IL6 for an appropriate HAMP response under inflammatory conditions (Rodriguez et 
al., 2014). 
In addition to the already mentioned effects of IL1α and IL1β on hepatocytes, which showed an 
IL6-independent increase in HAMP levels (Lee et al., 2005), it was recently demonstrated, in 
hepatoma cell lines (Hep 3B and HepG2), that treatment with IL22 induces HAMP (Armitage et al., 
2011). The increase in HAMP after treatment with IL22 was augmented when BMPs were added, 
indicating a crosstalk between the SMAD and STAT signalling pathways. This is supported by a 
study showing that mice lacking Smad4 failed to increase Hamp in response to IL6 (Wang et al., 
2005). Treatment of mice with recombinant IL22 (rIL22) induced an increase in Hamp; this 
increase was shown to be independent of IL6 as Il6 KO mice showed the same response as the WT 
mice (Smith et al., 2013). This response to IL22 was also observed in primary human hepatocytes 
where treatment with rIL22 increased HAMP irrespective of the presence of IL6 neutralising 
antibodies, indicating an IL6-independent regulation of HAMP. 
These studies have enabled us to understand the underlying mechanisms linking iron metabolism 
and inflammation. There is evidence supporting a crosstalk between the molecules involved in the 
iron sensing and inflammatory pathways. Previously it was shown that mice lacking Hfe were 
unable to increase Hamp in response to LPS treatment (Roy et al., 2004), but subsequently it was 
suggested that a Hamp response can be initiated in mice in response to inflammatory stimuli even in 
the absence of Hfe (Frazer et al., 2004; Lee et al., 2004). In a recent study published by our 
laboratory it was shown that mice lacking TfR2 alone or both TfR2 and Hfe have a decreased iron 
withholding response after an inflammatory stimulus (Wallace et al., 2011). This was attributed to 
lower basal levels of hepcidin (Wallace et al., 2011). The low levels of hepcidin also correlated with 
increased FPN protein expression in the spleens of the TfR2-/- and the Hfe-/-/TfR2-/- double knockout 
mice (Wallace et al., 2011). These results suggest that TFR2 could be required for increasing Hamp 
levels in response to inflammatory stimuli. 
5.1.2 Macrophages and hepcidin 
Macrophages are important for maintaining iron availability and hence iron homeostasis in the 
body. The macrophages of the reticuloendothelial system are responsible for recycling iron from 
senescent erythrocytes. This means of obtaining iron alone surpasses the amount of iron obtained by 
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absorption in the intestine and release from hepatocytes combined (Ganz, 2012). Another major role 
of resident macrophages of the liver (Kupffer cells) is believed to be in the production of IL6 
through a TLR4-dependent mechanism which then acts on hepatocytes to induce Hamp (Milward et 
al., 2007). 
In a clever experiment to delineate the role of Kupffer cells in inflammation and iron-related Hamp 
production, mice were treated with gadolinium chloride, an agent which selectively eliminates the 
Kupffer cells and reduces release of cytokines and free radicals in response to injury (Montosi et al., 
2005). The animals were then injected with iron dextran (to induce iron overload), LPS or 
turpentine (to induce an inflammatory response). The levels of Hamp increased in mice in response 
to iron overload irrespective of whether they had been treated with gadolinium chloride, indicating 
that Kupffer cell activity is not required for Hamp production in response to iron (Montosi et al., 
2005). In response to inflammatory stimuli the mice with inactivated Kupffer cells showed a 
diminished Hamp production as compared to animals which had active Kupffer cells (Montosi et 
al., 2005). At the same time a study using transplantation of the BM of Hfe-/- mice into WT mice 
and vice versa suggested that expression of HFE in macrophages significantly reduces iron loading 
in the spleen (Makui et al., 2005), thus pointing to a link between iron sensing mechanisms and 
macrophages. 
In addition, it has been shown that macrophages can produce Hamp in response to inflammatory 
signals; alveolar macrophages were shown to increase Hamp production in response to LPS 
treatment (Nguyen et al., 2006).The increase in Hamp was similar in the alveolar macrophages from 
Il1 receptor (Il1r) knockout, Il6 knockout and WT mice suggesting that neither IL1R nor IL6 were 
required (Nguyen et al., 2006). Interestingly, the levels of Fpn1 were also decreased in the 
macrophages treated with LPS, which suggests that LPS treatment limits the release of iron from 
macrophages by reducing Fpn levels at both transcriptional and post-translational levels (an 
increase in Hamp results in more hepcidin-ferroportin binding reducing, the amount of surface FPN 
protein) (Nguyen et al., 2006). 
Bone marrow-derived macrophages (BMDMs) treated with IFNγ produce Hamp when they are 
infected with mycobacterium (Sow et al., 2007), this increase was not observed in BMDMs treated 
with either IL1 or IL6 (Sow et al., 2007). In addition to suggesting that this increase in Hamp acts to 
limit the release of iron, it was shown that hepcidin localises in the phagosomes with the 
mycobacterium and it has a direct antibacterial effect against M. tuberculosis (Sow et al., 2007). 
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5.1.3 Iron and the macrophage phenotype 
Macrophages can be classified into two types: M1/the classically activated macrophages, and 
M2/the alternatively activated macrophages. The M1 macrophages are responsible for initiating Th1 
responses which includes production of pro-inflammatory cytokines, like IL6 and IL12, whereas the 
M2 macrophages produce a Th2 response characterised by the production of anti-inflammatory 
cytokines, like TGFβ and IL10 (Corna et al., 2010). It was suggested that M2 macrophages are 
more effective in recycling iron as they had lower expression levels of ferritin heavy chain, and 
higher levels of Fpn1, TfR1, Irp1, Irp2 and Hfe (Corna et al., 2010). The M2 macrophages also had 
a higher labile iron pool, although there was no difference in the total iron levels in the two different 
populations (Corna et al., 2010). Under normal iron conditions both cell types were able to 
effectively activate T-cells but in conditions of iron deficiency the ability of M2 macrophages to 
activate T-cells was reduced (Corna et al., 2010). These results indicate that the two different 
macrophage populations are probably required to perform different roles in relation to iron 
metabolism. The M1 macrophages appear to restrict iron release in response to infection or 
inflammatory stimuli while the M2 macrophages appear more involved in the recycling of iron from 
erythrocytes (Corna et al., 2010). 
Iron has been suggested to affect the function of macrophages. In patients with chronic venous 
ulcers it was shown that iron-loaded M1 macrophages were responsible for a persistent pro-
inflammatory profile (Sindrilaru et al., 2011). These macrophages failed to switch to the anti- 
inflammatory M2 phenotype, leading to a chronic inflammatory state and adding to severity of the 
disease. The deposition of iron was shown to be a cause of severity of the disease in both patients 
and mice (Sindrilaru et al., 2011). In mice injected with iron dextran (to induce iron overload), 
wound healing was delayed and again an increase in the iron-loaded unrestrained pro-inflammatory 
M1 macrophage population was observed (Sindrilaru et al., 2011). These results were one of the 
first where iron loading was linked to a specific macrophage population and the severity of disease. 
The link between iron and macrophage function is a relatively new field and has significant 
potential in designing therapies and in the management of patients with diseases where 
macrophages play an important role as part of the immune system, e.g. cancer and infectious 
diseases. It would also be worth looking at the possibility of iron affecting other macrophagic 
functions such as phagocytosis, as this process is one of the important ways of controlling foreign 
organisms in the host and forms the first line of defense against infection. 
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5.1.4 TFR2 and macrophages 
HFE was shown to be expressed on the surface of tissue macrophages, circulating monocytes and 
granulocytes (Parkkila et al., 2000). BM transplant experiments performed in mice suggest that 
HFE expressed in macrophages plays a role in maintaining iron levels in the spleen and liver, and 
hence the regulation of Hamp (Makui et al., 2005), however, the mechanism of this regulation is not 
yet clear. TfR2 mRNA was detected in the spleen, muscle, lung, prostate, immature erythroid cells 
and peripheral blood mononuclear cells, as well as being predominantly expressed in the liver 
(Jacolot et al., 2010; Kawabata et al., 1999; Kawabata et al., 2001b). It has also been shown to be 
expressed in human macrophage cell lines (Jacolot et al., 2008). TFR2 protein was also shown to be 
expressed in splenic and peritoneal cavity macrophages (Roetto et al., 2010). It was suggested that 
the β-form of TFR2 is required for spleen-specific regulation of iron removal as mice lacking β-
TFR2 had lower levels of Fpn1 in the spleen. These results pointed to a role for TFR2 in the 
transcriptional regulation of Fpn1. 
Although there have been a few studies suggesting that TFR2 is expressed in macrophages, the role 
of TFR2 in these cells is not clearly understood. In order to examine this, mice lacking TFR2 in the 
cells of the macrophage/monocyte lineage were generated by crossing LysM-Cre mice (generously 
provided by Prof. Christian Engwerda, QIMR Berghofer Medical Research Institute) with the 
TfR2f/f mice. LysM is a macrophage/monocyte specific protein; hence the Cre transgene expressed 
under the control of the LysM promoter would lead to a deletion of TFR2 from macrophages and 
monocytes in TfR2f/f LysM-Cre+/- mice. 
In addition to characterising the knockout mice, the role of macrophage/monocyte TFR2 was also 
examined in stress conditions by feeding mice an iron-rich diet of 2% carbonyl iron for 2 weeks or 
injecting them with LPS. These treatments enabled examination of the role of macrophage TFR2 
under conditions of iron overload and LPS-mediated inflammation, respectively. 
All the animals used for these experiments were sacrificed at 5 weeks of age, at which point their 
tissues were harvested and blood samples taken for further analyses, which included examining the 
mRNA and protein expression of molecules regulating iron metabolism in response to iron and 
inflammation. The expression levels were measured using qRT-PCR and western blotting (where 
antibodies were available). Iron parameters were measured using previously described methods for 
measuring serum iron, transferrin saturation, hepatic and splenic iron concentrations. In order to 
examine iron deposition in the liver and spleen, Perls’ staining was performed on paraffin sections 
from formalin-fixed tissues. The tissue morphology of the spleen and liver was analysed by 
performing H&E staining on the paraffin sections. 
Chapter 5 
 
101 
 
5.2 Results  
5.2.1 Deletion of macrophage TfR2 does not affect TfR2 expression levels in the 
liver or systemic iron parameters 
In order to delete TfR2 expression in the cells of macrophage/monocyte origin, LysM-Cre mice on a 
C57/BL6 background were crossed with TfR2f/f on the same background. Figure 5.1 shows a 
significant reduction (P<0.0001) in the expression levels of TfR2 in the spleens of the 
macrophage/monocyte-specific TfR2 knockout (TfR2f/f/LysM-Cre+/-; M-KO) mice as compared to 
the control (TfR2f/f) mice. This reduction in the levels of TfR2 expression was not observed in the 
livers of the M-KO mice suggesting that the LysM-Cre transgene does not have any off-target effect 
on the liver. 
 
Figure 5.1 TfR2f/f/LysM-Cre+/- have reduced expression of TfR2 in the spleen. mRNA expression 
levels of TfR2 (relative to the geometric mean of three reference genes: β-actin, Hprt and Polr2a) 
were measured in the spleen and liver of 5-week-old control (●TfR2f/f) and M-KO (■TfR2f/f/LysM-
Cre+/-) male mice (n = 5 per group) fed a control (Control diet) or iron-rich diet (High-Fe diet). 
Data are shown as dot plots, showing the mean and standard error of the mean (SEM). Statistically 
significant differences (two-way ANOVA using Tukey’s multiple comparison test; p<0.05) are 
denoted as (a) compared to the control genotype. 
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Figure 5.2 Mice lacking TfR2 in macrophages have normal systemic iron parameters. Splenic 
iron concentration (SIC), hepatic iron concentration (HIC), total serum iron and transferrin 
saturation were measured in the spleen and liver of 5-week-old control (●TfR2f/f) and M-KO 
(■TfR2f/f/LysM-Cre+/-) male mice (n = 5 per group) fed a control (Control diet) or an iron-rich diet 
(High-Fe diet). Data are shown as dot plots, showing the mean and SEM. Statistically significant 
differences (two-way ANOVA using Tukey’s multiple comparison test; p<0.05) are denoted as (b) 
compared to the respective control treatment group. 
There were no significant differences between the levels of splenic or hepatic iron in the control or 
M-KO animals (Figure 5.2). The iron indices increased significantly in the animals fed an iron-rich 
diet, as expected, but there were no significant differences between the control and M-KO animals 
suggesting that macrophage TfR2 is not required for maintaining systemic iron levels. 
H&E staining of paraffin sections did not reveal any significant abnormalities or differences in the 
morphology of either the liver or spleen in the M-KO animals as shown in Figures 5.3 and 5.4. The 
pattern of iron distribution was assessed by Perls’ staining which did not reveal any significant 
differences between the control and M-KO mice. The sections shown in Figures 5.5 and 5.6 are 
representative of each group. The animals used for these Figures represent the mice with the median 
HIC and SIC values for each group. As can be seen in Figures 5.3-5.6 there were no differences in 
the morphology or the pattern of iron distribution between the control and M-KO mice, even when 
the animals were fed an iron-rich diet. In the liver, iron distribution was in the normal periportal 
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pattern, accumulating in the hepatocytes of the animals fed an iron-rich diet, with no observable 
differences between the controls and the M-KO mice (Figure 5.5). Similarly, the spleens of the 
animals fed an iron-rich diet showed iron loading in the white pulp (Figure 5.6). 
   
Figure 5.3 TfR2f/f/LysM-Cre+/- mice do not show any morphological differences in the liver. 
H&E staining was performed on liver sections from 5-week-old control (TfR2f/f) and M-KO 
(TfR2f/f/LysM-Cre+/-) male mice (n = 5 per group) fed a control (Control diet) or an iron-rich diet 
(High-Fe diet). Scale bar = 200 µm. 
   
Figure 5.4 TfR2f/f/LysM-Cre+/- mice do not show any morphological differences in the spleen. 
H&E staining was performed on sections of the spleen from 5-week-old control (TfR2f/f) and M-KO 
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(TfR2f/f/LysM-Cre+/-) male mice (n = 5 per group) fed a control (Control diet) or an iron-rich diet 
(High-Fe diet). The nodularity of the red and white pulp was clearly identifiable in the control and 
M-KO mice. Scale bar = 200 µm. 
   
Figure 5.5 TfR2f/f and TfR2f/f/LysM-Cre+/- mice fed an iron-rich diet show iron loading in 
hepatocytes. Perls’ staining was performed on liver sections from 5-week-old control (TfR2f/f) and 
M-KO (TfR2f/f/LysM-Cre+/-) male mice (n = 5 per group) fed a control (Control diet) or an iron-rich 
diet (High-Fe diet). Scale bar = 200 µm. 
   
Figure 5.6 TfR2f/f and TfR2f/f/LysM-Cre+/- mice fed an iron-rich diet show iron loading in the 
macrophages of the spleen. Perls’ staining was performed on sections of the spleen from 5-week-
old control (TfR2f/f) and M-KO (TfR2f/f/LysM-Cre+/-) male mice (n = 5 per group) fed a control 
(Control diet) or an iron-rich diet (High-Fe diet). Scale bar = 200 µm. 
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5.2.2 Regulation of iron metabolism genes in the spleen of TfR2f/f/LysM-Cre+/- 
mice 
An analysis of the iron indices (HIC, SIC, serum iron and TF saturation, Figure 5.2) suggested that 
macrophage TfR2 is not required for maintaining systemic iron levels. In order to determine the 
effect of loss of TfR2 in the macrophage/monocyte compartment, the relative mRNA expression 
levels of iron metabolism related genes was measured in the spleens of control and M-KO mice fed 
a control and iron-rich diet. 
Surprisingly, the M-KO mice on the control diet showed slightly higher relative levels (but not 
statistically significantly) of Bmp6 and Hamp in the spleens (Figure 5.7). The levels of Bmp6 and 
Hamp did not differ in the control and M-KO mice when the animals were fed an iron-rich diet, 
suggesting that unlike in the liver, iron levels do not regulate Hamp or Bmp6 in the spleen. The 
mRNA levels of Hfe also did not show any significant differences between the control and the M-
KO animals irrespective of the diet (Figure 5.7). The mRNA levels of TfR1 and Fpn1 exhibited a 
downward trend in the M-KO mice (although not significant) as compared to the control mice 
(irrespective of the diet). The absence or presence of TfR2 in macrophages did not significantly alter 
the relative levels of any of the genes tested in Figure 5.7, suggesting that macrophage/monocyte 
expression of TfR2 may not be required for iron regulated expression of iron metabolism genes in 
the spleen. 
Previously it has been suggested that β-TfR2 could be required for Fpn1 transcription in 
macrophages (Roetto et al., 2010). The M-KO mice generated in our studies lack both α- and β- 
forms of TfR2, as the loxP sites in the TfR2f/f mice flank exons 2 and 6. The mice used in the study 
by Roetto et al. (Roetto et al., 2010) were different from the M-KO mice, as the mice lacking β-
TfR2 expressed the α-form of TfR2 in all other tissues. The M-KO mice do not develop iron 
overload, similar to the mice used in the previous study (Roetto et al., 2010), but since they lack 
both forms of TfR2 in the macrophages this is a novel model to study the function of TfR2 in the 
cells of macrophage or monocyte lineage. 
It is worth noting here that although the reduced levels of Fpn1 do not reach statistical significance 
(Figure 5.7), the levels are lower in the M-KO animals, hence, the possibility of TfR2 affecting the 
transcription of Fpn1 in the macrophages cannot be ruled out. It should be noted that the results 
shown here use total RNA extracted from the spleen which consists of other cell types in addition to 
cells of the monocyte/macrophage lineage. The levels of TfR1 exhibit a downward trend in the M-
KO animals irrespective of the dietary conditions, one of the mechanisms known to regulate the 
levels of TfR1 transcription is through the IRE-IRP system, where an increase in iron levels leads to 
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a decrease in the transcription of TfR1. The splenic iron concentrations are not significantly 
different between the control and the M-KO animals, hence, the possibility of iron levels affecting 
TfR1 expression is unlikely. 
    
Figure 5.7 TfR2f/f/LysM-Cre+/- mice have normal expression of iron metabolism related genes 
in the spleen. mRNA expression levels of Bmp6, Hamp. Hfe, Fpn1 and TfR1 (relative to the 
geometric mean of three reference genes: β-actin, Hprt and Polr2a) were measured in the spleens of 
5-week-old control (●TfR2f/f) and M-KO (■TfR2f/f/LysM-Cre+/-) male mice (n = 5 per group) fed a 
control (Control diet) or iron-rich diet (High-Fe diet). Data are shown as dot plots, showing the 
mean and SEM. Statistical analyses using two-way ANOVA and Tukey’s multiple comparison test 
did not reveal any significant differences between groups. 
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5.2.3 BMP-SMAD mediated-regulation of Hamp in the liver is not affected in 
TfR2f/f/LysM-Cre+/- mice 
There were no significant differences between the iron indices of control and M-KO animals when 
fed either a control or iron-rich diet (Figure 5.2). In order to determine whether the loss of TfR2 in 
cells of the macrophage/monocyte lineage had an effect on the regulation of liver Hamp or other 
molecules in the BMP-SMAD pathway, qRT-PCR analysis was performed. The relative expression 
of the molecules involved in the regulation of liver Hamp in response to iron (Bmp6, Smad7, Hjv, 
Tmprss6, and Hfe) or regulation of iron metabolism itself (Fpn1) are presented in Figure 5.8. 
The mRNA expression levels of Bmp6, Hamp, and the downstream targets of BMP-SMAD 
signalling i.e. Id7 and Smad7 were increased in the control and M-KO mice fed an iron-rich diet 
(Figure 5.8). There were no significant differences in the levels of Bmp6 and Hamp and the 
downstream targets of the BMP-SMAD signalling pathway between the control and M-KO groups 
in their respective diet group, suggesting that iron-mediated Hamp regulation is not affected in the 
mice lacking TfR2 in macrophage/monocyte cells. 
The levels of Tmprss6 show an interesting trend in the M-KO animals fed an iron-rich diet; these 
animals have significantly lower levels of Tmprss6 as compared to the M-KO animals fed a control 
diet (Figure 5.8). This down-regulation of Tmprss6 was not observed in the control mice. 
TMPRSS6 is a negative regulator of Hamp, which acts by cleaving HJV, a BMP co-receptor. This 
is interesting, as one would expect an increase in Hamp as a result of Tmprss6 down-regulation. 
There is some evidence to suggest that both iron deprivation (Zhang et al., 2011) and iron overload 
(Meynard et al., 2011) can result in an increase in Tmprss6 mRNA levels. The results shown here 
suggest that in the absence of macrophage/monocyte TfR2, Tmprss6 levels are significantly lower in 
the M-KO animals fed an iron-rich diet (P=0.0108). 
The levels of Fpn1 in M-KO animals fed an iron-rich diet were significantly lower compared to the 
control animals on the same diet (P=0.0356) (Figure 5.8); similarly in animals fed a control diet the 
Fpn1 levels exhibited a downward trend in M-KO animals,. A similar effect was seen in the spleens 
of M-KO animals (Figure 5.7), suggesting that macrophage TfR2 could have an as yet unexplained 
effect on Fpn1 transcription as suggested earlier (Roetto et al., 2010). 
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Figure 5.8 TfR2f/f/LysM-Cre+/- mice have normal hepcidin regulation in the liver. mRNA 
expression levels of Bmp6, Hamp, Hfe. Fpn1, Hjv, Tmprss6, Id1 and Smad7 (relative to the 
geometric mean of three reference genes: β-actin, Hprt and Polr2a) were measured in the livers of 
5-week-old control (●TfR2f/f) and M-KO (■TfR2f/f/LysM-Cre+/-) male mice (n = 5 per group) fed a 
control (Control diet) or an iron-rich diet (High-Fe diet). Data are shown as dot plots, showing the 
mean and SEM. Statistically significant differences (two-way ANOVA using Tukey’s multiple 
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comparison test; p<0.05) are denoted as (a) compared to the control genotype and (b) compared to 
the respective control treatment group. 
In order to analyse the regulation of BMP-SMAD signalling at the protein level, western blotting 
was performed on total liver homogenates of M-KO and control mice fed a control or iron-rich diet. 
Figure 5.9 shows a representative image of a blot performed at least three times and on all five mice 
from each group. There was an increase in the levels of TFR2 protein in the animals fed an iron-rich 
diet (Figure 5.8). This was expected, as it has been shown that increase in holo-TF stabilises the 
TFR2 protein in cells (Johnson and Enns, 2004) and livers of mice (Robb and Wessling-Resnick, 
2004). The levels of pSMAD1/5 were increased in the livers of mice fed an iron-rich diet as would 
be expected. These results suggest an appropriate BMP-SMAD signalling in the M-KO mice. 
  
Figure 5.9 An iron-rich diet increases phosphorylation of SMAD1/5 in the livers of TfR2f/f and 
TfR2f/f/LysM-Cre+/- mice. (A) Immunoblotting was performed using 25µg of total liver 
homogenates from 5-week-old control (TfR2f/f) and M-KO (TfR2f/f/LysM-Cre+/-) male mice fed a 
control (Control diet) or an iron-rich diet (High-Fe diet) (n = 5 per group) and probed with 
antibodies against TFR2, pSMAD1/5, and Actin. This is a representative image of a blot performed 
at least three times and on all five mice from each group. (B) Densitometric analysis of the protein 
bands were carried out for TFR2 and pSMAD1/5 and measured relative to Actin levels. The blots 
were quantitated using Genetools software version 4. The graphs show the ratios between TFR2 or 
pSMAD1/5 and Actin. Data are shown as dot plots, for control (●TfR2f/f) and M-KO 
(■TfR2f/f/LysM-Cre+/-) mice showing the mean and SEM (n = 5 per group). Statistically significant 
differences (two-way ANOVA with Tukey’s multiple comparison test; p<0.05) are denoted as (b) 
compared to the respective control treatment group. 
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The results of these experiments suggest that, although expression of TfR2 in macrophages/ 
monocytes is not required for an efficient BMP-SMAD mediated regulation of Hamp in response to 
increased iron levels, it could still play a role in the transcription of two other molecules, namely 
Fpn1 and Tmprss6. 
5.2.4 LPS treatment reduces serum iron levels 
The major function of macrophages is to maintain immune homeostasis and one aspect of this 
involves regulating Hamp in response to inflammation. In order to determine whether the absence 
of TfR2 in these cell populations affects their inflammation-related functions, control and M-KO 
animals were injected with LPS or saline (control) for 6 hours and their tissues were harvested for 
further analysis. 
Inflammatory stimuli such as turpentine and LPS are known to induce Hamp in both mice and 
humans. This increase in HAMP is thought to be mediated by the production of IL6 by 
macrophages, which then acts through the JAK-STAT pathway resulting in the production of 
HAMP (Milward et al., 2007; Nemeth et al., 2004a; Wrighting and Andrews, 2006). 
Mice lacking both Hfe and TfR2 or TfR2 alone have a reduced Hamp induction in response to 
inflammatory stimuli (Wallace et al., 2011) as compared to WT mice, suggesting that TfR2 could 
play a role in inflammation mediated Hamp induction. 
The animals treated with LPS for 6 hours had significantly lower serum iron levels as compared to 
controls (saline treated) (Figure 5.10). These results are in agreement with previous studies which 
have shown that in the presence of infections or inflammatory stimuli the serum iron levels of mice 
decrease (Nemeth et al., 2004a; Nicolas et al., 2002a). 
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Figure 5.10 LPS treatment reduces serum transferrin saturation and total serum iron in 
TfR2f/f/LysM-Cre+/-and TfR2f/f. Splenic iron concentration (SIC), hepatic iron concentration (HIC), 
total serum iron and transferrin saturation were measured in the spleen and liver of 5-week-old 
control (●TfR2f/f) and M-KO (■TfR2f/f/LysM-Cre+/-) male mice (n = 5 per group), treated with saline 
or LPS for 6 hours. Data are shown as dot plots, showing the mean and SEM. Statistically 
significant differences (two-way ANOVA using Tukey’s multiple comparison test; p<0.05) are 
denoted as (b) compared to the respective control treatment group. 
The decrease in transferrin saturation was observed in both the control and M-KO mice and no 
differences were observed between genotypes, suggesting that this was a LPS-specific effect and it 
did not require macrophage TfR2 expression. The splenic iron content of the LPS-treated mice was 
significantly lower than the controls. 
There was no difference in the pattern of iron loading in the control or M-KO mice, either in the 
spleens or livers, as seen in the Perls’ staining in Figures 5.11 and 5.12. The sections shown in 
Figures 5.11 and 5.12 are from a representative animal from each group. The animals used for these 
Figures represent the mice with the median HIC and SIC values for each group. These results 
suggest that expression of TfR2 in the macrophage/monocyte cells is not required for maintaining 
systemic iron levels and reducing transferrin saturation in response to LPS treatment. 
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Figure 5.11 TfR2f/f and TfR2f/f/LysM-Cre+/- mice treated with LPS do not load iron in the liver. 
Perls’ staining was performed on sections of liver from 5-week-old control (TfR2f/f) and M-KO 
(TfR2f/f/LysM-Cre+/-) male mice (n = 5 per group) treated with saline or LPS for 6 hours. Scale bar = 
200 µm. 
   
Figure 5.12 TfR2f/f and TfR2f/f/LysM-Cre+/- mice treated with LPS do not load iron in the 
spleen. Perls’ staining was performed on sections of spleen from 5-week-old control (TfR2f/f) and 
M-KO (TfR2f/f/LysM-Cre+/-) male mice (n = 5 per group) treated with saline or LPS for 6 hours. 
Scale bar = 200 µm. 
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5.2.5 Effect of LPS treatment on iron metabolism genes in the spleen  
Dietary iron loading did not have any significant impact on the expression of iron metabolism genes 
in the spleens of the TfR2f/f (control) mice and TfR2f/f/LysM-Cre+/- (M-KO) and, as shown in Figure 
5.7, treatment with LPS resulted in a significant reduction in the expression levels of Fpn1, Bmp6, 
Hfe and TfR1 (Figure 5.13). These results are in agreement with previous studies indicating that 
LPS treatment can reduce Fpn1 levels in macrophages. It was suggested that this reduction is 
independent of the IL6 pathway, as LPS-treated splenocytes from Il6 KO and WT mice had similar 
reductions in Fpn1 levels (Liu et al., 2005). The levels of TfR2 do not change with LPS treatment 
and as expected the M-KO mice have lower TfR2 mRNA expression levels in the spleens. 
Figure 5.13 LPS treatment results in a reduction in the expression levels of Fpn1, Hfe and 
TfR1 in the spleen. mRNA expression levels of TfR2, Bmp6, Fpn1,Hamp, Hfe, and TfR1 (relative 
to the geometric mean of three reference genes: β-actin, Hprt and Polr2a) were measured in the 
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spleens of 5-week-old control (●TfR2f/f) and M-KO (■TfR2f/f/LysM-Cre+/-) male mice (n = 5 per 
group) treated with saline or LPS for 6 hours. Data are shown as dot plots, showing the mean and 
SEM. Statistically significant differences (two-way ANOVA using Tukey’s multiple comparison 
test; p<0.05) are denoted as (a) compared to the genotype and (b) compared to the respective 
control treatment group. 
A reduction in the levels of TfR1 was shown to be due to decreased iron regulatory protein (IRP) 
activity when macrophages were treated with LPS (Tacchini et al., 2008). LPS treatment increased 
nitric oxide synthesis, which resulted in a decrease in IRP activity and stability, resulting in a 
decrease in the stability of TfR1 mRNA (Kim and Ponka, 2000; Recalcati et al., 1998). The 
reduction in Hfe reported in this study is, to our knowledge, the first time it has been shown that 
LPS treatment can affect Hfe transcription in the spleen. 
An interesting result was the difference observed in the Bmp6 levels of the M-KO and control 
animals treated with LPS. There was a significant reduction in the levels of Bmp6 in the control 
animals treated with LPS as compared to the control animals injected with saline (P=0.013), but 
Bmp6 was significantly higher in the M-KO animals treated with LPS as compared to the LPS 
treated control mice (P=0.0395). The reduction in Hfe and Bmp6 levels is contrary to what would be 
expected; in response to inflammatory stimuli, Hamp levels are increased to limit the release of 
iron, hence, one would expect that any mechanism to increase or maintain Hamp levels would at 
least not be affected. Although both Hfe and Bmp6 are believed to be a part of the iron sensing 
pathway for regulating Hamp levels, a reduction in their levels is unexpected. 
5.2.6 LPS treatment reduces TfR2 levels in the liver 
Inflammatory stimuli like LPS, turpentine and infectious agents have been shown to increase liver 
Hamp (Nemeth et al., 2003; Nicolas et al., 2002a). The mechanism of action has been studied in 
some detail and it is widely believed that the signalling pathway primarily involves the production 
of IL6 which acts on hepatocytes to induce Hamp through the JAK-STAT pathway (Nemeth et al., 
2003; Nemeth et al., 2004a; Pietrangelo et al., 2007; Weinstein et al., 2002; Wrighting and 
Andrews, 2006). 
As expected, the expression of Hamp increased significantly in the livers of animals treated with 
LPS (P=0.0016 and P=0.0198 for control and M-KO mice) (Figure 5.14), and there were no 
significant differences between the control and M-KO animals. This suggests TfR2 expression in the 
Kupffer cells (resident macrophages of the liver) is not required for the inflammation-mediated 
Hamp response. 
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Interestingly the level of liver TfR2 decreased significantly in the animals treated with LPS as 
compared to saline treated animals ( P=0.0004 and P<0.0001 for control and M-KO mice 
respectively); there was no significant difference in the levels between the control and M-KO 
animals (Figure 5.14). This reduction can be attributed to the LPS treatment, as the levels of TfR2 
did not vary significantly in the livers of any other groups of animals (see control diet and iron-rich 
diet groups in Figure 5.2). This appears to be a novel mechanism for the transcriptional control of 
TfR2 which has not been reported yet. In order to determine whether this reduction in mRNA levels 
translates to protein expression in the liver, an immunoblot was performed. Figure 5.15 shows a 
representative image of a blot performed at least three times and on all five mice from each group. 
Figure 5.15 A and B show that levels of TFR2 protein are reduced in the mice treated with LPS. 
 
Figure 5.14 LPS treatment induces Hamp and leads to a reduction in the levels of TfR2 in the 
livers. mRNA expression levels of TfR2 and Hamp (relative to the geometric mean of three 
reference genes: β-actin, Hprt and Polr2a) were measured in the livers of five-week old male 
control (●TfR2f/f) and M-KO (■TfR2f/f/LysM-Cre+/-) mice (n = 5 per group) treated with saline or 
LPS for 6 hours. Data are shown as dot plots, showing the mean and SEM. Statistically significant 
differences (two-way ANOVA using Tukey’s multiple comparison test; p<0.05) are denoted as (b) 
compared to the respective control treatment group. 
5.2.7 LPS treatment leads to a reduction in the expression levels of iron sensing 
genes 
The relative expression levels of genes known to be involved in regulating Hamp were determined 
in the livers of animals treated with LPS and saline. The relative levels of Bmp6, Hjv, Hfe, Fpn1 and 
Tmprss6 decreased in the animals treated with LPS (Figure 5.16). The levels of Id1 increased in the 
animals treated with LPS, but the difference was statistically significant only in the control animals. 
Similarly the relative levels of Smad7 were reduced in the LPS-treated animals. This decrease was 
significant only in the M-KO mice, suggesting that LPS treatment affects the downstream signalling 
of the BMP-SMAD pathway. 
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Figure 5.15 LPS treatment reduces TFR2 protein levels in the liver. (A) Immunoblotting was 
performed using 25µg of total liver homogenates from 5-week-old control (TfR2f/f) and M-KO 
(TfR2f/f/LysM-Cre+/-) male mice (n = 5 per group) treated with saline or LPS for 6 hours. The 
immunoblot was probed with antibodies against TFR2, pSTAT3 and Actin. This is a representative 
image of a blot performed at least three times and on all five mice from each group. (B) 
Densitometric analyses of the protein bands were carried out for TFR2 or pSTAT3 and measured 
relative to Actin. The blots were quantitated using Genetools software version 4. The graphs show 
the ratios between TFR2 or pSTAT3 and Actin. Data are shown as dot plots, for control (●TfR2f/f) 
and M-KO (■TfR2f/f/LysM-Cre+/-) mice showing the mean and SEM (n = 5 per group). Statistically 
significant differences (two-way ANOVA with Tukey’s multiple comparison test; p<0.05) are 
denoted as (b) compared to the respective control treatment group. 
These observations suggest that LPS treatment decreases the expression of many genes involved in 
the regulation of Hamp in response to iron levels. Several studies have reported the LPS-mediated 
down-regulation of Fpn1 and Hjv (Krijt et al., 2004; Liu et al., 2005; Niederkofler et al., 2005; 
Pagani et al., 2011; Yang et al., 2002). The mechanisms responsible for the LPS-mediated decrease 
in Fpn1 mRNA levels were suggested to be non-IL6 related (Liu et al., 2005), as splenocytes from 
Il6 KO mice also showed similar LPS-mediated reductions as those in WT mice. The inflammation-
mediated down-regulation of Fpn1 appears to be mediated by TLR4 signalling, as mice lacking 
TLR4 did not show any Fpn1 down-regulation following LPS treatment (Yang et al., 2002). 
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Figure 5.16 LPS treatment leads to a reduction in the levels of major genes involved in iron 
mediated regulation of Hamp in the liver. mRNA expression levels of Bmp6, Hjv, Hfe, Fpn1, Id1, 
Smad7 and Tmprss6 (relative to the geometric mean of three reference genes: β-actin, Hprt and 
Polr2a) were measured in the livers of 5-week-old control (●TfR2f/f) and M-KO (■TfR2f/f/LysM-
Cre+/-) male mice (n = 5 per group) treated with saline or LPS for 6 hours. Data are shown as dot 
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plots, showing the mean and SEM. Statistically significant differences (two-way ANOVA using 
Tukey’s multiple comparison test; p<0.05) are denoted as (a) compared to the genotype and (b) 
compared to the respective control treatment group. 
The LPS-mediated down regulation of iron sensing molecules in the liver does not depend on TfR2 
expression in macrophages, as the effect can be seen in both the control and M-KO animals. This is 
the first time that such a broad impact of an inflammatory signal on the transcription of molecules 
involved in iron sensing has been reported. These results were tested in additional C57BL/6 WT 
animals which were purchased from the Animal Resource Centre (ARC) in Western Australia and 
treated with either saline or LPS. Figure 5.17 shows that a similar reduction can be observed in the 
WT animals treated with LPS for 6 hours. 
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Figure 5.17 LPS treatment leads to a reduction in the levels of major genes involved in iron 
regulation in the livers of WT male mice. mRNA expression levels of TfR2, Hamp, Bmp6, Fpn1, 
Id1, Smad7, Hfe, Hjv and Tmprss6 (relative relative to the geometric mean of three reference genes: 
β-actin, Hprt and Polr2a) were measured in the livers of 5-week-old male WT C57BL6 mice 
treated with saline or LPS for 6 hours (n= 5 per group). Data are shown as dot plots, showing the 
mean and SEM. Statistically significant differences (un-paired t-test) are denoted as * (p<0.05), *** 
(p<0.001), and **** (p<0.0001). 
The results shown in Figure 5.17 confirm the observations made in Figure 5.16; a similar (or more 
significant) level of reduction was observed in the mRNA expression of TfR2, Bmp6, Fpn1 and Hjv 
in the livers of WT mice treated with LPS, suggesting that this reduction in transcription is 
mediated by LPS. Interestingly the mRNA levels of Id1 decreased slightly in the WT mice treated 
with LPS (Figure 5.17) as compared to the control mice treated with LPS in Figure 5.16 where the 
mRNA levels of Id1 had increased. 
5.3 Discussion 
Previous studies have suggested that TfR2 is expressed in macrophages (Kawabata et al., 2001b; 
Roetto et al., 2001). The β-form of TFR2 was suggested to be involved in the transcription of Fpn1 
specifically in macrophages (Roetto et al., 2001), but the mechanisms were not investigated. In 
order to examine the molecular functions of TfR2 in cells of macrophage/monocyte lineage, LysM-
Cre mice which express the Cre protein in the cells of macrophage/monocyte lineage were crossed 
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with TfR2f/f mice generated in our laboratory. This resulted in the deletion of TfR2 from the cells of 
the macrophage/monocyte lineage. The deletion could be detected specifically in the spleen but not 
in the liver (Figure 5.1). 
The deletion of TfR2 in macrophages did not affect systemic iron metabolism (Figures 5.2- 5.6), 
suggesting that macrophage TfR2 is dispensable for the systemic regulation of body iron. The 
expression levels of genes involved in regulating iron metabolism did not differ significantly 
between the control and M-KO animals in either the spleens or the liver. The levels of Fpn1 were 
lower in the spleens and significantly lower in the livers of the M-KO animals (fed an iron-rich diet) 
confirming the previous observation that TfR2 could be influencing Fpn1 transcription (Roetto et 
al., 2010). This difference did not reach statistical significance in the spleens. One of the reasons 
could be the presence of other cell types (lymphocytes, neutrophils and dendritic cells) in the spleen 
which may be contributing to Fpn1 expression levels and thus affecting the observations. An 
important experiment will be to determine the levels of Fpn1 in isolated macrophages and 
monocytes and determine whether the differences are significant. 
Another significant observation was that the M-KO animals fed an iron-rich diet had significantly 
lower Tmprss6 levels as compared to the M-KO animals fed a control diet. These results are 
contrary to the previously published results where it was suggested that Tmprss6 mRNA could 
increase in conditions of either iron deprivation or iron overload (Meynard et al., 2011; Zhang et al., 
2011). These results suggest a role for macrophage TfR2 in the regulation of Tmprss6 transcription. 
It would be interesting to examine whether these differences also translate to protein levels; due to a 
lack of specific antibodies for TMPRSS6 protein these studies were not performed. 
One of the most important results from these experiments was the observation that treatment with 
LPS suppresses the expression of genes involved in the iron-mediated regulation of Hamp. 
Previously it has been shown that Fpn1 (Liu et al., 2005; Yang et al., 2002), TfR1 (Kim and Ponka, 
2000; Recalcati et al., 1998; Tacchini et al., 2008) and Hjv (Krijt et al., 2004; Niederkofler et al., 
2005; Pagani et al., 2011) can be down-regulated in response to LPS treatment but the exact 
mechanism is not known. Two studies which looked at the transcriptional regulation of Fpn1 in 
response to inflammatory stimuli suggested that this reduction required the TLR4 signalling 
pathway (Yang et al., 2002) and did not involve the IL6 pathway (Liu et al., 2005). 
There has been some discussion about crosstalk between the JAK-STAT pathway and the BMP-
SMAD pathway in regulating Hamp, as it was shown that Smad4 knockout mice did not respond 
appropriately to inflammatory stimuli, the induction of Hamp being lower than that of WT animals 
(Milward et al., 2007; Wang et al., 2005). The results shown here suggest that inflammatory stimuli, 
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or LPS at the least, could be inhibiting the iron sensing mechanisms (which predominantly work 
through the BMP-SMAD signalling pathway) in the liver. 
One of the explanations for this phenomenon could be that in response to inflammatory stimuli the 
body limits the release of iron into the blood, leading to a decrease in serum iron and transferrin 
saturation. The iron sensing machinery in the liver would be able to detect this decrease and attempt 
to compensate for the lowered iron levels by reducing Hamp production to make more iron 
available. This would counteract the hypoferraemic response to inflammation, and in order to 
prevent this opposing effect the inflammatory pathway may shut down the production of molecules 
involved in the iron sensing pathway. These results will lead to some interesting new avenues for 
future research including: 
a. The mechanistic details of crosstalk between the inflammatory and iron sensing pathways in 
the liver. 
b. Examining how LPS mediates this down regulation, whether it is via a single pathway or an 
effect mediated by multiple pathways. Further research in this area may lead to the 
discovery of a novel molecule that regulates the expression of the entire iron sensing 
pathway. 
c. Previous studies have suggested that the LPS mediated regulation of Fpn1 is not IL6 
mediated and involves TLR4 mediated signalling, it would be interesting to explore whether 
this down-regulation is LPS-specific or if it can be observed in other inflammatory 
conditions. 
5.4 Future directions 
Future experiments will be directed at deciphering the mechanism of LPS action on suppressing the 
iron sensing pathway in the liver. One of the future aims will be to look at other inflammatory 
stimuli, e.g. infections with bacteria and other pathogens to see whether they cause the same 
response. In order to determine the pathways required for this downregulation, mouse models 
deficient in various immunological pathways (Tlr2-/-, Tlr3-/-, Tlr4-/-, NfκB-/-, Il6-/-) will be used. The 
KO models will be treated with various inflammatory agents and infected with pathogens to induce 
an inflammatory response and then analysed to determine the effect on the expression of iron 
sensing molecules. 
In order to determine the mechanisms, protein microarrays, and RNA microarrays will be 
performed on the livers of treated and untreated mice. This will help determine the molecules and 
the pathways involved in this regulation in response to inflammatory stimuli. 
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Recent studies on macrophage function have started to focus on the M1 and M2 phenotypes of the 
macrophages and their role in progression of inflammation. The results presented in this chapter 
suggest that macrophage/monocyte specific expression of TfR2 is not required for iron or 
inflammation-mediated regulation of Hamp. The role of TfR2 in determining the macrophage 
phenotype in response to various inflammatory stimuli (e.g. TNFα, IFNγ) was not examined. In 
order to examine this function of TfR2, macrophages will be isolated from the peritoneal cavity, 
spleen and BM and stimulated with various mediators of inflammation (IL6, TNFα, IFNγ)  and the 
expression of inflammatory and phenotypic markers for M1 and M2 macrophages will be measured 
using qRT-PCR. 
The results from this study suggest that in the absence of macrophage TfR2 the mRNA levels of 
Fpn1 are slightly lower in the livers and spleens of M-KO mice; similarly the LPS-mediated 
increase in Hamp is slightly lower in the livers of the M-KO mice. These differences are not 
significant in the experiments done in this study; one of the reasons could be the contribution from 
other cell types in these organs. In order to minimise this, macrophages from the M-KO and control 
animals will be used for future experiments. 
 
  
 
 
 
 
 
 
 
Chapter 6  
TfR2 expression in haematopoietic cells is 
required for stress erythropoiesis 
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6.1 Introduction 
6.1.1Erythropoeisis and iron metabolism 
In order to maintain a steady supply of erythrocytes most of the iron absorbed in the body is utilised 
in the production of haemoglobin. On the other hand recycling of iron from senescent erythrocytes 
is a major contributor to the body iron needs (Ganz, 2012), thus creating an important bridge 
between iron metabolism and erythropoeisis (the development of red blood cells). 
Iron is primarily required in erythrocytes for the production of haemoglobin; each haem molecule 
can bind to one atom of iron. The other requirement for iron in erythropoiesis relates to its 
functional requirement in metabolically active and dividing cells. Iron acts as a co-enzyme for a 
number of enzymes like the DNA replicases, the three DNA polymerases (POLα, POLδ and POLε) 
and DNA helicases (FANCJ) reviewed in (Zhang, 2014) which is required for cell division, hence 
making it an essential element for erythropoiesis. In fact, mice lacking TfR1 are embryonic lethal 
and develop abnormalities in erythropoiesis and neural development, even heterozygous TfR1+/- 
mice (with a single allele of TfR1) exhibited abnormalities in erythropoiesis (Levy et al., 1999). 
These observations confirmed the importance of iron in erythropoiesis. 
Erythropoiesis is one of the best studied haematopoietic processes. RBCs develop from 
haematopoietic stem cells (HSCs); this process involves a number of steps and is regulated by the 
interplay between a number of cytokines, growth factors and environmental cues (Hattangadi et al., 
2011). The first erythroid progenitors that commit to the erythroid lineage are distinguished by their 
abilities to form erythroid colonies when grown on methyl cellulose; these progenitors are called the 
burst forming unit-erythroid (BFU-E) (Gregory and Eaves, 1977). The BFU-E are the most 
immature cells which have committed to the erythroid lineage and differentiate into the more 
actively proliferating colony forming unit-erythroid (CFU-E) (Gregory and Eaves, 1977, 1978). 
Apart from the differences in their proliferating capacity, the major distinction between these two 
progenitors is their requirement for different cytokines and growth factors. Whereas BFU-Es 
primarily require stem cell factor (SCF) (Emerson et al., 1985) and some other growth factors, the 
CFU-Es are highly dependent on EPO (Iscove et al., 1974). 
The CFU-Es then differentiate into pro-erythroblasts which become morphologically distinct as the 
cells commit to the erythroid lineage. The pro-erythroblasts do not contain much haemoglobin, but 
rapidly proliferate and hence require a constant supply of iron (Gifford et al., 2006; Stephenson et 
al., 1971). The pro-erythroblasts then differentiate into the basophilic erythroblasts which start 
concentrating ribosomes in order to prepare for haemoglobin synthesis. The next stage is the 
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polychromatic erythroblasts which stain deeply for haemoglobin and divide to give rise to the 
orthochromic erythroblasts which form the last nucleated stage of this cycle. The enucleation of the 
orthochromic erythroblasts results in the formation of reticulocytes. The reticulocytes stay in the 
blood for about 24 hours before they finally adopt the distinct biconcave morphology of 
erythrocytes (Houwen, 1992). 
Although erythropoiesis requires a concerted effort of a number of cytokines, EPO is considered to 
be the major cytokine involved in the process, as mice lacking the EPO receptor (EPOR) show 
defects in erythropoiesis at day 12.5 of gestation (Lin et al., 1996). Binding of EPO to EPOR 
activates several signalling pathways including STAT5, phosphoinositide-3 kinase (PI3K)/ protein 
kinase B (AKT) and Src homology 2 domain containing protein (SHC)/ rat sarcoma protein 
homologue (RAS)/ MAPK pathways (Hattangadi et al., 2011). One of the downstream target genes 
affected by STAT5 activation is TfR1; mice lacking STAT5 had less TFR1 on the cell surface of 
erythroid cells. TfR1 also has three STAT5 binding sites in its first intron (Zhu et al., 2008). The 
levels of EPOR increase during the first few stages of erythropoiesis and then drop, this correlates 
with the observed decrease in the levels of TfR1 as the cells reach maturity. 
There is evidence supporting the theory that TfR1 regulation in erythroid cells is also haem-
dependent, and does not respond appropriately to the IRE/IRP system suggesting an erythroid-
specific regulation of iron uptake (Cotner et al., 1989). Using specific antibodies it was shown that 
erythroid cells express a specific isoform of TFR1 (Cotner et al., 1989). Unlike other cell types, 
when differentiating MEL cells were treated with iron chelators, they did not show a change in 
TFR1 expression. Similarly there was no change in the levels of TFR1 when the levels of iron were 
increased in the differentiating MEL cells (Cotner et al., 1989). 
On the other hand when nucleated erythroid cells (which includes any stage from pro- to 
orthochromatic erythroblasts) were treated with haem synthesis inhibitors, the TFR1 levels 
decreased (Cotner et al., 1989; Hradilek et al., 1992), indicating a haem-specific and IRP- 
independent regulation of TFR1. Contrary to these results, there are reports suggesting that the IRP 
system is still functional in regulating iron metabolism in erythroid cells and could be partly 
affecting the surface expression of TFR1 as shown in mice lacking IRP2 (Cooperman et al., 2005; 
Galy et al., 2005). Several recent studies have also provided another link between the IRE/IRP 
pathway where mice lacking Irp1 were shown to have elevated Hif2α mRNA levels in the liver 
(Anderson et al., 2013) and protein levels in the kidney (Wilkinson and Pantopoulos, 2013). The 
increased Hif2α leads to an increase in the levels of EPO in the serum (Anderson et al., 2013; 
Wilkinson and Pantopoulos, 2013). 
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In addition, it is also known that TF-bound iron can stimulate the PI3K/AKT and MAPK pathways 
(Moura et al., 2001). It was recently shown that polymeric immunoglobulin A can bind to TFR1 
and act synergistically with EPO to increase erythropoiesis in mice (Coulon et al., 2011). The 
process of erythropoiesis itself involves a very rapid proliferation, and at each stage there are 
considerable transcriptomic changes taking place (An et al., 2014) These cells would be 
metabolically very active, thus increasing the demands for iron, hence iron becomes an integral part 
of the developmental process itself. 
Besides TfR1, another iron metabolism gene which is known to be affected by erythropoiesis is the 
iron regulatory hormone - hepcidin. 
6.1.2 Erythropoietic regulation of Hamp 
Erythropoiesis is a known negative regulator of Hamp (Nicolas et al., 2002a; Vokurka et al., 2006). 
Although the exact molecular details of this regulation are not well described, several candidate 
regulators have been reported (Kautz et al., 2014; Tanno et al., 2007; Tanno et al., 2009). Since a 
proper erythropoietic response would require a constant supply of iron, it is believed that the 
erythroid compartment releases a soluble factor which limits the production of Hamp in the liver 
(Tanno et al., 2007). 
One of the candidates for erythropoiesis-mediated regulation of Hamp is EPO itself, treatment of 
cells and mice with rEPO (recombinant EPO) results in a reduction in Hamp levels (Nicolas et al., 
2002b; Pak et al., 2006). This was suggested to be an effect of erythropoietic activity induced by 
EPO rather than a direct effect, as mice treated with erythropoietic inhibitors (carboplatin) did not 
show a reduction in Hamp levels even when treated with rEPO (Pak et al., 2006). Contrary to this it 
was suggested that reduction in Hamp levels in response to treatment of cells and mice with rEPO is 
a direct effect of EPO. This effect of EPO was suggested to be mediated by changing mRNA and 
protein levels of CCAAT/ enhancer binding protein aplha (C/EBPα) (Pinto et al., 2008). C/EBPα is 
a transcription factor and was shown to bind to the HAMP promoter resulting in a decrease in 
transcription (Pinto et al., 2008). The differences in the two studies could be because of the 
supraphysiological concentrations of rEPO used in Pak et al. The authors suggested that similar 
concentrations of EPO were only found in cases with severe anaemia or hypoxia; hence EPO at 
normal physiological concentrations might not be contributing to Hamp regulation in hepatocytes. 
Human subjects treated with rEPO exhibited a rapid decrease in circulating HAMP levels, which 
decreased for up to 72 hours after treatment (Ashby et al., 2010), providing support for the 
hypothesis that erythropoiesis can regulate HAMP and this seems to be mediated directly (in part) 
by EPO. 
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Other ‘erythroid regulator’ candidate genes were identified by performing a microarray analysis on 
RNA isolated from primary erythroblasts donated by normal subjects (Tanno et al., 2007). This 
resulted in the identification of two secreted proteins which are members of the TGF family of 
proteins –GDF15 and TWSG1 (Tanno et al., 2007). Sera from β-thalassaemic patients were able to 
downregulate HAMP in primary hepatocytes, but this reduction was not observed in the absence of 
GDF15 (Tanno et al., 2007). Similar to the rEPO treatments supraphysiologic concentrations of 
GDF15 were used in these experiments, which only resembled that present in very severe cases of 
thalassaemia (Tanno et al., 2007); based on these results it was suggested that very high levels of 
GDF15 secreted by an expanding population of erythroblasts could be regulating HAMP levels in 
thalassaemia (Tanno et al., 2007). Recently, using Gdf15 knockout (KO) mice it was shown that 
GDF15 is not required for the suppression of Hamp in phlebotomised mice as the Hamp 
suppression was not significantly different in the KO mice (Casanovas et al., 2013). 
Unlike GDF15, TWSG1 has not received much attention and the only study which suggested that it 
could be a factor secreted by early erythroblasts regulating HAMP was published in 2009 (Tanno et 
al., 2009). It was suggested that TWSG1 acts through the BMP-SMAD pathway as the levels of 
pSMAD1/5 decreased in the cells treated with TWSG1. Interestingly this downregulation was 
synergistic with a treatment of BMP2 and BMP4 (Tanno et al., 2009). Based on these two 
observations a model for erythroid regulation of HAMP in thalassaemic patients was proposed: 
TWSG1 acts to repress HAMP initially, as it is produced by the early erythroblasts and 
subsequently this role is taken over by GDF15 (Tanno et al., 2009). 
Recently, there has been another addition to this list of potential erythroid regulators of HAMP: the 
product of the gene Fam132b, known as ERFE (Kautz et al., 2014). Similar to GDF15 and TWSG1, 
ERFE is expressed in erythroblasts and in response to rEPO treatment Fam132b levels increase 
only in the BM and spleen (organs involved in normal and stress erythropoiesis) of mice (Kautz et 
al., 2014). Fam132b levels were elevated in mouse models of β-thalassaemia and unlike Gdf15 KO 
mice, Fam132b-/- mice are unable to suppress Hamp in response to phlebotomy suggesting that 
Fam132b could be the erythroid regulator responsible for suppressing Hamp in response to stress 
erythropoiesis in non-thalassaemic scenarios as well. Although a recent study performed in our 
laboratory (one of the first to examine the relationship between ERFE and Hamp regulation after 
the initial discovery), suggests that in a model of stress erythropoiesis caused by the loss of 
Tmprss6, Hfe and TfR2, ERFE is unable to decrease Hamp levels (Wallace et al., 2014). Fam132b 
levels were higher in the mice which had severe extramedullary haematopoiesis (Tmprss6-/-/Hfe-/-
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/TfR2-/- and Tmprss6-/-/TfR2-/- mice) but the liver Hamp levels were still elevated. These results 
indicate that Fam132b is unable to regulate Hamp in some conditions. 
Erythropoiesis, inarguably, is a negative regulator of HAMP, but the results discussed above 
indicate that the exact molecular mechanism of this regulation is yet to be defined. So far the 
correlation between GDF15 and HAMP levels has only been established in sera from β-
thalassaemia patients suggesting that this molecule could be a thalassaemia-specific regulator. 
These varying results could also mean that the erythroid control is disorder specific - different 
molecules regulating HAMP in diverse pathological conditions.  
6.1.3 Erythropoiesis and TFR2 
The gene for TFR2 was mapped to chromosomal position 7q22 in the human genome and 5qG2 in 
the mouse genome; one of the genes on chromosome 7 in humans and chromosome 5 in mice is 
EPO (on the opposite strand). It is unknown whether TFR2 has an effect on the expression of either 
EPO or any of the nearby genes. An upstream analysis of the promoter region of TFR2 revealed 
binding sites for several erythroid-specific transcription factors (Kawabata et al., 2001a). There are 
two GATA1 binding sequences in both human and mouse DNA, -52 to -57 and -23 to -19 in mouse, 
and -61 to -56 and -26 to -22 in the human DNA (Kawabata et al., 2001a). Two putative C/EBP 
binding sequences were also found in both humans and mice, the first around -240 and the other in 
a reverse orientation at around -190 (Kawabata et al., 2001a). In addition to this, several CACCC 
consensus sequences were detected within 1kb upstream of the TfR2 promoter, these are potential 
erythroid Kruppel-like factor (EKLF) binding sites (another erythroid-specific transcription factor) 
(Kawabata et al., 2001a). It was shown that both EKLF and GATA1 increase the luciferase activity 
of the TFR2 promoter, although in one case where a shorter promoter was used EKLF decreased the 
activity suggesting it has an inhibitory effect (Kawabata et al., 2001a). These observations suggest 
that TfR2 could be regulated in an erythroid-specific fashion.  
TfR2 expression was detected in the BM and early erythroid progenitors (Kawabata et al., 2001b) 
and the expression decreased as the cells differentiated (Kawabata et al., 2001b). Real-time PCR 
analysis revealed that TfR2 expression begins between day 8 and 11, this coincides with the time 
when primary haematopoietic cells move from the yolk sac to the liver for initial haematopoiesis 
(Kawabata et al., 2001a). These observations are again indicative of a role for TFR2 in 
erythropoiesis. This hypothesis is supported by recent GWAS which have found an association 
between TFR2 and various haematological parameters. In one GWAS an association was found 
between RBC number and a SNP centred on the TFR2 gene (Soranzo et al., 2009), although the 
authors did mention that the other candidate for this association could be EPO (Kamatani et al., 
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2010; Soranzo et al., 2009). There was also a strong correlation between the haemoglobin content, 
haematocrit and mean cell volume and the TFR2-EPO locus in another study (Ganesh et al., 2009). 
More recently a low frequency 5’ donor splice variant of TFR2 was independently associated with 
higher haematocrit levels and haemoglobin concentration (Auer et al., 2014). 
A single study has so far been published which explored the mechanistic role of TFR2 in 
erythropoiesis (Forejtnikova et al., 2010). The results suggested that TFR2 can form a complex with 
EPOR in the UT7 cell line (endogenous protein) and transfected HEK293 cells (Forejtnikova et al., 
2010). The complex could be detected even after disassembling the Golgi apparatus by treatment 
with Brefeldin A, suggesting that the complex is formed in the early stages, probably in the 
endoplasmic reticulum (Forejtnikova et al., 2010). The expression of TFR2 in HEK293 cells 
seemed to increase the surface localisation of EPOR, indicating that TFR2 could be involved in 
trafficking of the EPOR. Erythroid progenitors from 4-week-old TfR2-/- mice had reduced colony 
forming ability in the presence of physiological concentrations of EPO suggesting that TFR2 is 
required for the differentiation of erythroid progenitors (Forejtnikova et al., 2010). TFR2 is required 
for production of GDF15 in response to EPO treatment as UT7 cells lacking TFR2 did not produce 
GDF15 (Forejtnikova et al., 2010). The results of these experiments suggested that TFR2 is 
required for the proper differentiation of erythroid cells. 
A comparison between mice lacking Tmprss6 and mice lacking Tmprss6 and Hfe or TfR2 revealed 
that the double knockout mice had increased numbers of RBCs (Lee et al., 2012); it was suggested 
that the lack of either HFE or TFR2 plays a protective role in anaemia by increasing the RBC 
number. This study used knockout mice on different genetic backgrounds to make the comparisons 
between the genotypes (TfR2 mutant mice were on an AKR background, Hfe knockout mice were 
on a C57/BL6J background whereas the Tmprss6 knockout mice were on a 129SvJ background). In 
a more recent study using Tmprss6-/- and Tmprss6-/-/TfR2-/- mice on a mixed background; 
(C57BL/6- Sv129) it was suggested that TfR2 plays a role in erythropoiesis (Nai et al., 2014). The 
results of this study suggested that the Tmprss6-/-/TfR2-/- were anaemic with microcytic anaemia 
similar to that observed in Tmprss6-/- mice, but the double knockouts had higher RBC numbers (Nai 
et al., 2014). These differences between the RBC numbers were not observed in mice that lacked 
TfR2 only in the hepatocytes (Nai et al., 2014); based on these results it was hypothesised that it 
was the absence of TFR2 in the erythroid compartment that resulted in the observed phenotype (as 
the Tmprss6-/-/TfR2-/- mice lack TfR2 in every tissue whereas the Tmprss6-/-/ TfR2f/f/AlbCre+/- mice 
lack TfR2 only in the hepatocytes). 
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In a recent study published by our laboratory it was shown that Tmprss6-/-/Hfe-/-/TfR2-/- (triple 
knockout mice) and Tmprss6-/-/TfR2-/- (double knockout) mice exhibited severe anaemia as 
compared to Tmprss6-/- and this was characterised by splenomegaly (indicative of extramedullary 
haematopoiesis (EMH)) and suggestive of stress erythropoiesis. It was also observed that Epo 
mRNA levels in the kidney were lower in the Tmprss6-/-/Hfe-/-/TfR2-/- and Tmprss6-/-/TfR2-/- mice 
and that this also correlated with lower EPO levels in the serum (Wallace et al., 2014). An analysis 
of the erythroid precursors by flow cytometry revealed that the mice lacking Tmprss6 and TfR2, 
irrespective of the presence or absence of Hfe, had significantly increased numbers of 
orthochromatic erythroblasts, suggesting a blockage in the differentiation of erythroblasts (Wallace 
et al., 2014). The results of this study were probably different from the two previous studies because 
the mice used here were on a pure C57BL/6 background, a strain known to have lower iron levels 
as compared to the Sv129 and AKR backgrounds used in the studies by Lee et al (Lee et al., 2012) 
and Nai et al (Nai et al., 2014). 
On the basis of this knowledge it was hypothesised that TFR2 expression in the erythroid 
compartment is essential for stress erythropoiesis or iron-restricted erythropoiesis. In order to test 
this hypothesis, mice lacking TfR2 in the erythroid compartment were produced by crossing the 
Vav-Cre+/- mice (kindly provided by Dr Steven Lane, QIMR Berghofer Medical Research Institute) 
with the TfR2f/f mice. The Vav-Cre transgene was shown to be effective in the excision of loxP 
flanked sequences in all nucleated cells of the haematopoietic lineage and not in non-
haematopoietic cells (Georgiades et al., 2002; Ogilvy et al., 1999) hence it was deemed as a suitable 
Cre transgenic line to inactivate TfR2 expression in haematopoietic cells. 
The control animals used for this study were heterozygous for the deleted and the floxed TfR2 
alleles, this was done to avoid potential issues due to germline transmission of the Vav-Cre+/- allele 
as has been reported previously (Georgiades et al., 2002). Previous studies from our laboratory have 
shown that haplo-insufficiency of TFR2 does not alter iron metabolism and a single allele in the 
heterozygous animals is sufficient to maintain appropriate iron levels (Wallace et al., 2005). The 
breeding strategy used to generate animals used for the experiments in this chapter is illustrated in 
Figure 6.1. Previous reports have suggested that the Vav-Cre allele could be expressed in the 
ovaries and hence increase the chance of germline transmission (Georgiades et al., 2002; Joseph et 
al., 2013), in view of this only the mice generated from a breeding between a Cre+/- male were used 
for the analysis performed in this study (this resulted in removing four animals from the control 
group of animals fed an iron-deficient diet as they had been generated from a cross between a 
female carrying the Cre allele). 
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Figure 6.1 Breeding strategy for generating TfR2Δ/f/Vav-Cre+/- mice. TfR2f/f female mice were 
bred with Vav-Cre+/- male mice, this resulted in four genotypes out of which TfR2f/f female mice 
and TfR2Δ/+/Vav-Cre+/- male mice were used to generate the desired genotypes (Control (TfR2Δ/f) 
and knock out (TfR2Δ/f/Vav-Cre+/-; V-KO) for experimental purposes. The genotypes of the mice 
used for breeding are marked by red boxes, while the green boxes mark the genotypes of the 
animals used for experiments. 
Previous studies have established that mice lacking TfR2 or with mutations in TfR2 do not develop 
any haematological abnormalities (Fleming et al., 2002; Wallace et al., 2005) and that the 
erythropoietic function of TfR2 becomes evident only in conditions of iron restriction (Lee et al., 
2012; Nai et al., 2014; Wallace et al., 2014). Based on these observations the mice were placed on 
an iron-deficient diet or an iron-rich diet to compare the effects of erythroid TFR2 under stress 
conditions. The three diet groups of control and knockout animals are as follows: 
a. Control (TfR2Δ/f) and knock out (TfR2Δ/f/Vav-Cre+/-; V-KO) animals on a control diet, 
b. Control and V-KO animals on a high iron (2% carbonyl iron) diet, these animals were fed an 
iron-rich diet for two weeks only, and 
c. Control and V-KO animals on a low iron diet, the animals were put on an iron-deficient diet 
from birth and were fed the diet until sacrificed. 
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6.2 Results 
6.2.1 TfR2Δ/f/Vav-Cre+/- animals have reduced TfR2 expression in the bone 
marrow 
qRT-PCR shows that the V-KO (TfR2Δ/f/Vav-Cre+/-) mice have significantly reduced expression of 
TfR2 in the BM as compared to the control (TfR2Δ/f) animals. The level of TfR2 was also reduced in 
the liver of the TfR2Δ/f/Vav-Cre+/- mice (Figure 6.2), suggesting some non-specific Cre activity in 
the liver, in spite of the breeding strategy adopted. Western blotting of homogenates from the BM 
cells (Figure 6.3) shows that TfR2Δ/f/Vav-Cre+/- do not express TFR2 in the BM. The mRNA and 
protein levels of TFR2 in the spleen of the TfR2Δ/f/Vav-Cre+/- mice do not differ from the control 
animals (Figure 6.3 and 6.4). In agreement with the real-time experiments, some of the TfR2Δ/f/Vav-
Cre+/- mice had low levels of TFR2 protein in the liver (Figure 6.5). Figures 6.3, 6.4 and 6.5 show 
representative images of blots performed at least three times and on all five mice from each group. 
     
Figure 6.2 TfR2Δ/f/Vav-Cre+/- mice have reduced expression of TfR2 in the bone marrow and 
liver. mRNA expression levels of TfR2 (relative to geometric mean of three reference genes: β-
actin, Hprt and Polr2a) were measured in the bone marrow (BM), spleens and livers of control 
(●TfR2Δ/f) and V-KO (■TfR2Δ/f/Vav-Cre+/-) 10-week-old male mice (n = 4-5 per group) fed a control 
(Control), iron-rich (High) or iron-deficient (Low) diet. Data are shown as dot plots, showing the 
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mean and the standard error of the mean (SEM). Statistically significant differences (two-way 
ANOVA using Tukey’s multiple comparison test; p<0.05) are denoted as (a) compared to the 
control diet for the same genotype, (b) compared to high iron diet on the same genotype and (*) 
compared to the corresponding genotype on the same diet. 
Figure 6.3 TfR2Δ/f/Vav-Cre+/- have reduced expression of TFR2 in the bone marrow. 
Immunoblotting was performed using 40µg of homogenates from the bone marrow of 10-week-old 
control (TfR2Δ/f) and V-KO (TfR2Δ/f/Vav-Cre+/-) male mice (n = 4-5 per group) fed a control 
(Control), iron-rich (High Fe) or iron-deficient (Low Fe) diet. The blot was probed with antibodies 
against TFR2 and Actin. This is a representative image of a blot performed at least three times and 
on all five mice from each group. 
Figure 6.4 Expression of TFR2 does not change in the spleens of TfR2Δ/f/Vav-Cre+/- mice. 
Immunoblotting was performed using 40µg homogenates from the spleens of 10-week-old control 
(TfR2Δ/f) and V-KO (TfR2Δ/f/Vav-Cre+/-) male mice (n = 4-5 per group) fed a control (Control), iron-
rich (High Fe) or iron-deficient (Low Fe) diet. The blot was probed with antibodies against TFR2 
and GAPDH. This is a representative image of a blot performed at least three times and on all five 
mice from each group. 
Figure 6.5 Expression of TFR2 in the livers of TfR2Δ/f/Vav-Cre+/- mice. Immunoblotting was 
performed using 25µg homogenates from the livers of 10-week-old control (TfR2Δ/f) and V-KO 
(TfR2Δ/f/Vav-Cre+/-) male mice (n = 4-5 per group) fed a control (Control), iron-rich (High Fe) or 
iron-deficient (Low Fe) diet. The blot was probed with antibodies against TFR2 and actin. This is a 
representative image of a blot performed at least three times and on all five mice from each group. 
6.2.2 Reduced TfR2 in the livers of TfR2Δ/f/Vav-Cre+/- mice does not affect iron 
indices significantly 
Figure 6.2 and 6.5 show that the V-KO animals have reduced TFR2 expression at mRNA and 
protein levels in the liver, these lower levels of TFR2 could potentially affect iron indices in the V-
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KO mice and hence the erythropoietic parameters, as iron is an important factor for proper 
erythropoiesis. 
In order to determine whether the loss of TFR2 affects systemic iron metabolism, hepatic and 
splenic iron concentrations (HIC and SIC respectively) were measured in livers and spleens of the 
control and V-KO mice. Figure 6.6 shows that there are no significant differences in the HIC and 
SIC of the V-KO and control animals on similar diets. The V-KO animals show an upward trend for 
HICs and a downward trend in SICs as compared to the control animals. 
Figure 6.6 Reduced expression of TFR2 in the livers of TfR2Δ/f/Vav-Cre+/- mice does not affect 
hepatic and splenic iron concentrations. Hepatic (HIC) and splenic iron (SIC) were measured in 
10-week-old control (●TfR2Δ/f) and V-KO (■TfR2Δ/f/Vav-Cre+/-) male mice (n = 4-5 per group) fed a 
control (Control), iron-rich (High) or iron-deficient (Low) diet. Data are shown as dot plots, 
showing the mean and SEM. Statistically significant differences (two-way ANOVA using Tukey’s 
multiple comparison test; p<0.05) are denoted as (a) compared to the control diet for the same 
genotype and (b) compared to high iron diet on the same genotype. 
The total serum iron and transferrin saturation was also measured in the V-KO and control animals, 
Figure 6.7 shows that there are no significant differences in the V-KO and control animals in their 
respective diet groups. 
In addition, the localisation of iron in the livers of V-KO and control animals was determined by 
Perls’ staining. Figure 6.8 shows that there are no visible differences in iron deposition in the livers 
of the V-KO and control animals. These results indicated appropriate systemic iron regulation even 
when hepatic TFR2 levels are reduced, as has been described previously (Wallace et al., 2005). The 
Perls’ staining of the spleen sections indicates that the control and V-KO mice on a control diet 
have some deposition of iron in the reticuloendothelial macrophages, which is absent in the mice 
fed an iron-deficient diet (Figure 6.9). The level of iron deposition in the spleens is less in the V-KO 
mice as compared to their control counterparts in both control and iron-rich diet groups; this is in 
agreement with the slightly decreased SIC levels observed in the V-KO mice (Figure 6.6). 
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The liver sections of the V-KO mice fed an iron-deficient diet appeared significantly different from 
the control animals. A significant number of patches of cells could be seen throughout the sections, 
these patches were also observed in the H&E stained liver sections (Figure 6.14) and on consulting 
an experienced haematologist these were identified as nucleated red blood cells in the liver, 
suggestive of haematopoeisis in the liver. 
Figure 6.7 TfR2Δ/f/Vav-Cre+/- mice have similar serum iron levels and transferrin saturation as 
compared to TfR2Δ/f mice on a similar diet. Total serum iron levels and transferrin saturation was 
measured in 10-week-old control (●TfR2Δ/f) and V-KO (■TfR2Δ/f/Vav-Cre+/-) (n = 4-5 per group) fed 
a control (Control), iron-rich (High) or iron-deficient (Low) diet. Data are shown as dot plots, 
showing the mean and SEM. Statistically significant differences (two-way ANOVA Tukey’s 
multiple comparison test; p<0.05) are denoted as (a) compared to the control diet for the same 
genotype and (b) compared to high iron diet on the same genotype. 
6.2.3 Effect of reduced TFR2 levels in the liver and bone marrow on iron 
homeostasis in the liver 
The relative mRNA expression of major genes involved in regulating iron homeostasis was 
measured in the livers of control and V-KO mice. The V-KO (TfR2Δ/f/Vav-Cre+/-) mice had slightly 
lower basal levels of hepatic Hamp as compared to the TfR2Δ/f mice (Figure 6.10). Although the V-
KO mice fed an iron-rich diet had significantly lower Hamp levels as compared to the control 
animals fed an iron rich diet (P=0.0003), they could still upregulate Hamp and Bmp6 in response to 
an increase in iron levels (Figure 6.10). Similarly the relative mRNA expression levels of 
downstream target genes of the BMP pathway (Id1 and Smad7) were significantly lower in the V-
KO animals fed an iron-rich diet as compared to the control mice fed an iron-rich diet (P= 0.0034 
and P<0.0001 respectively for Id1 and Smad7). These results suggest that the lower amount of TfR2 
in the livers of the V-KO animals does not affect the systemic response to increases in body iron 
levels. 
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Figure 6.8 Perls’ staining of the liver sections. Perls’ staining was performed on sections of the 
liver of 10-week-old control (TfR2Δ/f) and V-KO (TfR2Δ/f/Vav-Cre+/-) male mice fed a control 
(Control), iron-rich (High) or iron-deficient (Low) diet. The image shows Perls’ staining for a 
representative animal (representing the median HIC) from each group. The black arrows represent 
patches of nucleated red blood cells in the liver of TfR2Δ/f/Vav-Cre+/- mice fed an iron-deficient diet. 
Scale bar = 200 µm. 
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Figure 6.9 Perls’ staining of the spleen sections. Perls’ staining was performed on sections of the 
spleen of 10-week-old control (TfR2Δ/f) and V-KO (TfR2Δ/f/Vav-Cre+/-) male mice fed a control 
(Control), iron-rich (High) or iron-deficient (Low) diet. The image shows Perls’ staining for a 
representative animal (representing the median SIC) from each group. Scale bar = 200 µm. 
The V-KO mice have lower mRNA expression levels of Id1 as compared to the control mice 
(Figure 6.10) and the expression levels of both Id1 and Smad7 are lower in the V-KO mice fed an 
iron-rich diet as compared to their control littermates on the same diet. The reduction correlates 
with the lower TFR2 expression in the livers of these animals. These results are similar to the 
results presented in Chapter 4 where the levels of both Id1 and Smad7 were lower in the mice 
lacking TFR2 in the liver. This supports the hypothesis presented in Chapter 4 that TFR2 
expression in the liver is required for appropriate BMP-SMAD signalling. 
The mRNA levels of Hfe, Hjv and Tmprss6 were also measured in the livers of these mice, as 
shown in Figure 6.10, there were no significant differences in the levels of Hfe. Interestingly the 
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levels of Hjv mRNA in the liver of the V-KO mice fed an iron-deficient diet were significantly 
lower than the control animals on an iron-deficient diet (P=0.0012).  
Figure 6.10 Gene expression in the livers of the TfR2Δ/f and TfR2Δ/f/Vav-Cre+/- mice. mRNA 
expression level of genes involved in regulating iron homeostasis (relative to geometric mean of 
three reference genes: β-actin, Hprt and Polr2a) was measured in the livers of 10-week-old control 
Chapter 6 
 
139 
 
(●TfR2Δ/f) and V-KO (■TfR2Δ/f/Vav-Cre+/-) male mice (n= 4-5 per group) fed a control (Control), 
iron-rich (High) or iron-deficient (Low) diet. Data are shown as dot plots, showing the mean and 
SEM. Statistically significant differences (two-way ANOVA using Tukey’s multiple comparison 
test; p<0.05) are denoted as (a) compared to the control diet for the same genotype, (b) compared to 
high iron diet on the same genotype and (*) compared to the corresponding genotype on the same 
diet. 
6.2.4 Effect of reduced TFR2 levels in the liver and bone marrow on iron 
homeostasis in the spleen  
The mRNA expression levels of Fpn1, Hamp and TfR1 were also measured in spleens of control 
and V-KO mice. There were no significant differences in the relative levels of Fpn1 and Hamp in 
the spleens of V-KO and control mice (Figure 6.11), suggesting that reduced TFR2 levels in the 
BM or liver do not affect the expression of these genes in the spleens (although the levels in the 
knockout mice had a downward trend in the control and iron-rich diet groups). The control and V-
KO mice fed an iron-deficient diet had significantly higher Fpn1 and Hamp mRNA levels as 
compared to their counterparts fed a control or an iron-rich diet.  Surprisingly, the TfR1 levels in the 
spleens of V-KO mice on an iron-deficient diet were significantly higher as compared to the control 
mice on a similar diet. TfR1 levels have been shown to increase in conditions of iron deficiency 
previously (Klausner et al., 1993), hence an increase is expected. The significant difference between 
the control and the V-KO mice cannot be explained on the basis of differences in body iron levels, 
as both the groups have similar iron indices, as shown in Figure 6.6 and Figure 6.7. The second 
explanation for increased TfR1 levels is an increased erythropoietic drive, the immature developing 
stages of the RBCs have increased expression of TfR1, hence there could be differences in the 
erythropoietic populations in the control and V-KO mice fed an iron-deficient diet. 
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Figure 6.11 Gene expression in the spleens of the TfR2Δ/f and TfR2Δ/f/Vav-Cre+/- mice. mRNA 
expression level of Fpn1, Hamp and TfR1 (relative to geometric mean of three reference genes: β-
actin, Hprt and Polr2a) were measured in the spleens of 10-week-old control (●TfR2Δ/f) and V-KO 
(■TfR2Δ/f/Vav-Cre+/-) male mice (n = 4-5 per group) fed a control (Control), iron-rich (High) or 
iron-deficient (Low) diet. Data are shown as dot plots, showing the mean and SEM. Statistically 
significant differences (two-way ANOVA using Tukey’s multiple comparison test; p<0.05) are 
denoted as (a) compared to the control diet for the same genotype, (b) compared to high iron diet on 
the same genotype and (*) compared to the corresponding genotype on the same diet. 
6.2.5 TfR2Δ/f/Vav-Cre+/- mice fed an iron-deficient diet show splenomegaly and 
extramedullary haematopoiesis in the spleen and the liver.  
The control and V-KO mice fed an iron-deficient diet had significantly enlarged spleens as 
compared to the animals fed a control or an iron-rich diet (Figure 6.12). Moreover, the V-KO mice 
fed an iron-deficient diet had larger spleens as compared to their control counterpart littermates 
(Figure 6.12 and Figure 6.13). The spleen to body weight ratio of the TfR2Δ/f/Vav-Cre+/- mice fed an 
iron-deficient diet was also significantly higher as compared to the control mice on the same diet 
(Figure 6.13), this is indicative of EMH. 
      
Figure 6.12 TfR2Δ/f/Vav-Cre+/- mice fed an iron-deficient diet have enlarged spleens. A 
representative image of the spleen of a TfR2Δ/f (left) and TfR2Δ/f/Vav-Cre+/- (right) mouse fed an 
iron-deficient diet. 
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Various haematological parameters were also measured using whole blood from these mice (Figure 
6.13). There were no significant differences based on the genotype of the mice, while mice fed an 
iron-deficient diet (control and V-KO) had significantly lower haemoglobin, haematocrit, mean cell 
haemoglobin (MCH), mean cell volume (MCV) and RBC number as compared to the mice on a 
control or iron-rich diet. These lower values were expected as the iron-deficient diet was expected 
to induce anaemia in the mice. 
In order to assess the morphology of the liver and spleen of the TfR2Δ/f (control) and TfR2Δ/f/Vav-
Cre+/ (V-KO) mice, H&E staining was performed on the liver and spleen sections. Figures 6.14 and 
6.15 show that although the spleens of both control and V-KO mice show signs of EMH, only the 
livers of TfR2Δ/f/Vav-Cre+/- mice fed an iron-deficient diet had a significant accumulation of 
nucleated red blood cells as shown by the black arrows in the bottom right panel of Figure 6.14. 
These observations suggested that the V-KO mice had significantly increased EMH as compared to 
the control mice on an iron-deficient diet. 
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Figure 6.13 Haematological parameters and spleen to body weight ratios for TfR2Δ/f and 
TfR2Δ/f/Vav-Cre+/- mice. Spleen to body weight ratios were calculated for 10-week-old control 
(●TfR2Δ/f) and V-KO (■TfR2Δ/f/Vav-Cre+/-) male mice (n = 4-5 per group) fed a control (Control), 
iron-rich (High) or iron-deficient (Low) diet. Haematological parameters: haemoglobin, 
haematocrit, mean cell haemoglobin (MCH), mean cell haemoglobin concentration (MCHC), mean 
cell volume (MCV) red blood cell (RBC) number and number of platelets were also measured. Data 
are shown as dot plots, showing the mean and SEM. Statistically significant differences (two-way 
ANOVA using Tukey’s multiple comparison test; p<0.05) are denoted as (a) compared to the 
control diet for the same genotype, (b) compared to high iron diet on the same genotype and (*) 
compared to the corresponding genotype on the same diet. 
In order to examine the EMH phenotype more thoroughly, qRT-PCR analysis of the genes involved 
in erythropoiesis was performed on RNA isolated from the spleen, liver and BM of control and V-
KO animals. Relative levels of glycophorin A (Gypa) (an erythrocyte membrane protein), 
hydroxymethylbilane synthase (Hmbs), aminolevulinic acid synthase 2 (Alas2) (both Hmbs and 
Alas2 are important enzymes in the haem biosynthesis pathway), Epor and Gdf15 were measured. 
In addition to this levels of Bcl2l1 (a downstream target of EPO signalling) were also measured. 
Figure 6.16 shows that the relative levels of Alas2 (P<0.0001), Gypa (P=0.0003), and Hmbs 
(P<0.0001) were significantly increased in the spleens of mice fed an iron-deficient diet as 
compared to mice fed a control or iron-rich diet. The V-KO mice fed an iron-deficient diet have 
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significantly higher expression levels of genes involved in erythropoiesis as compared to the 
controls on the same diet, suggesting increased EMH. The levels of EpoR did not significantly 
change in any of the groups although they were higher in the animals on an iron-deficient diet. The 
expression of a downstream target of EPO signalling (Bcl2l1) was also significantly higher in the 
V-KO animals fed an iron-rich (P=0.0027) or iron-deficient (P=0.0107) diet as compared to their 
control counterparts suggesting increased signalling. 
Similarly, the levels of Alas2 (P<0.0001) and Hmbs (P=0.024) were significantly increased in the 
livers of the V-KO mice on an iron-deficient diet as compared to the control mice fed an iron-
deficient diet, suggesting increased EMH in the livers of these animals (Figure 6.17). Interestingly, 
the levels of EpoR were significantly lower in the animals fed an iron-deficient diet (P=0-0145 and 
P=0.0251 for control and V-KO mice respectively) as compared to animals fed a control diet. This 
is contrary to the expected results, as in a situation of increased erythropoiesis an increase in EpoR 
expression would be expected. 
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Figure 6.14 TfR2Δ/f/Vav-Cre+/- mice fed an iron-deficient diet show signs of extramedullary 
haematopoiesis in the liver. H&E staining was performed on the liver sections of 10-week-old 
control (TfR2Δ/f) and V-KO (TfR2Δ/f/Vav-Cre+/-) male mice (n = 4-5 per group) fed a control 
(Control), iron-rich (High) or iron-deficient (Low) diet. The image shows H&E staining for a 
representative animal (representing the median HIC) from each group. The black arrows represent 
patches of nucleated red blood cells prominently visible in the liver sections of TfR2Δ/f/Vav-Cre+/- 
mice fed an iron-deficient diet. Scale bar = 200 µm. 
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Figure 6.15 TfR2Δ/f and TfR2Δ/f/Vav-Cre+/- mice fed an iron-deficient diet show signs of 
extramedullary haematopoiesis in the spleen. H&E staining was performed on spleen sections of 
10-week-old control (TfR2Δ/f) and V-KO (TfR2Δ/f/Vav-Cre+/-) male mice (n = 4-5 per group) fed a 
control (Control), iron-rich (High) or iron-deficient (Low) diet. The image shows H&E staining for 
a representative animal (representing the median SIC) from each group. The spleen of the 
TfR2Δ/f/Vav-Cre+/- mice fed an iron-deficient diet has lost its red/white pulp nodularity as is seen in 
the bottom right panel Figure. Scale bar = 200 µm. 
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Figure 6.16 TfR2Δ/f and TfR2Δ/f/Vav-Cre+/- mice fed an iron-deficient diet have significant 
EMH in the spleen. Relative expression levels of genes (relative to geometric mean of three 
reference genes: β-actin, Hprt and Polr2a) involved in erythropoiesis were measured in the spleens 
of 10-week-old control (●TfR2Δ/f) and V-KO (■TfR2Δ/f/Vav-Cre+/-) male mice (n = 4-5 per group) 
fed a control (Control), iron-rich (High) or iron-deficient (Low) diet. Data are shown as dot plots, 
showing the mean and SEM. Statistically significant differences (two-way ANOVA using Tukey’s 
multiple comparison test; p<0.05) are denoted as (a) compared to the control diet for the same 
genotype, (b) compared to high iron diet on the same genotype and (*) compared to the 
corresponding genotype on the same diet. 
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Figure 6.17 TfR2Δ/f and TfR2Δ/f/Vav-Cre+/- mice fed an iron-deficient diet have significant 
EMH in the liver. mRNA expression levels of genes relative to geometric mean of three reference 
genes: β-actin, Hprt and Polr2a) involved in erythropoiesis were measured in the livers of 10-week-
old control (●TfR2Δ/f) and V-KO (■TfR2Δ/f/Vav-Cre+/-) male mice (n = 4-5 per group) fed a control 
(Control), iron-rich (High) or iron-deficient (Low) diet. Data are shown as dot plots, showing the 
mean and SEM. Statistically significant differences (two-way ANOVA using Tukey’s multiple 
comparison test; p<0.05) are denoted as (a) compared to the control diet for the same genotype, (b) 
compared to high iron diet on the same genotype and (*) compared to the corresponding genotype 
on the same diet. 
qRT-PCR analysis of BM did not reveal any significant increases in the expression of the genes 
involved in erythropoiesis (Figure 6.18). In addition to the above mentioned genes, expression of 
Bmp4, Gdf15, endothelial PAS domain containing protein 1 (Epas1/Hif2α) and Fam132b were also 
measured. The relative levels of several genes (Bcl2l1, Epor and Gdf15) in the V-KO animals fed 
an iron-deficient diet exhibited an upward trend as compared to the control animals on a similar 
diet. There was also a higher degree of variability in the expression levels of these genes compared 
to the liver and spleen, this variability was observed even when the experiment was performed with 
a new batch of cDNA, suggesting that the either the RNA was degraded or of poor quality. 
Unfortunately since all the BM tissue from these mice had been used for RNA preparation this 
experiment could not be repeated. 
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Figure 6.18 Erythropoietic markers do not differ in the bone marrow of TfR2Δ/f and 
TfR2Δ/f/Vav-Cre+/- mice fed an iron-deficient diet. Relative expression levels of genes (relative to 
geometric mean of three reference genes: β-actin, Hprt and Polr2a) involved in erythropoiesis were 
measured in the BM of 10-week-old control (●TfR2Δ/f) and V-KO (■TfR2Δ/f/Vav-Cre+/-) male mice 
(n = 4-5 per group) fed a control (Control), iron-rich (High) or iron-deficient (Low) diet. Data are 
shown as dot plots, showing the mean and SEM. Statistically significant differences (2-way 
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ANOVA using Tukey’s multiple comparison test; p<0.05) are denoted as (a) compared to the 
control diet for the same genotype, (b) compared to high iron diet on the same genotype and (*) 
compared to the corresponding genotype on the same diet. 
6.2.6 Accumulation of immature erythroid cells in the bone marrow and spleen 
of TfR2Δ/f/Vav-Cre+/- mice fed an iron-deficient diet 
In order to determine the cause of enlarged spleens and increased EMH in the spleens of V-KO 
mice on an iron-deficient diet, flow cytometric analysis of splenocytes and BM cells was 
performed. The cells were stained with TER119, an erythroid marker and CD44, another cell 
surface marker used for resolving differentiating erythroblasts into their five stages of development 
(Chen et al., 2009). An analysis of erythroid cells (TER119 positive cells) revealed that in 
comparison with control mice fed an iron-deficient diet, both the BM and spleen of the V-KO mice 
fed an iron-deficient diet had significantly increased numbers of immature erythroid cells (Bottom 
right panels in Figure 6.19 & 6.20), particularly in population 3, which predominantly represents the 
polychromatic erythroblasts (Chen et al., 2009). 
The percentage of erythroid cells that were polychromatic erythroblasts (population 3) was 
significantly increased in the spleen (P<0.0001) and the BM (P=0.0001) of the V-KO mice fed an 
iron-deficient diet as compared to the control mice fed an iron-deficient diet suggesting that there 
was a developmental block in erythropoiesis the V-KO mice as shown in Figure 6.21. These results 
are in agreement with previous studies that suggested a loss of TFR2 results in a delay in the 
differentiation of erythroblasts (Forejtnikova et al., 2010). A similar increase in the immature 
erythroblasts was seen in the spleens of mice lacking Tmprss6 and TfR2 (Wallace et al., 2014). In 
those animals it was suggested that this developmental block was due to a loss of TFR2 in the 
erythroid compartment although it was not a tissue-specific deletion of TfR2. The phenotype of the 
TfR2Δ/f/Vav-Cre+/- mice fed an iron-deficient diet is different from the Tmprss6-/-/Hfe-/-/TfR2-/- and 
Tmprss6-/-/TfR2-/- mice, and unlike the results shown here the mice in that study did not show a 
block in the BM (Wallace et al., 2014). 
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Figure 6.19 Accumulation of polychromatic erythroblasts in the bone marrow of TfR2Δ/f/Vav-
Cre+/- mice fed an iron-deficient diet. BM cells from 10-week-old control (TfR2Δ/f) and V-KO 
(TfR2Δ/f/Vav-Cre+/-) male mice (n = 4-5 per group) fed a control (Control), iron-rich (High) or iron-
deficient (Low) diet were stained with TER119-fluorescein, CD44-allophycocyanin and CD44 vs. 
forward scatter was plotted for all TER119 positive cells resulting in five distinct populations as 
described in Chen et al (Chen et al., 2009). 
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Figure 6.20 Accumulation of polychromatic erythroblasts in the spleen of TfR2Δ/f/Vav-Cre+/- 
mice fed an iron-deficient diet. Splenocytes from 10-week-old control (TfR2Δ/f) and V-KO 
(TfR2Δ/f/Vav-Cre+/-) male mice (n = 4-5 per group) fed a control (Control), iron-rich (High) or iron-
deficient (Low) diet were stained with TER119-fluorescein, CD44-allophycocyanin and CD44 vs. 
forward scatter was plotted for all TER119 positive cells, resulting in five distinct populations as 
described in Chen et al (Chen et al., 2009). 
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Figure 6.21 Increased proportion of polychromatic erythroblasts in the bone marrow and 
spleens of TfR2Δ/f/Vav-Cre+/- mice fed an iron-deficient diet. The percentage of erythroid cells 
(TER119+) belonging to each population of the erythroblasts (I, II, III, IV and V) was calculated for 
10-week-old control (C) (TfR2Δ/f) and V-KO (TfR2Δ/f/Vav-Cre+/-) male mice (n = 4-5 per group) fed 
a control (Control), iron-rich (High) or iron-deficient (Low) diet. Data are shown as stacked bar 
graphs showing the mean. Statistically significant differences (two-way ANOVA using Tukey’s 
multiple comparison test; are denoted * (p<0.05), ** (p<0.01), and **** (p<0.0001) compared to 
the corresponding genotype on the same diet. 
Figure 6.22 TfR2Δ/f/Vav-Cre+/- mice fed an iron-deficient diet have a decreased proportion of 
EPOR expressing erythroid cells in the spleen. Splenocytes and BM cells of 10-week-old control 
(●TfR2Δ/f) and V-KO (■TfR2Δ/f/Vav-Cre+/-) male mice (n = 4-5 per group) fed a control (Control), 
iron-rich (High) or iron-deficient (Low) diet were stained with EPOR-phycoerythrin and gated for 
TER119. The number of cells expressing EPOR was counted and expressed as a percentage of 
TER119 positive cells. Data are shown as dot plots, showing the mean and SEM. Statistically 
significant differences (two-way ANOVA using Tukey’s multiple comparison test; p<0.05) are 
denoted as (a) compared to the control diet for the same genotype, (b) compared to high iron diet on 
the same genotype and (*) compared to the corresponding genotype on the same diet. 
Previously it had been suggested that TFR2 is required for proper localisation of EPOR on the 
surface of erythroid cells, and a loss of TFR2 results in decreased EPOR expression, but mRNA 
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levels of Epor in the control and V-KO mice do not differ in the spleen and BM as shown in Figure 
6.16 and 6.18. The percentage of erythroid cells expressing EPOR on the surface was measured by 
flow cytometry; no significant differences were observed in the BM of the control and V-KO mice 
whereas the spleens of V-KO mice fed an iron-deficient diet (as compared to control mice fed an 
iron-deficient diet) had a significantly lower (P=0.002) proportion of erythroid cells expressing 
EPOR at the cell surface determined by flow cytometry (Figure 6.22). These results suggest that 
loss of TFR2 in the haematopoietic cells could affect the surface expression of EPOR on the surface 
of the erythroid cells in the spleen. 
6.2.7 Serum erythropoietin levels do not differ in the TfR2Δ/f and TfR2Δ/f/Vav-
Cre+/- mice fed an iron-deficient diet 
The serum EPO levels in the control (P=0.02) and V-KO (P=0.01) mice fed an iron-deficient diet 
were significantly higher than the mice fed a control or an iron-rich diet, indicating increased 
erythropoiesis (Figure 6.23). There was no significant difference between the V-KO and control 
animals fed an iron-deficient diet (Figure 6.23). 
   
Figure 6.23 TfR2Δ/f and TfR2Δ/f/Vav-Cre+/- mice fed an iron-deficient diet have significantly 
higher serum EPO levels. Serum EPO levels were measured of 10-week-old control (●TfR2Δ/f) and 
V-KO (■TfR2Δ/f/Vav-Cre+/-) male mice (n = 4-5 per group) fed a control (Control), iron-rich (High) 
or iron-deficient (Low) diet. Data are shown as dot plots, showing the mean and SEM. Statistically 
significant differences (two-way ANOVA using Tukey’s multiple comparison test; p<0.05) are 
denoted as (a) compared to the control diet for the same genotype, (b) compared to high iron diet on 
the same genotype and (*) compared to the corresponding genotype on the same diet. 
6.3 Discussion 
Previous studies have suggested that TFR2 is expressed in erythroid cells (Kawabata et al., 2001b) 
and is regulated by erythroid-specific transcription factors in vivo (Kawabata et al., 2001a). GWAS 
have suggested a correlation between the TFR2 genomic region and various haematological traits 
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(Auer et al., 2014; Ganesh et al., 2009; Kamatani et al., 2010; Soranzo et al., 2009). Recent studies 
using mouse models of anaemia have suggested that loss of TfR2 in the erythroid compartment 
could be responsible for either increased RBC counts (Lee et al., 2012; Nai et al., 2014) or a block 
in the development of erythroblasts (Wallace et al., 2014). TFR2 was shown to be required for 
proper localisation and trafficking of EPOR to the surface in an erythroleukemic cell line 
(Forejtnikova et al., 2010). These results taken together suggest that TFR2 has a role in 
erythropoiesis. 
In order to examine the role of TFR2 in erythroid cells, a haematopoietic-specific knock-out model 
of TFR2 was generated using Vav-Cre+/- mice on a C57/BL6 background. The mice used for this 
study were heterozygous for the floxed and knockout allele for TfR2 as has been previously 
suggested (Joseph et al., 2013). This was done to avoid the germ-line transmission of a TfR2-deleted 
allele that has been previously reported to occur when using the Vav-Cre transgene (Georgiades et 
al., 2002). While the analysis was being carried out the litter born out of a breeding between female 
Cre+/- mice were omitted as has been suggested in the literature (Joseph et al., 2013). 
The V-KO (TfR2Δ/f/Vav-Cre+/-) mice had lower levels of TfR2 in the liver (Figure 6.2 and 6.5) as 
compared to the control animals. It has been known previously that the Vav gene is expressed in the 
hepatic primordium, which gives rise to the hepatic parenchyma, intra and extra-hepatic bile ducts 
and gall bladder, and could have a mosaic non-specific expression pattern (Heffner et al., 2012). 
The hepatic parenchyma predominantly contributes to the formation of hepatocytes. This could be 
one of the reasons that the livers of TfR2Δ/f/Vav-Cre+/- mice have lower levels of TfR2 mRNA and 
protein. HSCs from human subjects when transplanted into sheep have been shown to differentiate 
into hepatocytes (Almeida-Porada et al., 2004). It was also shown that transplanted HSCs may 
contribute to regeneration after liver injury by differentiating into hepatocytes (Jang et al., 2004). 
These results support the notion that HSCs can contribute to the formation of hepatocytes, 
suggesting that hepatocytes arising from HSCs in the TfR2Δ/f/Vav-Cre+/- mice may contribute to 
lower TFR2 levels in the liver. 
The lower TFR2 levels in the liver did not affect the body iron status, as the iron indices (Figure 6.6 
& 6.7) were not significantly different between the two genotypes on the same diet. These results 
suggest that the residual amount of TFR2 in the V-KO livers is sufficient to regulate systemic iron 
metabolism. This was also true in the case of animals fed an iron-rich diet, where the liver was able 
to respond to an increase in body iron and increase Hamp appropriately (Figure 6.10), although the 
levels of Hamp were significantly lower in the V-KO mice fed an iron-rich diet as compared to 
corresponding controls. The lower Hamp levels in the V-KO mice could be due to lower basal 
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levels of Hamp in the V-KO mice (Figure 6.10). The lower Hamp levels can be attributed to the 
lower TfR2 level in the livers. The fold change in Hamp levels in the livers of control and V-KO 
groups on an iron rich diet was similar (3.9 fold increase in control mice and 3.5 fold change in V-
KO mice), suggesting that low levels of TFR2 can appropriately regulate Hamp. 
No significant differences were observed in the expression levels of molecules involved in the 
regulation of iron metabolism, except for Id1 and Smad7 which are downstream targets of BMP-
SMAD signalling (Figure 6.10). The V-KO mice fed an iron-rich diet had significantly lower levels 
of Id1 and Smad7, although there were no significant differences in the levels of Bmp6 in these 
mice. These results suggest that a reduction in TFR2 levels in the livers of the V-KO mice affects 
downstream signalling in the BMP-SMAD pathway. 
Previous studies have suggested that the erythropoietic function of TFR2 is evident only in stress 
conditions such as anaemia, where the anaemic mice lacking TfR2 had altered phenotypes (Lee et 
al., 2012; Nai et al., 2014; Wallace et al., 2014). In these studies the anaemia was achieved by 
disruption of the Tmprss6 gene, leading to increased Hamp expression in the liver and hence a 
reduction in iron levels. In the present study, in order to establish anaemic conditions the mice were 
fed an iron-deficient diet for 10 weeks from birth. The haematological parameters in these mice 
indicated anaemia compared to the animals fed a control diet or an iron-rich diet (Figure 6.13). 
There were no significant differences in the haematological parameters between the V-KO and the 
control mice fed an iron-deficient diet. 
One of the observations made while sacrificing the animals was that the spleens of the anaemic 
mice were enlarged (splenomegaly) (Figure 6.12). This is expected, as the drive to produce more 
erythrocytes in stress conditions like anaemia, results in EMH, and the primary organ involved in 
this is the spleen. There was a significant difference in the spleen/body weight ratio between the 
anaemic V-KO and control animals, suggesting that there was more EMH in the anaemic V-KO 
mice (Figure 6.13). H&E staining of the spleen revealed signs of EMH and surprisingly there were 
islands of nucleated erythroid cells also present in the livers of the anaemic V-KO mice, suggesting 
EMH in the liver in addition to the spleen. This was an observation different from the recent study 
published by our laboratory where the Tmprss6-/-/Hfe-/-/TfR2-/- and Tmprss6-/-/TfR2-/- mice had 
splenomegaly and EMH in the spleen, but the liver sections of these animals appeared normal 
(Wallace et al., 2014). 
qRT-PCR analysis of the genes involved in erythropoiesis confirmed that there was increased 
expression of erythropoietic genes in the anaemic mice, and that expression levels were 
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significantly higher in both the spleen and liver of the V-KO compared to control mice (Figure 6.16 
& 6.17). The relative expression of erythropoietic genes in the BM of the anaemic V-KO mice did 
not change (Figure 6.18). Flow cytometric analysis of the erythroid cells from splenocytes and BM 
revealed that there was a significant increase in immature erythroid cells of a specific cell 
population (polychromatic erythroblasts) in the anaemic V-KO mice (Figure 6.14 & 6.15). Unlike 
the Tmprss6-/-/Hfe-/-/TfR2-/- and Tmprss6-/-/TfR2-/- mice the anaemic V-KO mice had increased 
polychromatic erythroblasts in both spleen and BM. These results suggest that deletion of TfR2 in 
the haematopoietic stem cells results is a novel model to study the role of TfR2 in erythropoiesis 
(Wallace et al., 2014). 
Previous studies had suggested a role for TfR2 in erythropoiesis based on the assumption that the 
absence of TfR2 in the erythroid compartment was responsible for the phenotype observed, but the 
models used in those studies lacked TfR2 in other tissues (Nai et al., 2014; Wallace et al., 2014). In 
this study the deletion is shown to be in the BM cells and the phenotype can be attributed to the lack 
of TFR2 in the haematopoietic cells as it has not been reported that mice lacking TfR2 only in the 
hepatocytes have abnormalities in haematological parameters or splenomegaly (Nai et al., 2014; 
Wallace et al., 2007). Results published by our laboratory using a different model of anaemia where 
the anaemic mice lacking TfR2 had splenomegaly and EMH have also suggested a role for TfR2 in 
the stress erythropoiesis (Wallace et al., 2014). There are a few differences in the two models; 
firstly the anaemia in the V-KO mice used for this study was dietary anaemia in contrast to the iron 
refractory iron deficiency anaemia in the Tmprss6-/- mice. Secondly, the Tmprss6-/- also developed 
alopecia (loss of hair) whereas the anaemic V-KO mice did not. The anaemic V-KO mice in this 
study did not have high Hamp levels as the Tmprss6-/-/TfR2-/- mice did (Wallace et al., 2014). The 
serum EPO levels were not different in the anaemic V-KO mice, whereas the Tmprss6-/-/TfR2-/- 
mice had lower serum EPO levels and lower expression of Epo mRNA in the kidneys. (Wallace et 
al., 2014). Unlike the Tmprss6-/-/TfR2-/- mice the anaemic V-KO mice had increased numbers of 
polychromatic erythroblasts in the BM in addition to the spleen and also showed signs of EMH in 
the liver. Finally, the Tmprss6-/-/TfR2-/- mice did not have any significant differences in EPOR cell 
surface expression, whereas the erythroid cells in the spleens of anaemic V-KO mice had lower 
EPOR expression (Figure 6.22). These differences in results indicate that the model used in this 
study for examining the role of TFR2 in erythroid function is novel. 
This is a significant finding which confirms a novel role for erythroid TFR2 expression in 
erythropoiesis, although the model used for this study did not specifically delete TfR2 in the 
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haematopoietic compartment only, the results suggest that a reduction in TFR2 levels in the liver 
does not affect iron metabolism in these mice. 
6.4 Future Directions 
Future studies will be directed at isolating the five different cell populations of developing 
erythroblasts using fluorescence activated cell sorting and performing analyses on the isolated cell 
types. Initial experiments would involve transfection of the isolated cells with plasmids to express 
TFR2 and examining their in vitro differentiation to determine whether TFR2 can rescue the 
blockage in the polychromatic erythroblast stage in the presence of differentiating agents like delta 
aminolevulinic acid (δALA). 
RNA will be isolated from the different cell types and used for microarray studies, the results from 
these experiments will be used to identify molecular pathways that are affected in the absence of 
TFR2. 
It would be important to examine whether TfR2 has a role in other models of anaemia like β-
thalassaemia or the anaemia of chronic disease, and whether the absence of TfR2 in the 
haematopoietic compartment affects the severity of the disease in these models. 
. 
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Transferrin receptor 2 (TFR2) was discovered in 1999 (Kawabata et al., 1999), initial observations 
suggested that it was another receptor involved in the uptake of transferrin-(TF) bound iron, as TF 
binding to the surface of cells transfected with TfR2 was increased (Kawabata et al., 1999). The 
identity between the two transferrin receptors (45% identical and 66% similar extracellular 
domains) also suggested that they could have similar functions (Kawabata et al., 1999). At the same 
time it was shown that mice lacking transferrin receptor 1 (TfR1) are embryonic lethal, this 
suggested that the function of both the transferrin receptors is not redundant (Levy et al., 1999). 
Soon it was shown that patients with mutations in TFR2 develop a form of hereditary 
haemochromatosis (Camaschella et al., 2000). Mice with a deletion in TfR2 (Wallace et al., 2005) or 
a mutation in TfR2 (Fleming et al., 2002) exhibited similar symptoms of iron overload suggesting 
that TFR2 could be involved in regulating iron metabolism rather than iron uptake. This was 
confirmed when it was shown that patients and mice with a non-functional TfR2 have inappropriate 
Hamp levels with respect to their body iron levels (Nemeth et al., 2005; Wallace et al., 2005). The 
current hypothesis suggests that TFR2 plays a role as an iron sensor. It was shown to interact with 
HFE (Goswami and Andrews, 2006) in vitro and this interaction was suggested to be important for 
TFR2- and HFE-mediated regulation of HAMP (Gao et al., 2009). According to this hypothesis, 
under conditions of increased iron levels in the body, holo-TF binds to TFR1, thus releasing HFE. 
The free HFE then interacts with TFR2 and this binding initiates a signalling cascade to induce 
HAMP signalling. In support of this hypothesis a recent study suggested that HFE, TFR2 and HJV 
all form a multicomplex on the surface of the hepatocyte (D'Alessio et al., 2012). On the other hand 
studies from our laboratory and others have suggested that TFR2 and HFE do not interact to 
regulate Hamp. Mice lacking both Hfe and TfR2 have a more severe phenotype as compared to the 
single knockout mice (Delima et al., 2012; Wallace et al., 2009), similarly patients with mutations 
in both HFE and TFR2 have a more severe form of haemochromatosis which resembles juvenile 
haemochromatosis (Pietrangelo et al., 2005). The results of a recent study using mice expressing 
transgenic myc-tagged HFE also suggested that HFE does not require TFR2 to mediate Hamp 
regulation (Schmidt and Fleming, 2012). 
The focus of the first aim of this thesis was to test this hypothesis in cells which express both HFE 
and TFR2 under the same promoter and at relatively similar levels. The interactions between HFE, 
TFR1 and TFR2 were detected using a recently developed technique, proximity ligation assay 
(PLA). PLA enables the detection, visualisation and quantitation of the interaction of proteins of 
interest in their native state (Soderberg et al., 2006). The results of these experiments indicated that 
when HFE and TFR2 are stably expressed they do not interact with each other. These results were 
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confirmed using conventional co-immunoprecipitation (co-IP) assays. No interactions could be 
observed between HFE and TFR2 in the presence or absence of holo-TF (Rishi et al., 2013). 
It has been suggested that HFE and TFR2 are a part of the signalling cascade involving the BMP-
SMAD signalling pathway in response to iron levels (McDonald et al., 2014). In support of this a 
recent study suggested that HFE is required for proper localisation of the type I BMP receptor to the 
surface of hepatocytes in mouse livers and in primary human hepatocytes (Wu et al., 2014). 
Combined with the previously published  results from our laboratory (McDonald et al., 2014) and 
others (Wu et al., 2014) the results shown in Chapter 4 suggest that hepatocyte-specific expression 
of TFR2 may be involved in the appropriate regulation of Bmp6 signalling in response to increased 
iron levels, although further studies would be required to confirm this hypothesis. These results and 
the results from Chapter 3 and 4 have helped us understand the role of TFR2 in the regulation of 
Hamp and hence the molecular significance of HFE and TFR2 in regulating iron metabolism. Based 
on these results we propose a new model for HFE-and TFR2-mediated regulation of HAMP, as 
shown in Figure 7.1. 
    
  
Figure 7.1 Schematic representation of the proposed roles of HFE and TFR2 in the regulation 
of HAMP. Based on recently published studies from our laboratory (McDonald et al., 2014) and 
others (Wu et al., 2014) it can be hypothesised that in response to increased iron levels TFR2 may 
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be involved in a signalling pathway (denoted by the broken line and a question mark) which could 
result in the increased expression of BMP6 (McDonald et al., 2014) . BMP6 protein is then secreted, 
and interacts with the BMP receptors (BMPR). HFE is required to transport BMPR type I to the 
surface and hence is required for the proper interaction between BMPs and their receptors (Wu et 
al., 2014). In this model, the absence of a functional TFR2 may lead to reduced BMP signalling in 
response to increased iron levels resulting in an inappropriate HAMP response. In the absence of a 
functional HFE the type I BMPR is not properly localised to the surface of hepatocytes resulting in 
impaired pSMAD signalling and hence inappropriately low HAMP levels. 
Further experiments in order to verify this hypothesis will be carried out in the near future. These 
will involve chromatin immunoprecipitation assays with Bmp6 promoter elements in the livers 
(preferably hepatocytes) of TfR2-/- and Tfr2f/f/AlbCre+/- mice. The results will enable us to identify 
the factors and signalling pathways that require TFR2 in order to induce Bmp6 production. Co-IP 
assays using the TFR2 antibody will be used to identify binding partners of TFR2. The results from 
this assay would then be used for bioinformatic analysis to identify the molecular pathways acting 
downstream of TFR2 which could be affecting TFR2-mediated induction of Bmp6 in response to 
iron. 
In conclusion the results of the experiments in Chapters 3 and 4 have increased our understanding 
of the potential molecular role played by TFR2 in regulating Hamp and hence iron homeostasis. 
Initial experiments revealed that TfR2 is highly expressed in the liver, and some RNA was 
detectable in the bone marrow (BM), spleen, prostate gland (Kawabata et al., 1999; Kawabata et al., 
2001b), immature erythroid cells (Fleming et al., 2002; Kawabata et al., 2001b) and peripheral 
blood mononuclear cells (PBMCs) of leukaemic patients (Kawabata et al., 2001b). Using a mouse 
model with a hepatocyte-specific deletion of TfR2 our laboratory proved that hepatic expression of 
TfR2 is sufficient to maintain systemic iron metabolism, and regulate Hamp in the liver (Wallace et 
al., 2007). This suggested that the extra-hepatic expression of TFR2 was not required for regulating 
systemic iron levels in the body. 
Few studies have looked at the extra-hepatic function of TFR2. One of them used a complicated 
breeding strategy to generate mice which did not express the β-form of TfR2. These mice had a 
different pattern of iron loading in the spleen (iron was found in the red pulp) as compared to the 
mice lacking the α-form of TfR2 (iron loading in the macrophages of the white pulp). It was also 
suggested that β-TfR2 is involved in regulating ferroportin1 (Fpn1) levels in the macrophages of the 
spleen and peritoneal macrophages (Roetto et al., 2010). 
In another study it was suggested that TFR2 expressed in the dopaminergic neurons of the 
substantia nigra is involved in the delivery of iron to the mitochondria (Mastroberardino et al., 
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2009). The role of dopaminergic neurons in the pathogenesis of Parkinson’s disease (PD) is well 
established, and it was suggested that in models of PD, TFR2-TF mitochondrial iron transport is 
affected, leading to an accumulation of iron and hence increased oxidative damage 
(Mastroberardino et al., 2009), thus helping the disease to progress. 
It has been recently suggested that TfR2 could be playing a role in stress erythropoeisis (Nai et al., 
2014; Wallace et al., 2014); mice lacking both TfR2 and transmembrane serine protease 6 (Tmprss6) 
exhibited abnormalities in either red blood cell (RBC) numbers (Nai et al., 2014) or in their ability 
to respond to stress erythropoiesis (Wallace et al., 2014). The results of both the studies were 
contradictory as one did not see a change in the number of RBCs (Wallace et al., 2014).These 
differences could be due to the background of the mice used in both the studies. It was suggested 
that the phenotype in these mice was due to the absence of TfR2 in the erythroid compartment, 
although the phenotype was observed in mice which did not have TfR2 in any of the tissues. 
In order to examine the function of TFR2 in macrophages, mice lacking TfR2 in the cells of 
monocyte/macrophage lineage (Tfr2f/f/LysM-Cre+/-) (M-KO) were generated by crossing the LysM-
Cre+/- with the Tfr2f/f (control) mice. The mice did not have any abnormalities in the regulation of 
iron homeostasis and there were no significant differences in the iron indices between the M-KO 
and control mice fed a control or iron-rich diet. Although the relative expression of Fpn1 exhibited 
a downward trend in the spleens of the M-KO animals, it should be noted that the results shown 
here use total RNA extracted from the spleen which consists of other cell types (neutrophils, 
dendritic cells and lymphocytes) in addition to cells of the monocyte/macrophage lineage which 
could be contributing to the Fpn1 expression, but in the liver this was significantly lower in M-KO 
animals. It has been previously suggested that β-TFR2 (the truncated soluble version of TFR2) is 
required for the positive regulation of Fpn1 in the spleen and macrophages specifically. The results 
from the experiments in Chapter 5 suggest that monocyte/macrophage-specific expression may be 
required for Fpn1 transcription. It could not be verified whether this is true at the protein level as 
well. The other interesting result observed was a significant reduction in the levels of Tmprss6 in 
the M-KO mice fed an iron-rich diet, although it has been previously described that both iron 
deprivation (Zhang et al., 2011) and overload (Meynard et al., 2011) can influence Tmprss6 levels, 
these results suggest a specific role of TfR2 in the macrophages and monocytes. 
The most important finding from these experiments was that a 6 hour treatment with 
lipopolysaccharide (LPS) decreases the mRNA expression levels of most of the genes involved in 
the iron sensing pathway. Although previous studies have suggested that there is a crosstalk 
between the inflammation-mediated regulation of HAMP and BMP-SMAD mediated signalling, as 
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hepatocytes from mice lacking Smad4 had a blunted response to IL6 treatment as compared to 
wildtype hepatocytes (Wang et al., 2005). The results from these experiments suggest that there is 
an inhibitory effect of LPS on the molecules involved in BMP-SMAD signalling in the liver as well 
as the spleen. This is an interesting result as previous studies have shown that LPS treatment results 
in a reduction of Fpn1 (in the liver and splenocytes) (Liu et al., 2005; Yang et al., 2002), TfR1 (in 
the splenocytes) (Recalcati et al., 1998; Tacchini et al., 2008) and Hjv (in the liver), and the 
signalling mechanisms behind these phenomena is not IL6-mediated. These results suggest that 
inflammatory signals (particularly LPS) can affect iron homoeostasis via different mechanisms to 
reduce the release of iron into the blood. It can induce Hamp through IL6 induction and reduce the 
iron sensing role of the hepatocytes and other cells which might try to reduce Hamp in response to a 
reduction in the serum iron available. It is the first time that a reduction in the expression levels of 
molecules like TfR2 (both at mRNA and protein level), Hfe, Bmp6, Smad7 and Tmprss6 in response 
to LPS treatment has been shown. This in itself is an interesting finding that potentially relates to a 
novel mechanism for the regulation of all these molecules that has not been described before. In 
addition, this also represents a novel mechanism where one pathway (inflammation) is interfering 
with almost all the upstream molecules involved in another pathway (body iron stores). 
These results are of importance in studying the effect of chronic inflammation and other 
inflammatory states on different organs of the body. Similar to TFR2, many of the genes involved 
in the regulation of iron metabolism are predominantly expressed in the liver, but are expressed in 
some other tissues as well. For example, HJV is expressed in the muscle and HFE is expressed in 
the macrophages, however, deletion of these proteins in these cells/tissues does not affect systemic 
iron metabolism (Chen et al., 2011; Roetto et al., 2010; Vujic Spasic et al., 2008), suggesting that 
these molecules could have tissue-specific roles. If inflammatory signals in diseases like the 
anaemia of chronic disease or infections were able to affect the expression of such molecules in 
other organs in addition to the liver this could increase complications in the pathology of the 
disease. 
It would be interesting to determine whether this inhibition of the iron-sensing pathway is LPS-
specific or whether it works in other pathogenic or inflammatory conditions. Future studies will be 
directed at determining whether this inhibitory mechanism is mediated through a single pathway or 
a multitude of pathways which affect different molecules. In order to identify these molecules, 
protein microarrays will be performed on total liver homogenates from mice treated with LPS and 
other infectious or inflammatory agents. LPS-mediated inflammatory pathways require toll like 
receptor signalling, hence mice lacking various TLRs (TLR2/4) will also be used for these 
experiments. 
Chapter 7 
 
164 
As mentioned previously, recent studies using ubiquitous TfR2 knockout mice have suggested that 
TFR2 could have a role in stress erythropoiesis. In order to identify whether TfR2 expression in the 
erythroid compartment was specifically required for this function, mice lacking TfR2 in the 
haematopoietic stem cells were generated by using Vav-Cre+/- mice. The control mice used for this 
study were the TfR2Δ/f mice. TfR2Δ/f/Vav-Cre+/- (V-KO) mice had reduced expression of TfR2 in the 
BM, and also had reduced levels of TfR2 in the liver as well. This non-specific activity of the Vav-
Cre transgene in the liver did not affect the iron indices of the mice and the knockout mice were 
able to respond to increased iron levels by increasing Hamp levels in the liver. 
The V-KO mice fed an iron-deficient diet had a similar degree of anaemia as compared to the 
control mice on an identical diet. The spleens of the V-KO mice were significantly enlarged 
(splenomegaly) and H&E staining revealed extramedullary haematopoiesis (EMH) in the spleens 
and the livers of the anaemic V-KO mice. Real-time PCR analysis of the genes involved in 
erythropoiesis revealed significant differences between the V-KO and control mice on an iron-
deficient diet. Flow cytometric analyses of splenocytes and BM cells indicated that lack of TfR2 in 
erythroid cells blocks erythroblast development at the polychromatic erythroblast stage. The results 
of this study confirm the suggested role of TfR2 in stress erythropoiesis (Wallace et al., 2014). The 
mouse model of anaemia described in this thesis is different from the previously published models 
where the anaemia was related to higher Hamp expression due of the absence of matriptase-2, a 
negative regulator of Hamp (Lee et al., 2012; Nai et al., 2014; Wallace et al., 2014). The previous 
studies did not detect a change in the developmental stages of the erythroblasts in the BM (Wallace 
et al., 2014), whereas the anaemic V-KO mice have a delayed differentiation in both the spleen and 
BM. None of the studies reported EMH in the liver and the models used in those studies had an 
impaired systemic iron homeostasis (increased Hamp) due to a loss of Tmprss6, whereas in the V-
KO mice the iron metabolism in the livers is normal. These results suggest that V-KO mice are a 
novel model to study the role of TfR2 in stress or iron restricted erythropoiesis ruling out any 
contribution from increased Hamp levels. 
In conclusion the results presented in this thesis have helped to increase our understanding of the 
importance of TFR2 in different tissues. In the hepatocyte it appears that TFR2 is required to induce 
Bmp6 in response to increased body iron stores. In erythroid cells it is required for the proper 
differentiation of erythroblasts into erythroid cells. These results indicate that proteins which are 
expressed at lower levels in tissues other than their predominant site of expression could have 
different tissue-specific roles. 
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Abstract
The hemochromatosis associated proteins HFE and Transferrin Receptor 2 (TFR2) have been shown to be important
for the proper regulation of hepcidin. A number of in vitro studies using transient overexpression systems have
suggested that an interaction between HFE and TFR2 is required for the regulation of hepcidin. This model of iron
sensing which centers upon the requirement for an interaction between HFE and TFR2 has recently been questioned
with in vivo studies in mice from our laboratory and others which suggest that Hfe and Tfr2 can regulate hepcidin
independently of each other. To re-examine the postulated interaction between Hfe and Tfr2 we developed a novel
expression system in which both proteins are stably co-expressed and used the proximity ligation assay to examine
the interactions between Hfe, Tfr1 and Tfr2 at a cellular level. We were able to detect the previously described
interaction between Hfe and Tfr1, and heterodimers between Tfr1 and Tfr2; however no interaction between Hfe and
Tfr2 was observed in our system. The results from this study indicate that Hfe and Tfr2 do not interact with each
other when they are stably expressed at similar levels. Furthermore, these results support in vivo studies which
suggest that Hfe and Tfr2 can independently regulate hepcidin.
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Introduction
Mutations in HFE and transferrin receptor 2 (TFR2) cause
hereditary hemochromatosis [1,2], which is characterized by an
inappropriate hepcidin (HAMP) expression relative to body iron
levels [3]. Hepcidin, a 25 amino acid antimicrobial peptide is a
negative regulator of iron stores; in response to increased iron
levels in the serum, hepatic hepcidin expression is increased
which then relays a signal to the sites of iron absorption
(duodenal enterocytes), recycling (macrophages) and storage
(hepatocytes) resulting in a decrease in the release of iron from
these tissues into the circulation.
HFE has been shown to interact with transferrin receptor 1
(TFR1) [4–6]. TFR1 is a ubiquitously expressed
transmembrane receptor responsible for the uptake of
transferrin (Tf) bound iron. One model of iron sensing suggests
that HFE and TFR2 are required for the proper regulation of
hepcidin synthesis. In this model when TFR1 bound to iron
saturated transferrin (holo-Tf) is internalized, HFE is released
and made available for binding to TFR2. The interaction of HFE
and TFR2 is then thought to initiate a signalling cascade to
regulate hepcidin. Initial studies using extracellular domains of
HFE and TFR2 failed to detect an interaction between the two
molecules [7]. Subsequent studies using transient
overexpression systems, however, identified an interaction
between HFE and TFR2 [8–10] and suggested that this
interaction is required for the regulation of hepcidin [10]. In a
recent study using the human hepatoma cell line (HuH-7) and
transient expression systems it was shown that HFE, TFR2
and hemojuvelin (HJV) form a complex on the membrane, and
the formation of this complex is required for the regulation of
hepcidin [11].
In a recent study using transgenic mice expressing myc-
tagged Hfe, no interaction was detected between the myc-
tagged Hfe and Tfr2 [12]. In addition, hepatocyte specific
expression of myc-tagged Hfe reduced iron stores and induced
hepcidin synthesis in Tfr2 mutant mice. These results suggest
that Tfr2 is not required for Hfe-mediated hepcidin synthesis
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[12]. In a time-course study in subjects with HFE and TFR2
mutations, hepcidin levels were measured after administration
of oral iron [13]. It was shown that the patients with mutations
in TFR2 did not respond to increases in transferrin saturation
whereas there was a minimal hepcidin response in patients
with HFE mutations under the same conditions [13]. The
hepcidin response in patients with HFE mutations suggests
that TFR2 can regulate hepcidin independently of HFE.
The comparison of Hfe-/-, Tfr2-/- and double knockout mice
(Hfe-/- Tfr2-/-) [14] shows that there is a gradation in hepatic iron
overload, with the hepatic iron concentration and serum
transferrin saturation increasing from WT<Hfe-/-<Tfr2-/-< Hfe-/-
Tfr2-/-. It was also shown that there is a gradation in the levels
of hepatic hepcidin relative to body iron stores in the following
order WT>Hfe-/->Tfr2-/->Hfe-/- Tfr2-/-, indicating that both Hfe and
Tfr2 contribute to the sensing of body iron stores. In agreement
with this, subjects with mutations in both TFR2 and HFE
present with a more severe form of disease compared to
patients with either TFR2 or HFE mutations alone, with a
phenotype similar to juvenile hemochromatosis [15]. These
observations suggest that HFE and TFR2 do not need to
interact with each other to mediate a hepcidin response,
prompting us to re-examine the postulated interaction between
Hfe and Tfr2.
To circumvent potential artefact issues associated with
transient overexpression we used a novel co-expression
system, in which FLAG-tagged Hfe and myc-tagged Tfr2 are
stably expressed under the same promoter. Importantly, the
relative levels of Hfe and Tfr2 are similar, unlike the previous
studies where either of the two proteins was transiently over
expressed. The expression and cellular localisation of Hfe, Tfr1
and Tfr2 were determined by immunoblotting and
immunofluorescence. The interactions between Hfe, Tfr1 and
Tfr2 were examined at a cellular level by the use of a recently
developed commercial assay (DuolinkTM) based on the principle
of proximity ligation. Our results show that stably co-expressed
Hfe and Tfr2 do not interact. We were able to identify
previously reported interactions between Hfe and Tfr1 and the
formation of heterodimers between Tfr1 and Tfr2. These results
were confirmed using the conventional co-immunoprecipitation
approach.
Materials and Methods
a: Generation of the plasmids and stable expression
The mouse Hfe (mHfe) coding sequence minus the signal
peptide was amplified from mouse liver cDNA using the
following primers: FP2-mHfe-Mlu
CCGACGCGTGCACTGCCACCGCGT and RP2-mHfe-Mlu
CCGACGCGTTCACTCACAGTCTGT and cloned into the MluI
site of the pEFIRES-FLAG-S plasmid to create a bicistronic
construct containing the IL-3 signal peptide fused to amino-
terminally FLAG-tagged mHfe with the puromycin resistance
gene (pac) following an internal ribosome entry site (IRES).
This construct, pEFIRES-FLAG-mHfe and another bicistronic
construct encoding amino-terminally double myc-tagged mouse
transferrin receptor 2 (mTfr2), pEFIRES-NH2-Dmyc-mTfr2 or
pEFIRES-NH2-Dmyc-mTfr2Y245X (construction described in [16]
were used to create a tricistronic construct encoding the mHfe,
mTfr2 (wild type or mutant) and pac genes each separated by
an IRES sequence. The FLAG-tagged mHfe gene was PCR
amplified along with the downstream IRES sequence from the
pEFIRES-FLAG-mHfe plasmid using the following primers: 5’
IL-3-SP-IRES-NheI TAGGCTAGCACAATGGTTCTTG and 3’
IRES-NheI CATGCTAGCATCGTGTTTTTCAAAGGA and
cloned into the NheI site of the pEFIRES-NH2-Dmyc-mTfr2
plasmid upstream of the double-myc-tagged mTfr2 gene.
b: Transfections
The mouse hepatoma cell line Hepa 1-6 was obtained from
ATCC (CRL-1830; American Type Culture Collection,
Manassas, VA) and cultured in DMEM with 10% fetal calf
serum (FCS) in 25 cm2 flasks. Transfections were performed
using Lipofectamine 2000 reagent according to the
manufacturer’s instructions (Invitrogen, Mulgrave, Victoria,
Australia). Plasmid DNA (10 μg) was complexed with 25 μl
Lipofectamine 2000 reagent. The complexes were added to the
cells and incubated overnight. Stably transfected cell lines were
isolated by selection with 5 ug/ml puromycin for 1 day and were
then stably maintained in 1 ug/ml of the antibiotic. Expression
of transfectants was conﬁrmed by immunoblot analysis and
immunofluorescence analysis. In the experiments involving
treatment of the cells, Hepa1-6 cells expressing wild type Hfe
and Tfr2 were incubated with either apo-transferrin (apo-Tf) or
holo-transferrin (holo-Tf) (Sigma, Sydney, NSW, Australia)
(2mg/ml) for 24 hours. The apo and holo-Tf was prepared in
DMEM with 10% FCS and 1µg/ml puromycin.
c: Western blotting
Samples were separated by 12% SDS-PAGE, transferred
onto Hybond-C membrane, and blocked in 10% skim milk
powder-0.1% Tween 20 in TBS (Tris-buffered saline; blocking
buffer) at room temperature for 2 hours and incubated with
rabbit anti-Tfr2 [17] (1µg/ml) for 2 hours at room temperature or
mouse anti-FLAG M2 (1:2000; Sigma) in blocking buffer
overnight at 4°C. Blots were washed extensively with 0.1%
Tween 20 in TBS, and then incubated with anti-rabbit or anti-
mouse IgG horseradish peroxidise (Invitrogen) for 1 h at room
temperature. Lumina Forte Millipore chemiluminescent
substrate (Millipore, Kilsyth, Victoria, Australia) was applied for
5 min to the blot, which was then exposed to ﬁlm (Fujiﬁlm,
Brookvale, NSW, Australia). The blots were stripped with 50
mM Tris HCl pH 6.8, 1% SDS, 0.7% ß-mercaptoethanol at
50°C for 30 min, and then washed with 0.1% Tween 20 in TBS
and blocked before incubating with rabbit anti-actin (Sigma)
(1:3000) or mouse anti-Tfr1 (Invitrogen) (1:1500) in blocking
buffer, washed with 0.1% Tween 20 in TBS, incubated with
anti-mouse or anti-rabbit horseradish peroxidise (for 1 h at
room temperature and then incubated with Lumina Forte
Millipore chemiluminescent substrate (Millipore) for 5 min. The
blot was then exposed to ﬁlm. For the immunoblots for
immunoprecipitation experiments, anti-mouse or anti-rabbit
light chain IgG secondary antibodies (Jackson
Immunoresearch Inc, PA, USA) were used at 1:5000 for 1 hour
at room temperature.
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d: Immunofluorescence and Confocal Microscopy
Cells were seeded on collagen coated glass coverslips and
grown to a confluence of 75-80%. After washing with PBSCM
(PBS, 1mMCaCl2, 1mM MgCl2) three times the cells were fixed
with cold 3% paraformaldehyde (PFA) for 15 minutes at room
temperature (RT). The fixed cells were then washed with
50mM NH4Cl to quench the PFA followed by a PBSCM wash
and permeabilized with 0.1% saponin in PBSCM for 15 minutes
at RT and incubated with primary antibodies: rabbit anti-Tfr2
(1µg/ml), mouse anti-Tfr1 (1:500), mouse anti-FLAG M2
(1:1000) or rabbit anti-Tfr1 (Abcam, Cambridge, UK) (1:100)
diluted in fluorescence dilution buffer (FDB) (5% fetal calf
serum, 5% normal donkey serum, 2% bovine serum albumin in
PBSCM, pH7.6) for 2 hours at RT. After washing 3 times in
0.1% saponin/PBSCM the cells were incubated with donkey
anti-mouse Alexa488 and donkey anti-rabbit Alexa594
(Invitrogen) for 1 hour at RT. After washing with 0.1% saponin/
PBSCM the cover slips were then mounted using Prolong Gold
anti-fade with DAPI (Invitrogen). The imaging and visualisation
of the fluorescently stained cells was performed using the
Nikon C2 confocal microscope using a 63X oil immersion
objective. We used NIS Elements software for the acquisition
and processing of the images.
e: Co-Immunoprecipitation (Co-IP)
The cells were cultured to confluence in 25 cm2 flasks and
then lysed in an extraction buffer (200mM Tris pH8.0, 100mM
NaCl, 1mM EDTA, 10% glycerol, 1mM sodium orthovanadate,
1mM sodium fluoride, 1mM sodium pyrophosphate, 2mM
Phenylmethylsufonylfluoride, DNAase (1:1000), Protease
Inhibitor Cocktail (1:100; Sigma) and 20 % NP 40). To perform
a Co-IP with Hfe, anti-DYKDDDDK beads were used (Clontech
Laboratories Inc. CA, USA). All the other antibodies used for
immunoprecipitation were crosslinked with protein A/G beads
(Roche, Dee Why, NSW, Australia) using dimethyl
pimelimidate (Sigma). After pre-clearing with a mixture of anti-
rabbit and anti-mouse IgG agarose (Sigma), 1mg of protein
was incubated with anti-DYKDDDDK, anti-Tfr2, anti-rabbit IgG
or anti-mouse IgG beads overnight at 4°C. The beads were
then washed with 0.5% NP-40, 150mM sodium chloride, 50mM
Tris pH 8.0, 5mM EDTA (NET) buffer without the detergent and
resuspended in 1X sample buffer containing 5 % β-
mercaptoethanol and stored at -20°C till further use.
f: Proximity Ligation Assays (PLA, ‘In Cell’ Co-IP)
The mouse/rabbit red starter Duolink kit (Olink, Uppsala,
Sweden) was used for this experiment. Hepa1-6 cells stably
expressing FLAG-tagged Hfe and myc-tagged Tfr2 were
seeded at 15x103 cells per well in a 16-well chamber slide
(Thermofisher, Scoresby, Victoria, Australia). The cells were
fixed and permeabilized as described above for
immunofluorescence studies. After permeabilization the cells
were incubated in the blocking buffer (provided with the kit)
overnight at 37°C in a humidified chamber. The following day
the cells were incubated with the primary antibodies diluted in
the antibody diluents for 2 hours at room temperature (used at
the same concentrations as in immunofluorescence studies).
For the rest of the protocol the manufacturer’s instructions were
followed. Briefly, the cells were washed in Buffer A (supplied
with the kit) 3 times for 15 minutes and incubated with the PLA
probes for one hour at 37°C in a humid chamber. This was
followed by a 10 minute wash and a 5 minute wash in Buffer A.
The ligation reaction was carried out at 37°C for one hour in a
humid chamber followed by a 10 and 5 minute wash in Buffer
A. The cells were then incubated with the amplification mix for
two hours at 37°C in a darkened humidified chamber. After
washing with 1x Buffer B (supplied with the kit) for 10 minutes
followed by a 1 minute wash with 0.01X buffer B the cells were
mounted using the mounting media supplied with the kit.
Results
a: Stable co-expression of Hfe and Tfr2 in Hepa 1-6
cells does not affect their localization
In order to determine the interactions between Hfe, Tfr1 and
Tfr2, Hepa 1-6 cells stably expressing N-terminal myc-tagged
wild type (WT) Tfr2 or Y245X (YX) mutant Tfr2 alone or with
FLAG-tagged WT Hfe were utilised. The Y245X Tfr2 mutant
used here has been characterised previously [18] and in
humans the corresponding truncation mutation, Y250X, is
associated with hereditary hemochromatosis (HH) type III [1].
Figure 1 shows the relative expression of Hfe, Tfr1 and Tfr2 in
untransfected and transfected cells. We observed two bands
for Tfr2 which could be due to a glycosylated form of the
protein [19]. Figure 1B shows the truncated Tfr2Y245X protein at
approximately 40kDa. Tfr1 is endogenously expressed in
Hepa1-6 cells.
Overexpression of tagged proteins may lead to their
aggregation [20] or mislocalization [21,22] thus affecting their
function. In order to determine whether stable co-expression of
Hfe and Tfr2 in Hepa1-6 cells affects their localization, we
examined the localization patterns of these proteins in cells
expressing either myc-tagged WT Tfr2 or FLAG-tagged WT
Hfe singly or cells co-expressing both Hfe and Tfr2. The
confocal images in Figures 2, 3, 4 and 5 show that both Hfe
and Tfr2 have a similar localization whether expressed singly
or together. This indicates that the co-expression of Hfe and
Tfr2 does not affect their localization and function. FLAG-
tagged Hfe, endogenous Tfr1 and myc tagged Tfr2 localized
mostly intracellularly but expression of all three proteins on the
plasma membrane was also detected as shown in Figures 2, 3,
4, and 5.
Co-localization of two proteins suggests that they are present
in the same subcellular compartments. In order to examine the
co-localization between Hfe, Tfr1 and Tfr2 a double
immunofluorescence experiment was performed. Panels 3C
and 3D show that Tfr1 partially co-localizes with WT Tfr2. We
had shown earlier that Tfr2Y245X has a defect in trafficking and is
retained in the endoplasmic reticulum [16]; panel 3F shows that
there is a change in the localization of the truncated protein as
compared to 3B. The change in localization of Tfr2Y245X leads to
a decrease in co-localization of Tfr1 and Tfr2 as seen in 3H.
The co-localization signal could be observed intracellularly as
well as on the surface of the cells.
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In the cells expressing Hfe and WT Tfr2 and Tfr2Y245X, we
observed a significant co-localization between Hfe and Tfr1
(Panel 4 C and D).
It was reported previously that HFE and TFR2 co-localize
intracellularly in the crypt cells of the duodenum [23]. In our co-
expression system we observed nominal co-localization
between Hfe and WT Tfr2 in punctuate intracellular vesicles
(Panel 5 C and D). The minimal co-localization of the two
proteins suggests that they could transiently co-exist in the
Figure 1.  Analysis of expression of Hfe, Tfr1 and Tfr2 in transfected Hepa 1-6 cells.  Hepa1-6 cells stably co-expressing
FLAG-tagged Hfe and myc-tagged Tfr2 (WT), or truncated Tfr2 (YX) were analysed by Western blotting. (A) Immunoblot showing
the relative expression levels of Tfr1, Tfr2 and Hfe in untransfected Hepa1-6 cells (UT), Hepa1-6 cells transfected with a vector to
co-express Hfe and WT Tfr2. (B) Immunoblot showing the expression of FLAG-tagged Hfe, Tfr1 and truncated YX Tfr2 (~45kD). β-
actin was used as a loading control in all the immunoblots.
doi: 10.1371/journal.pone.0077267.g001
Figure 2.  Co-localization of Tfr1 with Hfe and Tfr2.  Confocal microscopy analysis of Tfr1, Tfr2 and Hfe in Hepa1-6 cells
expressing either (A, B and C) myc-tagged Tfr2 alone or (E, F and G) FLAG-tagged Hfe alone. The transfected proteins were co-
localized with endogenous Tfr1. Images were obtained using a Nikon C2 confocal microscope. The insets D and H show the co-
localization represented by arrows. Scale bar= 20µm.
doi: 10.1371/journal.pone.0077267.g002
Interaction between Hemochromatosis Proteins
PLOS ONE | www.plosone.org 4 October 2013 | Volume 8 | Issue 10 | e77267
same sub-cellular compartment and hence could be involved in
an interaction.
b: In situ proximity ligation assay shows that Hfe and
Tfr2 do not interact
Co-immunoprecipitation (Co-IP) is a standard method to
determine whether two proteins of interest form a complex;
however sometimes this technique fails to detect weak or
transient interactions [24]. Co-IP involves lysis of the cells, this
could bring proteins which are usually in different subcellular
compartments together and result in false positive detection of
an interaction [24]. The nominal co-localization observed
between Hfe and Tfr2 in Figure 5 suggests that a small
proportion of molecules may be involved in an interaction. A
recently developed commercial assay (Duolink) based on
proximity ligation (PLA) overcomes these limitations [25]. The
advantage of PLA over conventional Co-IP is that it identifies
individual interactions between two proteins in their native form
that may be weak or transient in nature. The assay results in a
fluorescent signal in the form of a spot when the two proteins of
interest are closer than 40nm. To determine the interactions
between Hfe, Tfr1 and Tfr2 using the PLA we used Hepa1-6
cells stably expressing Hfe and Tfr2.
The specificity of the assay was tested using a single
antibody directed against FLAG, Tfr1 and Tfr2, these also
served as negative controls (Figure 6 A, B, C, D). The absence
of any spots indicates that the assay is specific with minimal
non-specific proximity signals. The PLA was able to identify
Tfr1 and Tfr2 as partners in Hepa1-6 cells, as indicated by the
red dots in the panels (Figure 7 A); each red dot represents a
molecular interaction between the two proteins of interest. This
is in agreement with previously published data [26] where it
was shown that Tfr1 and Tfr2 can form heterodimers. Similarly,
Hfe and Tfr1 were also identified as proximity partners (Figure
7 B). The absence of any PLA signal in panel 7 C indicates that
Hfe and Tfr2 do not interact in the Hepa 1-6 cells co-expressing
Hfe and Tfr2.
The proposed iron sensing model suggests that in the
presence of holo-Tf, HFE is released from TFR1 and made
available to interact with TFR2. We did not observe an
interaction between Hfe and Tfr2, suggesting that under normal
conditions there is little or no interaction between Hfe and Tfr2.
In order to determine the dynamics of Hfe and Tfr2 interaction
in the presence of holo-Tf, we treated the cells expressing WT
Hfe and Tfr2 with 2 mg/ml of holo-Tf or apo-Tf (as previously
described [8]) for 24 hours; PLA was performed on these
treated cells. The panels 7 D-F represent the cells treated with
apo-Tf and panels 7 G-I represent the cells treated with holo-
Figure 3.  Co-localization of Tfr1 and Tfr2 in Hepa1-6 cells.  Confocal microscopy analysis of Hepa1-6 cells stably co-expressing
Hfe and either Tfr2 (WT) or truncated Tfr2YX (YX). The localization of Tfr1 (A, E) appears to be endosomal as previously shown, the
wild type Tfr2 (B) also localizes to an endosomal compartment and to the plasma membrane, represented by white arrows whereas
the Tfr2YX (F) appears to accumulate in ER (as previously described by our laboratory, [16]. Tfr2YX does not co-localize with Tfr1 (H).
Images were obtained using a Nikon C2 confocal microscope. Scale bar =20µm.
doi: 10.1371/journal.pone.0077267.g003
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Tf. The results show that in the presence of apo- or holo-Tf,
Tfr1 and Tfr2 form heterodimers (7 D and G, respectively), and
Hfe and Tfr1 interact (7 E and H, respectively). The holo-Tf
treatment resulted in a decrease in the number of red spots per
nuclei (panel 7 G and H). It has been shown that in the
presence of holo-Tf Tfr1 is internalized and the interaction
between Hfe and Tfr1 decreases [10]. The absence of any
proximity signals in the panels 7 F and I indicates that Hfe and
Tfr2 do not interact in the presence of either apo- or holo-Tf in
Hepa 1-6 cells. These results are contrary to the previously
published data which suggests that in the presence of holo-Tf,
the interaction between Hfe and Tfr2 increases.
c: Co-Immunoprecipitation experiments confirm the
absence of interactions between Hfe and Tfr2
Since we did not detect any interaction between Hfe and Tfr2
using the highly sensitive PLA, we hypothesized that any
interaction could be transient. To ensure that the weak and
transient interactions were stabilized the cells were treated with
Bissulphosuccinimidyl suberate (BS3) a surface crosslinker for
30 minutes at 4 °C before harvesting the cells for protein
extraction. The lysates from Hepa 1-6 cells stably expressing
Hfe and Tfr2 were used to precipitate proteins which form
complexes with either Hfe (FLAG) or Tfr2. Rabbit IgG and
mouse IgG were used as controls to detect any non-specific
binding. Figure 8 A shows that Tfr1 can form a complex with
Hfe and Tfr2 as previously characterized. These results were
indicative that both the expressed proteins were functional. A
small amount of non-specific binding of Tfr1 can be detected in
the lanes representing rabbit IgG and mouse IgG IPs. Figure 8
B indicates that neither Hfe nor Tfr2 are present in a protein
complex with each other in the Hepa 1-6 cells. The absence of
any bands in the IgG lanes indicates that the assay is specific.
In a previous study involving a domain swap of Tfr1 and Tfr2
[8] it was shown that amino acid residues 104-249 of TFR2 are
sufficient for it to interact with HFE. We performed a Co-IP
experiment with anti-FLAG and anti-Tfr2 using lysates from
cells expressing Hfe and Tfr2Y245X; Figure 8 C shows that the
truncated form of Tfr2 which contains only the first 244 amino
acids of Tfr2 does not exist in a complex with FLAG-tagged
Hfe.
A Co-IP performed on the lysates of cells treated with apo-
and holo-Tf shows that Hfe and Tfr2 do not interact with each
other in either of the conditions (8 D). These results are
contrary to the previously published data which suggested that
in the presence of holo-Tf, Hfe and Tfr2 form a complex.
Discussion
Previous studies using transient overexpression systems
showed that HFE and TFR2 interact [8–10] and that this
interaction is important for HFE and TFR2 mediated regulation
of hepcidin [10,11]. Some recent studies have suggested that
HFE and TFR2 can independently regulate hepcidin and could
Figure 4.  Co-localization of Hfe and Tfr1.  Confocal analysis was performed to determine the co-localization of Hfe and Tfr1 in
Hepa1-6 cells stably co-expressing Hfe and either Tfr2 (WT) or truncated Tfr2YX (YX). Hfe (A and E) and Tfr1 (B, and F) co-localize
in endosomal compartments and on the membrane (represented by white arrows) in the cells stably co-expressing Hfe and WT Tfr2
(C and G) or YX Tfr2 (D and H). The images were obtained using a Nikon C2 confocal microscope. Scale bar=20µm.
doi: 10.1371/journal.pone.0077267.g004
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be acting in parallel to each other rather than synergistically
[12–14].
To examine putative interactions between these proteins we
developed a novel expression system where both Hfe and Tfr2
are stably co-expressed using a tricistronic vector. Using
Figure 5.  Co-localization between Hfe and Tfr2.  Confocal microscopy analysis of Hepa1-6 cells stably co-expressing Hfe and
either Tfr2 (WT) or truncated Tfr2YX (YX) reveals that Hfe and Tfr2 do not co-localize significantly in cells stably co-expressing Hfe
and WT Tfr2 (C and D) or truncated YX Tfr2 ( G and H). There is a small degree of overlap seen in some structures in WT (D)
suggesting that Hfe and Tfr2 could be transiently present in the same sub-cellular structures. Images were acquired using Nikon C2
confocal microscope. Scale bar=20µm.
doi: 10.1371/journal.pone.0077267.g005
Figure 6.  Specificity of PLA for transfected Hepa 1-6 cells.  PLA was performed on Hepa1-6 cells stably co-expressing Hfe and
Tfr2 (WT).The non-specific signal was examined by incubating Hepa1-6 cells with single antibodies directed against FLAG (A), Tfr1
(mouse) (B), Tfr1 (Rabbit) (C), or Tfr2 (D). The absence of any proximity signal indicates that the assay is specific. Tfr1 (mouse) –
anti Tfr1 antibody raised in mouse, Tfr1 (Rabbit)- anti Tfr1 antibody raised in rabbit.
doi: 10.1371/journal.pone.0077267.g006
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immunofluorescence and Co-IP we were able to show that a
stable co-expression of Hfe and Tfr2 does not affect their
localization or function. We observed partial co-localization
between Tfr1 and Hfe, and Tfr1 and Tfr2 suggesting that these
proteins could be present in similar subcellular compartments
and hence could interact or form a complex. As previously
described, we again showed that the YX mutant of Tfr2 (which
contains only the first 244 amino acids of the protein) is
retained in the endoplasmic reticulum [16].
Figure 7.  PLA shows that Hfe and Tfr2 do not interact.  PLA was performed on Hepa1-6 cells stably co-expressing Hfe and Tfr2
(WT). Previously characterized interactions between Tfr1 and Tfr2 (A, D and G) and Hfe and Tfr1 (B, E and H) were detected. Hfe
and Tfr2 do not interact in untreated WT cells (C) or cells treated with apo-Tf (F) or holo-Tf (I). The arrows indicate the red spots
representative of the interactions between the proteins of interest, each red spot is equivalent of one molecular interaction. Images
were acquired using a Nikon C1 confocal microscope. Scale Bar=20µm. Apo-Tf cells were cultured in 2mg/ml of apo-Tf for 24 hours
and Holo-Tf cells were cultured in 2mg/ml of holo-Tf for 24 hours. FLAG+ Tfr1 represents the experiment where antibodies against
FLAG tagged Hfe and Tfr1 (raised in Rabbit) were used, Similarly Tfr1+Tfr2 represents the experiment where Tfr1 (raised in mouse)
and Tfr2 were used, and FLAG+Tfr2 represents the experiment where antibodies against FLAG tagged Hfe and Tfr2 were used.
doi: 10.1371/journal.pone.0077267.g007
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The co-localization studies indicated some overlap between
Hfe and Tfr2 in the cells expressing WT Hfe and Tfr2; hence
we hypothesized that they could be involved in transient or
weak interactions which sometimes cannot be detected using
Co-IP. The PLA is a sensitive technique which can be used to
visualize weak and transient interactions at a cellular and
molecular level. A signal is observed only if the two proteins of
interest are in close proximity with each other (40nm or less).
This is the first report describing the interactions between Hfe-
Tfr1 and Tfr1-Tfr2 at a cellular level. The images in Figure 7
suggest that there are more Tfr1-Tfr2 dimerisation events as
compared to interactions between Hfe and Tfr1. Although
previous studies have suggested that HFE and TFR2 interact,
we did not detect any interactions between Hfe and Tfr2 in our
Figure 8.  Co-immunoprecipitation experiments reveal that Hfe and Tfr2 do not form a complex.  Hepa1-6 cells stably co-
expressing FLAG-tagged Hfe and myc-tagged Tfr2 (WT) were used to determine interactions between Hfe, Tfr1 and Tfr2. (A) Tfr1
interacts with Hfe and Tfr2. A Co-IP with IgG rabbit and mouse antibody shows some non-specific binding with Tfr1. (B) Co-
immunoprecipitation with anti-DYKDDDDK beads and anti-Tfr2 antibody reveals that Hfe and Tfr2 do not form a complex with each
other. (C) Hfe and Tfr2 do not interact with each in Hepa 1-6 cells co-expressing FLAG-tagged Hfe and myc-tagged Tfr2YX. (D) WT
cells were cultured in 2mg/ml apo- or holo-Tf for 24 hours and a Co-IP was performed with anti DYKDDDDK beads and anti Tfr2
antibody. Hfe and Tfr2 do not interact with each other in the presence of either apo- or holo-Tf. SM - starting material or input, IgG M
- IgG mouse, IgG Rb - IgG Rabbit, Apo-Tf- apotransferrin, Holo-Tf- holotransferrin.
doi: 10.1371/journal.pone.0077267.g008
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stable expression system when using either the highly sensitive
PLA or Co-IP. It was shown earlier that a chimera of TFR1 and
TFR2 consisting of TFR2104-250 is able to interact with HFE [8]. A
Co-IP experiment performed using cell lysates from our co-
expression system shows that Tfr2YX and Hfe do not form a
complex with each other.
The iron sensing model suggests that in the presence of
holo-Tf the interaction between HFE and TFR2 increases and
this interaction signals a cascade of events which leads to HFE
and TFR2 mediated regulation of hepcidin. We treated the
Hepa1-6 cells stably co-expressing Hfe and WT Tfr2 with apo-
or holo-Tf in order to determine whether Hfe and Tfr2 interact in
our co-expression system. The results suggest that Hfe and
Tfr2 do not form a complex with each other when they are
stably co-expressed. The results from our experiments and
recent studies [12,14] indicate that Hfe and Tfr2 can act
independently and do not need to interact as earlier studies
had suggested. Although previous in-vitro studies using
transient expression systems have been able to detect the
interactions [8–10], our results probably differ because of a
stable co-expression of the two proteins. This is supported by a
recent in-vivo study showing that mice expressing transgenic
Hfe could regulate hepcidin independently of Tfr2 [12]. The
authors did not observe any interaction between Hfe and Tfr2
and had suggested that some inhibitor in the tissue lysate
could be responsible for degrading or inhibiting the complex.
However, our results indicate that even in pure cell populations
expressing the two proteins, Hfe and Tfr2 do not form a
complex. One of the drawbacks of our system is that unlike
some previously published studies [10] we could not measure
the regulation of hepcidin in the presence of holo-Tf.
In addition to this, a large scale immunoprecipitation was
performed in our laboratory using a previously characterized,
highly specific Tfr2 antibody generated in the laboratory [17]
and total liver homogenates (results not shown), to identify the
protein partners that could interact with Tfr2. A mass
spectrometric analysis of the immunoprecipitated complexes
did not reveal Hfe as a binding partner of Tfr2. In the same
experiment we were able to identify Tfr1 as a binding partner
for Tfr2.
The results from our studies combined with that of previous
studies suggest independent roles for Hfe and Tfr2 in
regulating hepcidin. Future studies should be directed at
dissecting these roles and identifying whether Hfe and Tfr2 are
a part of a single signalling cascade, or if they act in parallel to
each other to regulate hepcidin.
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